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compartment after administration of Ciproxin® oral suspension in healthy conditions (scale 
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Gastrointestinal (GI) diseases affect a large number of people and drug treatment in this 
patient population includes the treatment of the GI condition, of associated systemic 
symptoms and of concomitant conditions. Preferably, drugs are administered via the oral 
route and the respective pharmaceutical formulations are designed to overcome 
physiological challenges before reaching the systemic circulation. Pathophysiological 
changes in GI disease patients can affect the absorption, distribution, metabolism and 
excretion of drugs but clinical studies are rarely performed in patients with GI diseases. In 
the absence of those studies, in vitro and in silico tools can be used to identify drugs at risk 
of altered performance in this patient population and were developed as aim of this thesis. 
To simulate the solubility and dissolution of drugs in the GI fluids of patients with Crohn’s 
disease (CD), Ulcerative colitis (UC) and Coeliac disease (CED) compared to healthy 
subjects, biorelevant media were developed based on pathophysiological differences in these 
patient populations using a Design of Experiment (DoE) approach. The characterisation of 
the GI disease media revealed differences compared to healthy biorelevant media, mostly in 
terms of surface tension, osmolality and buffer capacity. Solubility studies in the respective 
media indicated that a risk of altered drug solubility in patients with GI diseases was in the 
majority of cases related to the drugs’ lipophilicity or ionisation properties. 
To predict the performance of a controlled-release budesonide formulation in healthy 
subjects and CD patients, in vitro dissolution studies representative of CD and healthy 
conditions were performed and integrated in a physiologically-based pharmacokinetic 
(PBPK) model. The developed PBPK model revealed a higher drug exposure for CD patients 
compared to healthy subjects as observed in vivo, mainly due to differences in drug 
metabolism and distribution. 
The performance of complex formulations in GI disease patients was investigated using a 
complex GI simulator (TIM-1, TNO). The simulation of dynamic conditions to which a 
lipid-based formulation of ciprofloxacin is exposed to after oral administration in healthy 
subjects and CD patients revealed a similar drug performance in this specific case. A delayed 
and reduced lipid digestion was observed in CD, indicating a possible impact for other drugs. 
Overall, this thesis provides a range of in vitro and in silico tools that can be used in 
combination or separately to identify drugs and formulations at risk of altered performance 




Aims and Objectives 
The overall aim of the thesis is the development of in vitro and in silico tools to predict drug 
product performance in patients with GI diseases as a means to improve drug therapy in 
patients with GI diseases in absence of clinical studies. Such tools can be used to assess 
which drugs are at risk of an altered performance in patients with GI diseases. 
For poorly soluble drugs, in vitro methodologies serve to identify the risk for altered drug 
absorption in patients with GI diseases due to differences in drug solubility and dissolution. 
In silico methods are used to consider differences in terms of absorption, distribution, 
metabolism and excretion of drugs and to predict plasma concentration profiles in patients 
with GI diseases. 
The objectives specified for each chapter of the PhD thesis are:  
 
1. To review and describe pathophysiological differences in patients with GI diseases 
with possible implications on drug product performance. Investigated GI diseases 
comprise inflammatory bowel diseases, coeliac disease (CED), irritable bowel 
syndrome and short bowel syndrome. Approaches to predict drug product 
performance for these patient populations in vitro and in silico are discussed and the 
background for the development of the respective tools as part of the PhD project is 
set. [Chapter 1] 
 
2. To develop biorelevant media representative of the GI fluid composition in patients 
with GI diseases as tool to investigate the risk of altered drug solubility in their GI 
fluids compared to healthy subjects. More specifically, the objectives are to develop 
biorelevant media for patients with GI diseases based on a Design of Experiment 
(DoE) approach in order to reflect interpatient variability in terms of the luminal fluid 
composition and subsequently, to characterise them according to their media 
properties. In order to identify the risk of altered drug solubility in respect to drug 
physicochemical properties, multivariate statistical analysis is used for the analysis 
of drug solubility in GI disease biorelevant media. This approach was followed for 
patients with Crohn’s disease (CD) [Chapter 2], patients with Ulcerative Colitis 





3. To combine in vitro and in silico tools to predict drug product performance in patients 
with CD using the model drug budesonide. The objective is to predict drug release 
from a budesonide formulation with in vitro biorelevant dissolution tests 
representative of conditions in healthy subjects and CD patients. Furthermore, a 
physiologically-based pharmacokinetic (PBPK) model for budesonide is developed 
and the in vitro release profiles are integrated with the aim to predict the plasma 
concentration profile after budesonide administration. By accounting for 
pathophysiological differences, the purpose of the PBPK model is to predict 
budesonide performance in healthy subjects and CD patients. [Chapter 5] 
 
4. Investigating the risk of altered performance of a lipid-based formulation in CD 
patients using a complex dynamic GI simulator (TIM-1, TNO, Zeist, Netherlands) 
with ciprofloxacin as model drug. This includes the development of an in vitro 
methodology representative of conditions in CD patients and the assessment of the 
ciprofloxacin performance under such conditions. Additionally, the aim is to 
investigate if differences between CD conditions and healthy conditions are present 











Impact of Gastrointestinal Disease States on Oral Drug 





Drug product performance in patients with gastrointestinal (GI) diseases can be altered 
compared to healthy subjects due to pathophysiological changes. In this review relevant 
differences in patients with inflammatory bowel diseases, coeliac disease, irritable bowel 
syndrome and short bowel syndrome are discussed and possible in vitro and in silico tools 
to predict drug product performance in this patient population are assessed.   
Key findings 
Drug product performance was altered in patients with GI diseases compared to healthy 
subjects, as assessed in a limited number of studies for some drugs. Underlying causes can 
be observed pathophysiological alterations such as the differences in GI transit time, the 
composition of the GI fluids and GI permeability. Additionally, alterations in the abundance 
of metabolising enzymes and transporter systems were observed. The effect of the GI 
diseases on each parameter is not always evident as it may depend on the location and the 
state of the disease. The impact of the pathophysiological change on drug bioavailability 
depends on the physicochemical characteristics of the drug, the pharmaceutical formulation 
and drug metabolism. In vitro and in silico methods to predict drug product performance in 
patients with GI diseases are currently limited but could be a useful tool to improve drug 
therapy.  
Conclusions 
Development of suitable in vitro dissolution and in silico models for patients with GI 
diseases can improve their drug therapy. The likeliness of the models to provide accurate 
predictions depends on the knowledge of pathophysiological alterations and thus, further 






Oral drug absorption is a very complex process which is dependent on the physiological 
conditions in the gastrointestinal (GI) tract, the pharmaceutical formulation and the 
physicochemical characteristics of the drug.1 Pharmacokinetic properties of drugs often 
display high variability in a healthy population group and pathophysiological changes in 
patients with GI diseases can further intensify this variability and affect drug product 
performance.2 
Patients suffering from GI diseases take a variety of medicines not only for the GI condition 
but also for concomitant conditions. Differences in the bioavailability of drugs due to the GI 
disease state can provoke sub-therapeutic or toxic levels of drugs and therefore, have an 
impact on the safety and efficacy of drug therapy.3  
Differences in the pharmacokinetics of orally administered drugs between healthy subjects 
(controls) and patients with GI diseases have frequently been observed.4, 5 Careful 
interpretation is needed, as some of these studies are poorly controlled, include only a small 
patient population and study findings are conflicting. Numerous physiological factors 
affecting drug absorption can be altered in GI disease states. Differences in GI transit time 
and hydrodynamics influence the passage of the drug and formulation through the GI 
compartments.6, 7 Changes in the composition and characteristics of GI fluids such as bile 
salt concentrations, pH and osmolality can affect the drug release from formulations and the 
solubilisation of the drug.8 Alterations of the GI membranes and dissimilar expression of 
transporter systems can affect drug permeability.9 Differences in the expression pattern of 
metabolic enzymes in the GI membrane can influence the intestinal first pass metabolism.8 
Alterations in the composition and the location of the GI microbiota can change the exposure 
of drugs and formulations to bacterial enzymes and may therefore change the metabolism or 
release of the drug, respectively.10, 11 
To enable prediction of the in vivo performance of drug products in healthy adults, the use 
of in vitro dissolution methods and in silico models has been established.12, 13 Knowledge of 
the pathophysiological GI conditions can improve the design of in vitro and in silico models, 
improve the ability to predict the drug product performance in patients with GI diseases and 




The current review gives an overview of altered GI conditions in patients with inflammatory 
bowel disease (IBD), coeliac disease, irritable bowel syndrome (IBS) and short bowel 
syndrome (SBS). The consequences of these disease states on drug absorption are analysed. 
Finally, the suitability of existing in vitro dissolution and in silico models to predict the drug 
product performance in patients with GI diseases is critically discussed. 
1.2. Physiological alterations in GI diseases affecting absorption 
1.2.1. Inflammatory bowel diseases 
1.2.1.1. General information 
IBD is a recurrent or continuous inflammation of the bowel. Numerous factors 
(environmental, microbial and genetic) contribute to IBD while its aetiology remains still 
unknown.14 In the US 1.4 million people suffer from IBD and 396 per 100 000 persons 
worldwide.8 The prevalence of IBD is constantly rising. It is higher in northern, 
industrialized countries and emerges in newly industrialized countries.15, 16 The two main 
forms of IBD are Crohn’s disease (CD) and Ulcerative Colitis (UC). Numerous alterations 
in the GI physiology of IBD patients (e.g. mucosal lesions, thickened bowel wall and 
strictures) may influence drug absorption.17 
1.2.1.1.1. Ulcerative Colitis 
UC is a continuous uniform inflammation of the colon and rectum with periods of relapse 
and remission. Typically, the inflammation spreads from the rectum/descending colon to the 
ascending colon. Depending on the affected area and extent of the disease, it can be grouped 
into ulcerative proctitis, left-side colitis, sub-total colitis and pancolitis.18 The diffuse 
inflammation involves only the mucosa and submucosa which appear granular and 
haemorrhagic. During active disease UC histology reveals neutrophil-mediated damaged 
epithelium.19 This includes cryptitis, crypt abscesses where the lumen is filled with 
neutrophils and debris, and mucosal ulceration.19 As the disease progresses, neutrophils 
infiltrate the lamina propria, crypts get shorter and branched and Paneth cells occur in the 
left colon.19 The typical clinical manifestation of UC includes chronic diarrhoea with blood 
in the stool.20 
1.2.1.1.2. Crohn’s disease 
The second type of IBD is CD. CD can affect the entire GI tract from mouth to anus, often 




Initially the disease is limited to the submucosa which appears red and swollen due to 
lymphoid hyperplasia and lymphedema.22 In a later stage, the disease extends transmurally 
and involves the full thickness of the GI wall.21, 22 Endoscopic examination of CD patients 
reveals cobble-stoning mucosa and linear or aphthous ulcers with a haemorrhagic rim form. 
Radiological findings in CD typically illustrate ileac involvement, fistulas and asymmetric 
manifestation. The typical clinical presentation of CD involves diarrhoea and recurrent 
abdominal pain. Other symptoms include abdominal cramps, fever, malaise and weight loss. 
CD complications include malabsorption, bowel obstruction, strictures, crypt abscesses and 
fistulae.22 
1.2.1.2. Gastrointestinal transit time/motility and pH 
1.2.1.2.1. Ulcerative Colitis 
GI transit time varies between healthy adults and patients with UC (Table 1.1). Different 
results considering the total GI transit time (TGTT) have been published. TGTT was strongly 
increased in patients with UC, and this finding was even more pronounced in patients in 
remission compared to patients with severe disease.23, 24 Similar TGTT to controls has been 
observed in one study possibly attributed to the methodology (large size of the telemetery 
capsule).25 UC patients with severe disease have shown high variability in TGTT.26  
Gastric residence time in the fed state was slightly prolonged in patients with UC, but this 
was not statistically significant.23, 27 In the fasted state, patients with UC have shown similar 
gastric residence times as controls.26 Small intestinal transit times were slightly prolonged 
(0.2-1.3 h) in patients with UC compared to controls as confirmed by a prolonged orocecal 
transit time as monitored using the lactulose breath test.23, 24, 27-30  
Colonic transit times measured with a telemetry capsule were increased in patients with UC, 
mainly due to a prolonged residence time in the middle and distal colon.23, 28 However, 
decreased colonic transit times were also observed which could be attributed to the mild 
disease state.27 The range of colonic transit times in healthy volunteers is 7-20 h, whereas a 
much wider range (2-97.7 h) was observed for patients with very active UC consistent with 
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Meal Number of 
study subjects 
Method Reference 
sUC: 44.5 h  
rUC: 51.8 h 
Controls: 27.6 h 
sUC: 4.1 h  
rUC: 3.4 h 
Controls: 3.2 h 
sUC: 5.9 h  
rUC: 6.2 h 
Controls: 4.9 h 
sUC: 34.9 h  




















UC: 20 (relapse 
n = 20, 
remission 






(diameter 8 mm, length 
21 mm, density 
1.6 g/cm3) 
Haase et al 
[23] 
            UC: 2.04 h 
(0.86)  
Controls: 
1.51 h (0.51) 
  UC: 95 
Controls: 115 
Lactulose breath test Rana et al 
[29] 
  UC:  
10.59 h (7.10) 
Controls:  
5.19 h (2.13) 
UC: 8.03 h 
(1.38) 
Controls: 7.38 h 
(2.04) 
  UC: 12.66 h (5.37) 
Controls: 30.68 h 
(21.47) 
  Overnight fast, 
breakfast, SP 
swallowed  
UC: 5 (mild to 
moderate) 
Controls: 5 
SmartPill system Bosworth 
et al [27] 
  UC: 4.4 h 
Non-IBD 
patients: 3.6 h 
    Overnight fast, light 












UC: 24 h 
Controls: 26 h 
            Overnight fast, 
capsule swallowed  




Radiotelemetry capsule Ewe et al 
[25] 
    aUC: 7 h (2.3)  
Controls: 6 h 
(2.6) 
  aUC: 7 h 
(5.5)  
Controls: 
8 h (9.2)  
aUC: 12 h 
(6.9)  
Controls: 
7 h (1.4)  
  Standardised 
ambulatory and 
dietary protocol 
aUC: 4  
Controls: 8 
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Meal Number of 
study subjects 
Method Reference 
  UC: 1.6 h  UC: 3.4 h 
Controls:  
3.2 h (0.94) 





UC:6 (2 active, 
4 quiescent) 
Gamma scintigraphy of 
a radiolabelled tablet 
with cellulose acetate 
coating 
Hardy et al 
[31], Davis 
et al [32] 
 UC:2.7 h (0.6) UC:4.0 h (1.5)     Light breakfast, 
tablet swallowed 
afterwards 
UC:5 Gamma scintigraphy of 
a tablet containing 
111indium-labelled 
granules and coated 
with Eudragit L® 
(Evonik Industries AG, 
Darmstadt, Germany) 
Hardy et al 
[33] 
UC:  
8h - >122.5h 
UC:  
1.05 h (1.05)  
UC:  
8.93 h (5.90) 
  UC: 2 h - >97.7 h 
  
  Overnight fast, 
swallowed capsule, 
fasting until 
capsule had passed 
the stomach 
UC:6 (severe) Fluoroscopic 
localisation of capsule 
Fallingborg 
et al [26] 
aUC:  
54.6 h (21.8) 
rUC:  
53.0 h (32.6) 
daUC:  
55.0 h (22.0) 
drUC: 
 60.5 h (42.0) 
Controls:  
48.8 h (22.3) 
aUC:  
0.81 h (0.32) 
rUC:  
0.88 h (0.52) 
daUC:  
0.96 h (0.44) 
drUC:  
1.13 h (0.45) 
Controls: 
0.85 h (0.37) 
    aUC:  
4.93 h (0.95) 
rUC:  
5.28 h (1.33) 
daUC:  
5.45 h (1.28) 
drUC:  
5.23 h (1.47) 
Controls: 
3.82 h (1.08) 







meal and stool output 
Rao and 
Read [24] 




GI motility in the jejunum and ileum as quantified by magnetic resonance imaging (MRI) 
was not altered in patients with UC compared to controls.34 After the intake of a meal, the 
colonic motility in patients with UC in remission was similar to controls.35 Whereas the low-
amplitude propagating contractions in the colon responsible for the transport of liquid 
contents and gases were found more often in UC patients in remission than in controls, the 
amount of high-amplitude propagating contractions, which mainly transport solid contents, 
was similar to controls.35 
The pH profile in patients with UC was investigated in several studies (Figure 1.1).25-28, 36-38 
In the stomach, pH was slightly higher and no major pH changes in the small intestine were 
observed in patients with UC compared to healthy subjects. Only the time to reach a pH of 
7 in the small bowel was prolonged in patients with UC compared to controls.27 
For colonic pH values, conflicting results have been published (Table 1.2). A decrease in 
colonic pH was mainly observed apart from two studies in which similar or even higher pH 
values were detected possibly due to the individual form of the disease, the status of the 
inflammation process and the current treatment of the patients. 
 
Figure 1.1: Gastrointestinal pH profile in patients with Ulcerative Colitis (x: mean/median 




Table 1.2: Colonic pH values in patients with Ulcerative Colitis.  
pH in controls pH in patients with 
Ulcerative Colitis in 
remission 
pH in patients with active 
Ulcerative Colitis 
Special observations Method Reference 
6.7(0.3) (n = 7) 4.90 (1.3)a 
5.52 (1.13)b 
5.51 (0.37)c 
(n = 6) 
4.7 (0.72) 
(n = 7) 
 
Radiotelemetry capsule Raimundo et al [38] 
Caecum: 5.7 
Rectum: 6.6 
(n = 39, previous study) 
 4.63 (1.93) (n = 6, very 
active) 
Very active disease: 2 patients 
transferred for surgery during 
the study, 1 patient died 
Radiotelemetry capsule, fast of at 
least 8 h until capsule passed the 
stomach 
Fallingborg et al [26] 
Right: 5.88 
Left: 6.12 
(n = 12) 
Right: 7.19 
Left: 6.45 
(n = 4) 
Right: 7 
Left: 6.8 
(n = 7) 
 Radiotelemetry capsule, 
overnight fast until capsule 
passed the stomach 
Press et al [36] 
Right: 6.5 
Left: 7 
(n = 15) 
 Right: 7.4 
Left: 7.6 
(n = 5) 
Lowest individual pH values 
were reached in the caecum 
(involved in two of five 
cases), pH did not fall under 
5.5 
Radiotelemetery capsule Ewe et al [25] 
Right: 6.5 (0.6) 
Left: 6.7 (0.1) 
(n = 4) 
 Right: 6.7 (0.5) 
Left: 6.7 (0.9) 
(n = 8) 
In 2 patients with active distal 
UC a low pH  < 5.5 was 
measured 
Radiotelemetry capsule, 
standardised ambulatory and 
dietary protocol 
Nugent et al [28] 
Colon: 7.06 (0.41) 
(n = 5) 
 Colon: 6.14 (0.37) 
(n = 5, mild to moderate UC) 
 Smart Pill following a 
standardised egg sandwich meal 
and water 
Bosworth et al [27] 
Right: 7.8  
(n = 12) 
Right: 6.5 (6.1–7.3) 
(n = 12) 
Right: 6.6 (5.5–7.7) 
(n = 12) 
 
Collection of the ascending colon 
fluid, measurement of pH 
Vertzoni et al [37] 
Diakidou et al [39] 




1.2.1.2.2. Crohn’s disease 
An overview over the studies investigating GI transit time in CD is given in Table 1.3. 
Gastric emptying times in patients with CD in the fed state were prolonged as measured by 
scintigraphy of a capsule containing 111In-labelled pellets.40 In the fasted state, gastric 
emptying times in CD patients were similar to patients with different diagnosis using small 
capsule endoscopy studies.40, 41 Small intestinal transit times were prolonged when measured 
with small capsule endoscopy studies but similar when measured by scintigraphy of labelled 
pellets, and thus, the GI passage could be altered according to the pharmaceutical dosage 
form.30, 40, 41 This finding could also be attributed to the disease state as a recent study showed 
that CD patients with active disease have an increased small intestinal transit time while 
patients with inactive disease showed similar small intestinal transit times compared to non-
IBD patients.30 Orocecal transit times were prolonged in patients with CD.29, 42 The passage 
through the ascending colon was not significantly different, but high disease activity was 
linked to a shorter transit time.40 
Jejunal and ileac motility in patients with CD were similar to controls, whereas terminal 
ileum motility was decreased.34 Differences in bowel hydrodynamics could occur due to the 
thickened bowel wall in CD and as a result of strictures which hinder the passage of GI 
fluids.17 
The pH profile in patients with CD was investigated in several studies (Figure 1.2).25, 36, 43, 
44 Patients with CD showed a tendency to higher pH in the stomach compared to controls 
which correlated with decreased gastric acid secretion especially when patients were 
malnourished (mean basal acid output: 0.64 mEq/h (0.33) (malnourished), 2.12 mEq/h 
(0.88) (nutritional support) vs. 3.85 mEq/h (0.93) in controls, maximal acid output: 
7.36 mEq/h (1.38) (malnourished), 12.76 mEq/h (2.50) (nutritional support) vs. 
25.53 mEq/h (4.58) in controls).25, 36, 45 Mean or median pH values in the small intestine of 
patients with CD were similar compared to controls whereas the observed pH range was 
higher in patients with CD. Similar results with more fluctuations were found for colonic pH 
values in CD patients with the exemption of one study with an overall mean decreased 













Meal Number of subjects Method Reference 
CD: 0.61 h (0.75) 
controlsa: 0.58 h 
(0.29) 
CD: 5.62 h (0.78) 
controlsa:  
4.06 h (1.39) 
    Overnight fast CD:19 
Patients with other 
diagnosis:178 
Small capsule endoscopy 
studies  
Niv et al [41] 
 Active CD: 4.2 h 
Inactive CD: 3.1 h 
controlsa: 3.6 h 
  Overnight fast, light 
breakfast 4h after 
swallowing the 
capsule  
Active CD: 33 
Inactive CD: 22 
Patients with other 
diagnosis: 125 
Small capsule endoscopy 
studies 
Fischer et al [30] 
      CD: 2.32 h (0.83) 
Controls:  
1.51 h (0.51) 
  CD:42 
Controls:115 
Lactulose breath test Rana et al [29] 
      CD: 2.00 h 
controls: 1.47 h 
  CD:45 
Controls:20 
Lactulose breath test Tursi et al [42] 
CD: 4.0 h 
controls: 3.0 h 
CD: 2.4 h 
controls: 3.0 h 
CD: 8.1 h 
controls: 15.5 h 
  Fed state CD:6 
Controls:8 
Scintigraphy using a capsule 
containing  
111In-labelled pellets  
Edsbacker et al [40] 
CD: 3.2 h (0.13) 
controls: 2.78 h (0.11) 
   Fed state CD (inactive): 26 
Controls: 19 
13C octanoic acid breath test Nobrega et al [46] 
CD: 6.7 h (4.2) CD: 3.3 h (1.7) 
(n=3) 
  Fed state CD:5 Gamma scintigraphy of a 
tablet containing 
compressed 111In-labelled 
granules and coated with 
Eudragit L® (Evonik 
Industries AG, Darmstadt, 
Germany) 
Hardy et al [33] 






Figure 1.2: Gastrointestinal pH profile in Crohn's disease (x: mean/median values). 
 
1.2.1.3. Composition of luminal contents 
1.2.1.3.1. Ulcerative Colitis 
The composition of the ascending colon fluid in the fasted state in UC patients in relapse 
and remission differed from healthy adults with elevated concentrations of soluble proteins 
(relapse: 18.9 mg/ml (8.1), remission: 19.0 mg/ml (10.8), healthy: 8.1 mg/ml (8.6)), in 
contrast, no difference in soluble carbohydrates (relapse: 5.4 mg/ml (2.7), remission: 
6.4 mg/ml (4.1), healthy: 9.7 mg/ml (4.6)) was observed.37 Phosphatidylcholine, an essential 
constituent for the normal mucus barrier function, was strongly decreased in the colonic 
mucus barrier of patients with UC (-70%) [as measured by mass spectrometric analysis of 
lipid extracts of specimens of rectal mucus]. Beneficial effects were shown when 
phosphatidylcholine was used as a treatment option for UC.47-49 Due to the low number of 




the ascending colon fluids of UC patients in relapse (0.31 mM) or remission (0.30 mM) in 
the fasted state compared to controls (0.36 mM).37, 39 The faecal fluids of patients with UC 
were found to have a lower concentration of potassium (33.0 mmol/l vs. 84 mmol/l) and a 
higher concentration of sodium (67.8 mmol/l vs. 34 mmol/l) and chloride (53.1 mmol/l vs. 
18.5 mmol/l) compared to healthy subjects.50 
Regarding the properties of the ascending colon fluid of patients with UC, both the volume 
and surface tension were similar compared to controls (relapse: 26.8 ml (13.5), remission: 
21.2 ml (8.8), controls: 22.3 ml (7.7) and relapse: 41.6 mN/m (3.1), remission: 40.6 mN/m 
(3.4), controls: 39.2 mN/m).37 The buffer capacity of the ascending colon fluid in remission 
and relapse were similar but higher than in controls (with hydrochloric acid relapse: 
32.0 mmol/l/ΔpH (18.1), remission: 37.7 mmol/l/ΔpH (15.4), controls: 21.4 mmol/l/ΔpH 
(7.9); with sodium hydroxide solution: relapse: 18.3 mmol/l/ΔpH (10.4), remission: 
16.7 mmol/l/ΔpH (5.8), controls: 10.3 mmol/l/ΔpH).37 Osmolality values were higher in 
patients with UC in relapse (199.6±127.4 mOsmol/kg) and remission 
(290.1±165.6 mOsmol/kg) compared to controls (80.6±102.5 mOsmol/kg).37 Faecal fluid 
osmolality was similar to controls (341.1 mOsm/kg vs. 348.5 mOsm/kg).50 
1.2.1.3.2. Crohn’s disease 
The composition of GI fluids in patients with Crohn’s disease has not been described. The 
bile acid pool size (weight of total bile acids) was decreased to only 38-58% in patients with 
CD compared to controls as measured by induced gall bladder evacuation, subsequent 
aspiration of the duodenal fluid and analysis of labelled bile acid (previously administered) 
vs total bile acid concentrations.51-53 It has been reported that >90% of patients with resected 
CD and 11-52% of patients with unresected CD suffer from bile acid malabsorption.54 As a 
consequence, postprandial duodenal bile acid concentrations were decreased in 9 of 19 CD 
patients with a mean value of 6.04 mM (3.92).55 The failure in the reabsorption of bile acids 
is a result of the disease localisation in the ileum, as the ileac sodium/bile acid cotransporter 
is responsible for the active reabsorption of the conjugated bile acids. As a consequence, bile 
acid malabsorption is particularly severe in CD patients after resection of the distal ileum.56  
With regard to the properties of the GI fluids, faecal fluid osmolality in CD patients was 




Changes in the exocrine pancreatic function have also been reported in CD. A significant 
decrease of amylase (33-85%), trypsin (29%) and lipase (28-80%) activity in the fed state in 
the duodenum of CD patients compared to controls was observed which was particularily 
strong in malnourished patients.45, 58, 59 
1.2.1.4. Permeation and transport systems 
Transporters in the GI tract can increase drug bioavailability by transferring drugs from the 
luminal to the basolateral site (uptake transporters) or decrease drug absorption by transport 
in opposite direction (efflux transporters).  
For uptake transporters, differences in the transporter expression have been reported in IBD. 
The expression of OCTN1 and OCTN2, transporters for cationic drugs, is downregulated in 
UC patients, and patients with IBD were found to have mutations in the genes encoding their 
expression.60, 61 The expression of PepT1, an important influx transporter for 
peptidomimetics, is upregulated in the colon in chronic inflammation associated with IBD, 
with no information being available for its expression in the small intestine of these 
patients.61 In healthy adults, PepT1 is majorly expressed in the small intestine and only very 
low amounts of PepT1 are expressed in the colon.61 Therefore, alterations in the colonic 
expression pattern of PepT1 may have only limited influence on drug absorption of 
peptidomimetics such as β-lactam antibiotics and angiotensin-converting enzyme inhibitors. 
1.2.1.4.1. Ulcerative Colitis 
The composition of the GI membranes can be altered by GI diseases, and thus, influence 
drug permeation. The thickness of the colonic and rectal mucus layer was reduced in patients 
with UC compared to controls which was more pronounced in distal regions (right colon: 
90(79) vs 107(48) µm, left colon: 43 µm (45) vs 134 µm (68), rectum: 60 µm (86) vs 155 µm 
(54)).62 
The efflux transporters, P-glycoprotein(P-gp), BCRP and MRP2 are the most important 
efflux transporters in the luminal membrane of the small intestine and they act by limiting 
cellular uptake into the enterocyte and enhancing the excretion of xenobiotics.63 The 
expression levels of BCRP, MRP2 and P-gp in the colonic and rectal mucosa of patients 
with UC are strongly decreased during active inflammation.64 In contrast, elevated levels of 
P-gp in the colon of patients with UC were found in another study possibly due to a milder 




and BCRP and prescribed for IBD, could thus be increased in UC and produce more side 
effects.61  
1.2.1.4.2. Crohn’s disease 
The thickness of the colonic and rectal mucus layer was increased in patients with CD 
compared to controls (right colon: 190(83) vs. 107(48) µm, left colon: 232(40) vs. 
134(68) µm, rectum: 294(45) vs. 155(54) µm).62 
Baseline permeability in surgical specimens from the distal ileum of CD patients was similar 
compared to patients with colon cancer as measured by permeability to 51Cr-EDTA and 
electrical resistance in Ussing chambers.66 However, after exposure to sodium caprate, a 
stimulus to the luminal epithelium, the increase in paracellular permeability in CD was more 
pronounced.66 This hyper responsiveness might be of particular interest because certain 
drugs may act as luminal stimulus.  
Paracellular permeability for various compounds like 51Cr-EDTA, [99mTc]DTPA, sucrose 
and lactulose was increased in patients with CD compared to controls probably caused by 
the opening of tight junctions.67-70 
Transcellular permeability, as indicated by mannitol’s permeability in in vivo 
lactulose/mannitol intestinal permeability studies, was not altered in patients with CD 
compared to controls.71, 72 Mannitol is absorbed via the paracellular pathway in in vitro 
permeability studies (e.g. Ussing chambers), whereas in in vivo intestinal permeability 
studies, it is used as marker for the transcellular route due to a solvent drag effect caused by 
the hyperosmolality of villus tips.73 
Active transport systems can also be altered in CD. The expression of P-gp was increased to 
over 200% in the duodenal biopsy specimens and in the colon of patients with CD.65, 74 This 
increased P-gp expression could be responsible for the decreased absorption of tacrolimus 
and justify the higher doses of tacrolimus required in a patient with CD.74 
1.2.1.5. Metabolism 
1.2.1.5.1. Ulcerative Colitis 
The expression of metabolizing enzymes in the large intestine of patients with UC is altered 
compared to controls. In colorectal tissue, the expression of the most abundant metabolising 




and UDP-glucuronic acid transferase was decreased in enterocytes (74%, 81%, 72%).65 In 
biopsy samples of the terminal ileum and various regions of the colon, the expression of 
CYP3A and CYP2D6 was not altered but the expression of CYP1A1 was increased.75 
Whereas, in the terminal ileum and colon, no difference in CYP2E1 expression compared to 
controls was observed, one study found increased expression (137%) in colorectal tissue 
probably due to the inflammation processes in active disease.65, 75  
Considering conjugation reactions, sulphation by sulfotransferases in the colonic mucosa of 
patients with UC was reduced to <15% compared to controls.76 The systemic sulphation 
pathway is not reduced as shown by no alteration in paracetamol metabolism in patients with 
UC.77 
1.2.1.5.2. Crohn’s disease 
Patients with CD displayed different expression patterns for metabolizing enzymes. The 
expression of CYP3A4 was more than doubled in the colon of CD patients compared to 
controls and also increased, together with CYP3A5 expression, in duodenal biopsies of 
children with CD.65, 78 This may alter the bioavailability of substrates for both enzymes such 
as corticosteroids. In a recent study, lower CYP3A4 activity was shown in patients with CD 
as assessed after intravenous and oral administration of midazolam (CYP3A4 substrate).79 
This finding was mainly attributed to a lower hepatic CYP3A4 activity (hepatic extraction 
ratio in CD patients 0.11 vs. 0.36-0.62 in healthy subjects; intestinal extraction ratio in CD 
patients 0.64 vs. 0.30-0.61 in healthy subjects). Furthermore, in the same study, 25% of the 
variability in budesonide pharmacokinetics (CYP3A4 substrate) was attributed to the 
reduced CYP3A4 activity. 
Elevated expression of other metabolizing enzymes such as CYP2C9 (130%), CYP1A1 
(134%) and UDP-glucuronic acid transferase (135%) was also observed.65, 75 CYP2B6 levels 
were augmented to 178% in patients with CD and the expression of glutathione-S-transferase 
was strongly raised (159-167%).65 A tendency to increased levels of CYP2E1 (122%) was 
reported.65, 75 CYP3A and CYP2D6 expression was similar to controls.75  
1.2.1.6. Microbiota 
In recent years, the importance of the GI microbiota in IBD patients is increasingly 
recognised. At the early stages of IBD differences in the microbiota (dysbiosis) are already 




investigated.80 The emergence of several new methodologies (metagenomic sequencing, 
transcriptomics and metabolomics) in the last years has provided information on bacterial 
functions over and above the broad taxonomic profiles.80 The microbiota of patients with 
IBD was decreased in diversity, as the gene catalogue of the human gut microbiome in IBD 
patients showed 25% less bacterial genes compared to controls, with a shift to more 
potentially inflammatory and less potentially protective bacterial species.80, 81 Reduced 
amounts of Faecalibacteria, Leuconostocaceae, Odoribacter splanchnius, 
Phascolarctobacterium and Roseburia in patients with IBD led to decreased levels of short 
chain fatty acids (SCFA) which are involved in immune regulatory functions and stimulate 
bile acid production and mucosal protection.80, 82-84 Several drugs are processed by bacterial 
enzymatic action which is possibly affected by the altered composition of the microbiota 




Table 1.4: Effect of IBD on drug interactions with gut bacterial enzymes.11, 85-88 
Reaction Enzyme Substrates Bacteria with high enzymatic expression Changes in IBD 





Clostridium sp. Azoreductase 
activity reduced in 
CD, Clostridium 
clusters IV and XIVa 
reduced in UC 
Reduction Nitroreductase Nitrazepam Bacteroides fragilis/thetaiotamicron/vulgatus, 
Clostridium perfringens, Eubacterium limosum, 
Escherichia coli, Fusobacterium 
pseudonecrophorum, Peptostreptococcus 
asaccharolyticus 
Bacteroides sp. and 
Eubacterium sp. 
decreased 
Deglucuronidation β-glucuronidase SN-38G  











Levamisole Bacteroides and Clostridium sp. (Strongest 
metabolisers) 




IV and XIVa 




1.2.1.6.1. Ulcerative Colitis 
The microbiota of patients with UC was richer in Proteobacteria, Bacteroides, Fusobacteria 
and Enterobacteriaceae compared to controls.89 Decreased levels of Faecalibacterium 
prausnitzii, Bacteroides fragillis, Ruminococcus albus, Roseburia intestinalis, Clostridium 
coccoides, Eubacterium rectale, enterohepatic Helicobacter species and the Clostridium 
leptum group were observed.89 
Small intestinal bacterial overgrowth (SIBO) was slightly more prevalent in patients with 
UC compared to controls (17.8 % vs 0.86%).29 In terms of enyzmatic bacterial function, 
differences in the colonic mucus of patients with UC were observed. Proteinase activity 
(657.6 units h-1mg dry wt.-1 (150.6) vs. 77.2 units h-1mg dry wt.-1 (25.9)) and non-specific 
esterase activity (39.8 µmol h-1 mg dry wt.-1 (3.3) vs. 33.9 µmol h-1 mg dry wt.-1 (3.7)) were 
increased compared to controls.90 
1.2.1.6.2. Crohn’s disease 
Changes in bacteria species colonising the intestine of CD patients were observed with 
higher amounts of Bacteroidetes and Enterobacteriaceae, specifically Eschericia coli, and 
lower amounts of Firmicutes and F. prausnitzii compared to healthy subjects.91  
45.2% of patients with CD suffered from SIBO compared to only 0.86% of controls.29 With 
regard to bacterial enzyme activity, decreased faecal azoreductase activity (11.39 mU/g vs. 
51.13 mU/g), extremely high proteinase activity (585.8 units h-1mg dry wt.-1 (202.1) vs. 
77.2 units h-1mg dry wt.-1 (25.9)) and elevated non-specific esterase activity (51.7µmol h-1 
mg dry wt.-1 (19.7) vs. 33.9µmol h-1 mg dry wt.-1 (3.7)) were observed in CD.85, 90 
1.2.2. Coeliac disease 
1.2.2.1. General information 
Coeliac disease, affecting 1% of the population, is a genetic autoimmune enteropathy with a 
hypersensitivity of the patient to gluten.92, 93 A small intestinal biopsy which shows villous 
atrophy, crypt hyperplasia and intraepithelial lymphocytosis serves as an additional 
diagnostic criteria.93 Normally, the villous atrophy, occurs in patches and is localized at the 
duodenal bulb and in the descending duodenum but more distal GI segments can also be 
affected. The villous atrophy results in decreased availability of absorptive surface area 




1.2.2.2. Gastrointestinal transit time/motility and pH 
The mouth-to-caecum transit time in untreated patients with coeliac disease was prolonged 
compared to controls using the lactulose breath test but significantly decreased after 
treatment with a gluten-free diet (Table 1.5).95-97 Gastric emptying time measured with 13C-
octanoic acid breath test and ultrasonographic emptying studies in untreated patients with 
coeliac disease was increased but normalized after treatment with a gluten-free diet.92, 98, 99 
However, with another methodology (small bowel PillCam® [Given Imaging Ltd, 
Yoqneam, Israel]) gastric emptying was found to be similar to controls.100 No alteration of 
small intestinal transit time was found in patients with coeliac disease. The faster mean 
colonic transit time, as measured in one study (n=40) only, was attributed to a subpopulation 
of patients with very fast colonic transit.97  
Motility changes in patients with coeliac disease compared to controls were observed with 
increased oesophageal motility disturbances.101 
With regard to the pH profile in patients with coeliac disease, a higher jejunal surface pH 
value with a pH of 6.42 (0.06) or 6.56 (0.14) in untreated patients, 6.32 (0.07) or 6.19 (0.09) 
in treated patients compared to 5.96 (0.05) or 5.93 (0.05) in controls was observed which 
might favour the absorption of weakly basic drugs.102, 103 Intraluminal pH measurements 






Table 1.5: Gastrointestinal transit time in Coeliac disease [Mean/Median (SD)]. 
Gastric emptying time Small intestinal 
transit time  
Orocecal transit time Meal Number of study 
subjects 
Method Reference 
Coeliac disease (children):3.75 h 
(1.12) (untreated), 1.46 h (0.43) 
(treated) 
Controls: 2.02 h (0.7) 
    Overnight fast, standard 
meal enriched with 13C 
Coeliac disease: 9 
Controls: 9 
13C-octanoic acid breath test Perri et al [92] 
Coeliac disease: 5.43 h 
Controls: 3.55 h 
 




Benini et al [98] 
Coeliac disease: 3.38 h (0.53) 
Controls: 2.22 h (0.25) 




Bardella et al [99] 
    Coeliac disease 
(untreated): 4.05 h 
(0.17) 
Controls: 1.95 h (0.1) 
Fasting period of at least 
12 h 
Coeliac disease: 16 
Controls: 20 
Hydrogen breath test Battaglia et al [95]  
    Coeliac disease: 2.13 h 
Controls: 1.01 h 
Overnight fast, test meal Coeliac disease: 25 
Controls: 7 
Hydrogen breath test Spiller et al [96] 
Coeliac disease: 0.51 h (0.37)  
Controls: 0.73 h (0.81) 
Coeliac disease: 
4.20 h (1.12) 
Controls: 4.08 h 
(1.47) 
  Bowel cleansing day 
before, fasting since 
midnight, drinking 2 h/ 
eating 4 h after capsule 
ingestions 
Coeliac disease: 30 
Controls: 30 




1.2.2.3. Composition of luminal contents 
The composition of GI fluids in patients with coeliac disease has not been described. About 
20% of patients with untreated coeliac disease showed a decreased secretion of at least one 
pancreatic enzyme.105 Reduced cholecystokinin secretion as response to a meal, which was 
observed in patients with coeliac disease, could lead to decreased gall-bladder motility and 
small intestinal transit time.106 This could further provoke an increase and stasis of the bile 
acid pool.106, 107 Additionally, increased biliary outputs of phospholipids (0.26 mg/kg*h 
(0.05) vs 0.08 mg/kg*h (0.02)), cholesterol (0.82 mg/kg*h (0.10) vs 0.43 mg/kg*h (0.06)) 
and bile acids (9.28 mg/kg*h (1.65) vs 4.64 mg/kg*h (0.45)) were all observed in patients 
with coeliac disease.108 
Protein concentrations in jejunal perfusion fluids were altered in patients with coeliac disease 
compared to controls. The concentration of glycosaminoglycan hyaluronan, a connective 
membrane component, was increased twofold in the basal state of coeliac disease compared 
to controls.109 After provoking an immune response by challenging the jejunal segment with 
gliadin (protein present in wheat), concentrations of albumin and glycosaminoglycan 
hyaluronan increased up to twofold indicating increased protein leakage through the GI 
membrane.109  
1.2.2.4. Permeation and transport systems 
Differences in paracellular passive diffusion were observed in patients with coeliac disease 
compared to controls with a higher GI permeability of lactulose and 51Cr-EDTA, possibly 
due to opening of the tight junctions.71, 110-113  
For the transcellular pathway, a lower permeability for mannitol and polyethylene glycol 
400 was observed in in vivo intestinal permeability studies, possibly due to the decrease in 
the absorptive surface area.110-113 
In the case of efflux transporters, the expression of P-gp in untreated and treated children 
with coeliac disease was elevated compared to controls whereupon gluten withdrawal 
resulted in a further increase.114 
1.2.2.5. Metabolism 
Jejunal morphological changes like flattened villi in coeliac disease were accompanied by 




coeliac disease, but treatment with a gluten-free diet subsequently resulted in increased 
activity.115 Accordingly, the expression and activity of CYP3A4 in children with coeliac 
disease were reduced.116 
1.2.2.6. Microbiota 
The microbiota of patients with coeliac disease was found to be rich in potentially pathogenic 
Gram-negative bacteria and poor in species such as Lactobacilli and Bifidobacteria 
compared to controls.117 After treatment with a gluten-free diet, the microbiota shifted to 
more beneficial species.117 The prevalence of SIBO in patients with coeliac disease is not 
evident due to the heterogeneity of studies (differences in inclusion criteria, no homogeneous 
control groups, low study quality), whereas SIBO prevalence appears to be higher in patients 
with coeliac disease with persisting symptoms following withdrawal of gluten.118-121 
1.2.3. Irritable bowel syndrome 
1.2.3.1. General information 
Irritable bowel syndrome (IBS) is a chronic GI disorder, prevalent in 5-11% of the 
population in most countries, with symptoms such as recurring abdominal pain, bloating and 
changes in the pattern of bowel movements.122 The disease can either be predominated by 
diarrhoea (IBS-D) or constipation (IBS-C) or it can be a combination of both (IBS-M). The 
recrudescence of the symptoms is often linked with psychological stress.  
1.2.3.2. Gastrointestinal transit time/motility and pH 
Gastric emptying time and small intestinal transit time were not significantly different in 
patients with IBS compared to controls measured with a SmartPill GI monitoring system 
(51.23 min (59.1) vs 76.81 min (73.2) and 218.56 min (59.60) vs 199.20 min (82.31)).123 
Differentiation between IBS subtypes revealed that small bowel transit time and total GI 
transit time were shorter in patients with IBS-D (3.3 h (0.3) vs. 4.2 h (0.2) and 35 h (5) vs 
53 h (4)) and prolonged in patients with IBS-C (5.4 h (0.3) vs. 4.2 h (0.2) and 87 h (13) vs 
53 h (4)).124  
The pH profile in patients with IBS in the fasted state was similar to controls throughout the 
four quartiles of the small intestine indicating no alteration in the ionisation of administered 






1.2.3.3. Composition of luminal contents 
The composition of GI fluids in patients with IBS has not been described. Around 32% of 
patients with IBS suffer from moderate bile acid malabsorption with a 10% prevalence of 
severe bile acid malabsorption.125 Patients with IBS-D, showing a decreased bile acid 
deconjugation activity in the faeces, have increased levels of faecal primary bile acids, 
chenodeoxycholic acid, sulphated bile acids and ursodeoxycholic acid and decreased levels 
of faecal secondary bile acids.126 Bile acid deconjugation activity was also decreased in the 
faeces of patients with IBS-C.126 
1.2.3.4. Permeation 
Not all patients with IBS showed an increase in intestinal permeability, but for the subgroup 
of patients with IBS-D a higher intestinal permeability was observed more frequently.127 
Rectal permeability tests in patients with IBS-D observed that the passage of 
macromolecular compounds through rectal biopsies was increased.128 
1.2.3.5. Microbiota 
The GI microbiota of patients with IBS has been analysed in several studies, but inconsistent 
results have been published due to the lack of differentiation between disease subtypes, the 
pathophysiology of the disease and the methods used. Patients with IBS had a higher amount 
of mucosa-associated bacteria at the rectal epithelium than healthy controls.129 The faecal 
microbiota was reduced in the C. coccoides subgroup and the Bifidobacterium catenulatum 
group and a high ratio of Firmicutes to Bacteroidetes was found in a subgroup of patients 
with IBS.130-132 The IBS-D subtype could be distinguished by decreased levels of 
Lactobacillus spp., Bifidobacteria and increased levels of E. coli.126, 129, 132 The microbiota 
of patients with IBS-C was richer in Bacteroides, Veillonella spp. and Bifidobacterium.126, 
132  
1.2.4. Short Bowel Syndrome 
1.2.4.1. General information 
Short bowel syndrome (SBS) is a malabsorption disorder as a result of the loss of a large 
part of the bowel due to surgical resection, congenital defects or disease resulting in a 




impedes absorption and, thus, causes the dehydration and malnutrition with micronutrients 
and macronutrients of patients with SBS which cannot always be overcome with enteral 
supplements.135, 136 Drug absorption can equally be impaired in patients with SBS and for 
poorly absorbed drugs alternative routes of administration should be considered.137 
1.2.4.2. Gastrointestinal transit time/motility and pH 
GI transit time in patients with severe SBS was largely decreased impeding nutrient 
absorption as well as drug absorption.138 Different GI transit times according to the method 
used were observed in patients with SBS: 52.5 min (lactulose hydrogen breath testing), 
967 min (radiopaque markers) and 96.3 min (blue food colour to appear in ostomy effluent 
or stool). Limitations of the methods include that lactulose hydrogen breath testing can only 
be used in patients with intact ileocecal valve and the much longer transit time with a 
radiopaque marker indicates that anatomical changes prevent the passage of the marker.138 
Therefore, stagnation of solid oral dosage forms in the GI tract of SBS patients might also 
occur and result in a different exposure to the absorptive surfaces and increased variability 
of drug absorption.  
The pH profile in the stomach of patients with SBS was similar compared to controls but 
higher pH values in the small intestine (6.03 vs. 5.39) and right colon (6.7 vs. 5.8) were 





Figure 1.3: pH values in the small intestine of SBS patients (x: mean value, HC: healthy 
controls, blue line: mean value of controls, red line: mean value of patients with short bowel 
syndrome). 
1.2.4.3. Composition of luminal contents 
Gastric acid hypersecretion, which can be fivefold greater than basal levels in healthy 
subjects, is often experienced during the acute stage after surgical resection by patients with 
SBS.142 This can result in a pH reduction causing the inactivation of GI fluid components 
such as pancreatic enzymes. Due to adaptation processes the hypersecretion is normalised 
during the first weeks or month after resection.143  
Bile acid malabsorption as a result of the removal of parts of the ileum, their main 
reabsorption area, results in decreased recirculation of bile salts and a spill over of bile salts 
to the colon.142 To compensate for the bile acid loss bile salt production is increased in SBS 
patients, reaching 10 to 20 fold the production of healthy individuals.144 If the increased 




prevent the solubilisation and absorption of fatty acids as well as of lipophilic drugs.145 
Choleretic diarrhoea, caused by increased levels of bile salts in the colon and the subsequent 
loss of chloride and water, could also affect colonic transit time.142 
1.2.4.4. Permeation 
After removal of a large part of the intestine, the remnant parts of the bowel undergo a natural 
adaption process including changes in the expression of membrane transporters in order to 
improve the absorption of nutrients.146 Patients with SBS had an increased amount of PepT1 
mRNA in the colon 1.5–2.5 years after resection with normalization over time (9.8 ± 5.7 
years after resection).147, 148 
1.2.4.5. Microbiota 
The faecal and mucosa-associated microbiota of patients with SBS was deeply altered 
compared to controls. It was rich in Lactobacillus, resulting in a greater absorption of 
carbohydrates in patients with SBS, and the specific species Lactobacillus mucosae was 
prevalent in most samples of SBS patients, while it was not detected in controls.147 
Decreased amounts of C. leptum, C. coccoides, Bacteroidetes, Firmicutes, Bifidobacterium 
and Methanobrevibacter smithii were found in patients with SBS.134, 148 
The higher risk of SIBO in patients with SBS is a result of the stagnation of intestinal 
contents, the impairment of the ileocecal valve and the reduction of the terminal ileum which 
favours bacterial growth in higher parts of the GI tract.142 As a consequence, deficiencies of 
fat-soluble vitamins, problems in fat absorption and increased intestinal permeability can 
occur.142 
In summary, an overview of the changes affecting drug absorption in patients with GI disease 










1.3. Drug-related factors affecting absorption in gastrointestinal diseases 
1.3.1. Molecular weight 
The molecular weight (MW) in conjunction with other physicochemical characteristics such 
as the charge of the molecule, its hydrophilicity and shape determines the pathway and extent 
of drug permeability.149 The rate of diffusion of a drug is inversely proportional to its 
molecular weight with high molecular weight compounds having low permeability.149 
Molecules with MW <200 g/mol can permeate through tight junctions between intestinal 
cells via paracellular passive diffusion.150  
In CD and coeliac disease, ruptures of the tight junctions can increase the permeability of 
larger drugs (MW >200 g/mol) via the paracellular route by impairing the sieve effect of the 
tight junctions (Section 1.2.1.2.3 and 1.2.2.3). In coeliac disease, the decreased absorptive 
surface area hinders the absorption of small drugs (MW <200 g/mol) via the transcellular 
pathway, probably resulting in a decreased bioavailability compared to controls as indicated 
by the decreased permeability of mannitol (Section 1.2.2.3).  
Passive transcellular diffusion is restricted for drugs with MW>500 g/mol whereas lipophilic 
drugs with MW 350±150 g/mol can readily permeate through the intestinal membrane. In 
coeliac disease, no correlation between drug absorption of different antibiotics and their 
molecular weight was observed since sulphamethoxazole (MW 253 g/mol) and 
erythromycin stearate (MW 1018.4 g/mol) showed a similar absorption pattern.151 A 
possible explanation for this may be that the drugs use different pathways to pass the 
epithelial membrane.   
The bioavailability of methyldopa (MW 211 g/mol, BCS class III compound) was 
significantly increased in coeliac disease patients (n = 10, Cmax 5.0 µg/ml (2.2) vs 3.1 µg/ml 
(1.1), AUC 20.5 µg ml-1h (9.6) vs 13.4 µg ml-1h (4.9)), without a change in the 
pharmacological response.152, 153 It should be noted that the patients were already on 
treatment (gluten-free diet), and more pronounced differences could be expected in patients 
without treatment. As levodopa is completely absorbed via efficient transepithelial carrier 
transport and the recovery of methyldopa in urine and faeces was not altered in patients with 
coeliac disease, increased paracellular permeability might not be relevant and the finding 
might be attributed to other factors such as increased renal excretion.154 In contrast, patients 




ml-1h (4.9)) and a reduction in the pharmacological response (sedation, smaller decrease in 
systolic blood pressure).153 
Acetaminophen (BCS class I compound) with a low MW of 151 g/mol is partly absorbed 
via the paracellular pathway.152, 155 Acetaminophen absorption in patients with coeliac 
disease and CD was delayed (coeliac untreated AUC0-1h 9.0 μg min/ml (1.6), coeliac treated 
AUC0-1h 8.2 μg min/ml (2.0), CD 9.3 μg min/ml (3.5) vs. controls AUC0-1h 12.4 μg min/ml 
(3.2)) probably due to delayed gastric emptying, but the overall acetaminophen absorption 
was not impaired as indicated by urinary recovery.156 In patients with SBS, total absorption 
of acetaminophen was decreased as the drug is absorbed in the jejunum, and thus, rectal drug 
administration should be preferred.157 It should be noted that the changes in the jejunal 
morphology due to coeliac disease did not impair the overall absorption of acetaminophen.156 
Tioguanine (MW 167 g/mol, log P -0.07) showed highly variable absorption in patients with 
CD possibly due to altered paracellular passive diffusion, with possible implication in 
treatment.158 Differences in AUC were fourfold to sevenfold, and in two patients, no 
tioguanine absorption was observed within 6 h after oral intake for at least one of three 
different formulations investigated.159 
1.3.2. Lipophilicity 
Lipophilicity has a high influence on the bioavailability of a drug by affecting its solubility, 
permeability and metabolism.160 Drugs can be classified according to their log P in highly 
(log P > 3), moderately (log P 1-3) and low (log P < 1) lipophilic drugs.161 For highly 
lipophilic drugs (log P>3), the dissolution and solubility in the aqueous GI fluids are often 
the rate-limiting factor for drug absorption as only the dissolved part of a drug can permeate 
through the GI membranes and, thus, reach the systemic circulation. Alterations in GI 
diseases can provoke changes in the bioavailability of lipophilic drugs due to changes in GI 
transit times, reduced GI volumes leading to non-sink conditions and increased surface 
tension hindering the wetting of the drug surface. Micellar drug solubilisation can also be 
affected by decreased concentrations of amphiphilic bile components, and a reduction in 
absorptive surface area limits the permeation of drugs via transcellular passive diffusion.  
In CD, decreased amounts of bile acids in the luminal fluids, reduced absorptive surface area 
depending on the location of the disease and increased small intestinal transit time can affect 




the increased concentrations of bile salts and lecithin, increased orocecal transit time and the 
highly decreased absorptive surface area (Section 1.2.2). 
In patients with CD, a highly lipophilic drug, propranolol (log P 3.48, pKa 9.42), showed a 
higher bioavailability and increased plasma levels possibly due to prolonged small intestinal 
transit time. Since propranolol is a highly soluble compound (BCS class I), decreased bile 
salt concentrations are expected to be only secondary.162, 163 Further investigations with 
multiple dosing are needed in order to assess if the increased bioavailability is clinically 
relevant. It should be noted that conflicting results regarding propranolol absorption in 
patients with coeliac disease have been reported with in some cases higher propranolol 
absorption in coeliac disease compared to controls whereas in other cases similar absorption 
was found.4, 102, 162, 164, 165 Higher propranolol absorption correlated in one study with a 
measured higher jejunal surface pH resulting in a higher unionised fraction of propranolol 
but could also be the result of higher bile salt and phospholipid concentrations or the atropic 
mucosa favouring the transport of lipophilic drugs. However, jejunal perfusion showed 
lower propranolol absorption in the jejunum which was apparently compensated in lower 
intestinal parts.165  
For levothyroxine, another highly lipophilic drug (log P 3.51) with a narrow therapeutic 
index, patients with coeliac disease needed higher initial doses to maintain an euthyroid state 
(154 µg (65) vs 106 µg (46)), which decreased (111 µg) after gluten withdrawal.166, 167 This 
could be attributed to the reduced absorptive surface area in the small intestine in patients 
with coeliac disease (Section 1.2.2). 
In CD and UC, the absorption of prednisolone (log P 1.62, BCS class I), a moderately 
lipophilic drug, was delayed possibly attributed to the increased gastric emptying time.152, 
158, 168  
In one study, overall prednisolone absorption in patients with CD was only impaired in 
patients with extensive disease manifestation in the small bowel, whereas in another study, 
a decreased bioavailability of 0.6 (0.2) compared to 0.86 (0.09) in controls was observed 
also for patients with CD with a different disease localisation.168, 169 The authors of the first 
study postulated that the methodology of the latter study might have been more sensitive as 
it included measurements of serum, urine and stool recovery of prednisolone. Highly 




attributed to altered CYP3A4 activity.170 Surprisingly, prednisolone absorption was not 
altered in patients with coeliac disease where absorptive surface area is reduced due to the 
villous atrophy.170, 171 
For drugs with low lipophilicity and high hydrophilicity following paracellular permeability, 
molecular weight (Section 1.3.1) and charge (Section 1.3.3) need to be considered for the 
evaluation of absorption of these drugs in GI diseases.  
1.3.3. Degree of ionisation 
The degree of ionisation influences both the solubility and the permeability of drugs and 
subsequently the rate of drug absorption. The degree of ionisation is dependent on the drug 
itself and the pH value of the enclosed GI fluids. 
Weak bases are protonated and, therefore, more soluble in the more acidic compartments of 
the GI tract (stomach, proximal small intestine). Subsequent increase in pH, when the drug 
enters the duodenum, may result in a supersaturated state and enhance drug absorption.172 
The unionised form of a drug permeates more readily through the GI membrane, and 
therefore, drug absorption of weak bases is higher in GI compartments with higher pH. In 
CD, the pH of the stomach is elevated (Section 1.2.1.2), and decreased solubilisation of weak 
bases would be expected.  
Weak acids are more soluble in GI compartments with a higher pH due to their ionisation 
profile, but membrane permeation for the more ionised fraction of the drug is impeded.173 In 
coeliac disease and SBS, small intestinal pH was higher compared to controls which could 
possibly increase absorption of weak bases (Section 1.2).  
The absorption of a weak acid, folic acid (pKa 4.7), was decreased in patients with coeliac 
disease possibly due to the lower absorptive surface area and the slightly elevated jejunal pH 
(Section 1.2.2) and, therefore, higher ionised amount of folic acid.102, 174 Folate is highly 
absorbed in the more acidic milieu in the duodenum and proximal jejunum as the removal 
of these parts results in folate deficiency that is commonly observed in patients with coeliac 
disease.175 
For two other weak acids, indomethacin (BCS class II) and acetylsalicylic acid (BCS class 
I), no effect on overall absorption was observed in patient with coeliac disease. Only a faster 




for acetylsalicylic acid probably due to faster gastric emptying in the fasted state (Section 
1.2.2.2) or differences in drug permeability.152, 176 Thus, the slightly higher jejunal pH that 
might decrease the unionised fraction of the drug available for absorption has no effect on 
absorption (Section 1.2.2.3). With acetylsalicylic acid, therapeutic outcomes were achieved 
in patients with SBS revealing no impairment of drug absorption.177  
1.4. Formulation-related factors affecting absorption in gastrointestinal diseases 
Pharmaceutical formulations are designed to overcome the challenges of the GI tract and to 
deliver the active pharmaceutical ingredient into the systemic circulation. A variety of 
different approaches is used to optimise the bioavailability, safety and efficacy of the drug. 
Enteric-coated formulations protect the drug from gastric acid or the stomach from the 
toxicity of the drug. Modified-release formulations can ensure constant drug levels, facilitate 
drug therapy by minimizing the administration frequency and deliver the drug locally to 
specific compartments of the GI tract. Immediate-release formulations are a simple approach 
if no further modification of the drug bioavailability is needed. To fulfil their purpose, the 
different formulations are designed based on the conditions of the GI tract in healthy 
subjects, for example, pH, microbiota and transit time (Section 1.2). However, these 
parameters can be altered in patients with GI diseases impacting the drug release/dissolution 
from the formulation. 
1.4.1. Immediate-release formulation 
For immediate release formulations, the disintegration of the pharmaceutical formulation, 
the disaggregation of the granules and finally the dissolution of the particles will be affected 
by the hydrodynamics in the GI tract. Transit times in the different GI compartments, altered 
by GI diseases (Section 1.2), affect the time until the absorption site is reached and the time 
available for absorption. Delayed gastric emptying as observed in CD and untreated coeliac 
disease in the fed state (Section 1.2) can result in a delayed Tmax since for most drugs, the 
main absorptive area is the large surface area of the small intestine. Patients with faster 
gastric emptying may also show a shorter Tmax.
4 Differences in terms of bile salts as observed 
in coeliac disease, CD and SBS (Section 1.2) can affect the wetting of the pharmaceutical 





1.4.2. Modified-release formulation 
1.4.2.1. Time-controlled release 
For the treatment of IBD, pharmaceutical formulations with time-controlled release 
mechanism have been developed to deliver drugs to their target site in the colon. Depending 
on the transit times in the different compartments of the GI tract, the amount of drug 
available in each compartment may vary for these formulations. For UC, a high variability 
in colonic transit time was observed, while in CD, the passage through the colon was 
accelerated (Section 1.2.1.2.1 and 1.2.1.2.2). Faster colonic transit time can lead to a large 
amount of drug not being released, and therefore, failure of the therapeutic effect may occur. 
When a micro pellet formulation of mesalazine coated with ethyl cellulose (Pentasa®, 
Ferring Pharmaceuticals, Copenhagen, Denmark) was administered to healthy subjects, drug 
product performance was not affected by laxative-induced diarrhoea.178, 179 Thus, reduced 
colonic transit time as observed in CD (Section 1.2.1.2.2) is not expected to affect drug 
release from this formulation.  
Administration of an enteric coated multimatrix formulation of mesalazine (Mezavant®, 
Shire Pharmaceutical Contracts Ltd, London, UK; Lialda®, Shire US Inc., Massachusetts, 
USA) in patients with UC could be affected by longer small intestinal and colonic transit 
times, as following the dissolution of the gastro-resistant coating drug release occurs after 
diffusion from the lipophilic and hydrophilic matrix (Section 1.2.1). Drug release might 
occur in more proximal GI compartments differing from controls in which disintegration of 
the formulation was observed between 4.8 and 17.4 h after administration.178  
Administration of a controlled release pellet formulation of budesonide (Entocort®, 
AstraZeneca UK Ltd, London, UK) showed increased systemic bioavailability in patients 
with CD compared to controls (20.5% (15.1, 27.8) vs. 11.5% (8.8, 15.0), AUC0-∞ 
114.0 nmol*h ⁄ L (81.4, 159.5) vs. 60.4 nmol*h ⁄ L (45.1, 80.8)).40 This effect could be 
attributed to the delayed gastric emptying observed and other factors such as the composition 
of GI fluids, differences in permeability and the colonic bacterial and intestinal metabolism. 
Differences in the pharmacokinetics of budesonide in patients with CD could possibly result 





1.4.2.2. pH-controlled release  
The alteration of the typical pH profile in GI compartments changes the release profile of 
pharmaceutical formulations with pH sensitive coatings. For enteric coated formulations, the 
reduction in acid in the stomach in CD can lead to premature drug release in the stomach 
(Section 1.2.1.2.2). Increased gastric residence time as observed in coeliac disease, UC and 
CD could delay drug absorption of enteric coated formulations (Section 1.2). 
Different mesalazine formulations with pH-controlled release behaviour are available for the 
therapy of IBD. Formulations with a coating of Eudragit L® (e.g. Salofalk®, Dr Falk GmbH, 
Freiburg, Germany), dissolving at pH ≥6, target the mid-ileum and colon, whereas a tablet 
coated with Eudragit S® (e.g. Asacol®,Tillotts Pharma AG, Ziefen, Switzerland), dissolving 
at pH ≥ 7, targets the terminal ileum and colon.178 Based on the lower colonic pH values in 
UC (Section 1.2.1.2.1), impairment of drug release from these formulations may take place 
where failure to reach the pH needed for dissolution of the polymer coating occurs.  
1.4.3. Azo-bonded prodrug formulations 
Colonic drug delivery, often used in IBD, can be achieved by administering prodrugs or 
polymer coatings, which are cleaved by colonic bacterial enzymes such as azoreductase 
leading subsequently to the release of the active metabolite/drug.  
In GI diseases, three different aspects can affect drug release of azo-bonded prodrugs such 
as sulfasalazine and olsalazine. Firstly, a decreased intestinal transit time has been associated 
with less exposure of the prodrugs to bacterial action and enhanced faecal loss of the 
prodrugs.179 The therapeutic efficacy could be affected in some IBD patients as colonic 
transit time was highly variable (Section 1.2.1.2). Secondly, reduced activity of bacterial 
azoreductase as observed in CD (Section 1.2.1.6.2) could lead to reduced prodrug activation. 
Thirdly, small intestinal bacterial overgrowth as observed in CD and UC (Section 1.2.1.6) 
could provoke prodrug activation in upper parts of the GI tract.  
1.5. Methods to predict drug product performance 
Throughout the different stages in pharmaceutical drug development, in vitro biorelevant 
release/dissolution models linked with physiologically based pharmacokinetic (PBPK) 
models are used to predict drug product performance.12, 180 Media, that simulate closely the 




bile salts and lipids, are termed biorelevant. By using biorelevant media and applying 
hydrodynamics to reflect the conditions in healthy subjects, successful predictions of the 
drug product performance can be established with in vitro dissolution/release testing.181, 182 
Nowadays, in vitro dissolution/release profiles are often further linked with PBPK models 
resulting in better in vivo predictions of drug bioavailability.183-185 It should be noted that the 
design of in vitro dissolution/release and PBPK models is based on conditions in healthy 
subjects. A remaining challenge is the prediction of drug product performance in patients 
with GI diseases where absorption is expected to be impaired (Section 1.2). Therefore, the 
development of biorelevant in vitro dissolution/release tests in patients with GI diseases 
linked with PBPK models would be desirable. In the following sections, the need to develop 
both in vitro dissolution/release tests and PBPK models reflecting conditions found in GI 
disease which can be confidently used to predict drug product performance is discussed. 
1.5.1. In vitro dissolution and release testing 
In vitro dissolution testing has been established in the pharmaceutical industry for quality 
control purposes for stability testing and to assure batch to batch consistency. For drug 
development, biorelevant in vitro dissolution and release testing is used for the development 
of pharmaceutical formulations, to predict the in vivo performance of a drug product and to 
develop in vitro/in vivo correlations (IVIVC) with the intention to reduce time-consuming 
and cost-intensive animal or human studies. For the development of a suitable biorelevant 
in vitro dissolution testing method, the physicochemical characteristics of the drug and the 
physiological conditions in the GI tract should be considered. Current in vitro dissolution 
tests incorporate hydrodynamic conditions and media based on the physiological conditions 
in healthy subjects.  
There is a need for biorelevant dissolution methodology to simulate the GI conditions in 
patients with GI diseases since pathophysiological changes (Section 1.2) are expected to 
have an impact on drug solubilisation and dissolution and subsequently on drug absorption. 
Currently, no in vitro dissolution and release tests reflect changes observed in patients with 
GI diseases.  
In vitro dissolution and release tests used for drugs in GI diseases, especially IBD, have been 
developed reflecting mainly the GI pH profile in healthy subjects. To study the release and 




vitro dissolution methods have been developed (Figure 1.5).186-189 In terms of media, GI 
fluids were simulated using simple pharmacopeia buffers (SGF, SIF and SCoF), biorelevant 
media (Fasted-State Simulated Intestinal Fluid) or media enriched with enzymes. Different 
buffer systems were used (phosphate and bicarbonate), whereas bicarbonate buffers were 
superior in predicting the in vivo performance of mesalazine formulations.190 The passage 
through the different GI compartments is simulated by media changes, modifications of the 
pH value at various time points and the total duration of the experiment (360-1440 min). The 
models vary in the applied hydrodynamics due to differences in volumes of the media (200-
1000 ml), in the agitation rate (50-100 rpm, 10 dips/min) and in the choice of the dissolution 
apparatus (USP II or III dissolution apparatus).  
Bacterial enzymatic action, needed for colon-targeting drug delivery, was included in in vitro 
dissolution tests with USP dissolution apparatus in several ways spanning the simple 
addition of enzymes to the addition of rat caecal contents and human faecal slurries.191 Drug 
metabolism by intestinal microbiota can further be tested in more complex in vitro GI 
simulators such as semi-continuous culture systems and continuous culture systems (e.g. 
TNO TIM-2 in vitro model of the colon) with anaerobic conditions in which pH, temperature 
and redox potential can be controlled.11, 192, 193 
For the development of biorelevant in vitro dissolution and release tests for patients with GI 
diseases, pathophysiological changes in terms of media, hydrodynamics and microbiota 






Figure 1.5: In vitro dissolution/release models for modified release dosage forms; a: Klein et al190, b: Schellekens et al187, c: Ahmed and Ayres189, 










1.5.2. PBPK models 
PBPK models use preclinical in vitro data, physicochemical drug properties and 
physiological parameters to predict in vivo plasma concentration-time profiles.12 PBPK 
modelling was first introduced to assess the toxicology of drugs and was in recent years 
established as useful biopharmaceutical tool to predict drug bioavailability. The 
mathematical modelling framework used incorporates the different compartments of the GI 
tract and evaluates absorption, distribution, metabolism and elimination of the studied 
compound. 
For patients with GI diseases, PBPK models present a special opportunity to improve their 
drug therapy. Pathophysiological changes can affect drug absorption (Section 1.2), but only 
a minor part of drugs and pharmaceutical formulations is tested in a GI disease population. 
Especially for the medication of concomitant conditions, for example oncological or 
cardiovascular drugs, the impact of the GI disease on drug product performance is unknown. 
As human studies are very cost-intensive, this might not change in the coming years 
considering the heterogeneous and therefore small patient population in the different types 
of GI disease. Establishing predictive in silico models for the different GI disease states can 
help to implement appropriate dosing regimen and improve drug therapy management. 
For GI diseases, PBPK models should include all the pathophysiological changes relevant 
for drug absorption in patients with GI diseases compared to healthy subjects (Section 1.2). 
However, due to only a limited number of studies with small patient populations and a high 
inter- and intra-study variability, the characterisation of the pathophysiological changes is 
challenging. Up to now, no PBPK models for patients with GI diseases have been developed, 
but recently, a PBPK model for patients after bariatric surgery (post sleeve gastrectomy, post 
Roux-en-Y gastric bypass, post biliopancreatic diversion with duodenal switch, post 
jejunoileal bypass) was developed.194 The virtual model showed that the bioavailability of 5 
drugs (omeprazole, diclofenac, fluconazole, ciprofloxacin, simvastatin) in patients after 
bariatric surgery was highly dependent on drug-specific parameters. The model, based on 
the template for morbidly obese in the Simcyp Simulator v10 (Simcyp Limited, Sheffield, 
UK), integrated changes in gastric volume and emptying rate, GI pH, differences in small 
intestinal dimensions and motility, transit time, bile properties, renal function and serum 
protein levels as observed in literature. Predictions of oral bioavailability of atorvastatin and 
cyclosporine in patients post Roux-en-Y gastric bypass were confirmed by clinical data; 
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however, the absorption of atorvastatin was not captured in the model for patients with post 
biliopancreatic diversion with duodenal switch.195 
1.6. Conclusion and outlook 
Further elucidation of drug absorption profiles in patients with GI diseases could be highly 
beneficial. The significance of current studies is often limited by small patient populations, 
conflicting data and the difficulty to assess changes in different disease states. More in vivo 
data is needed to further assess the GI physiological conditions in patients with GI diseases. 
Oral absorption already shows a high interindividual variability in healthy adults. Different 
disease states and disease localisation make it even more difficult to assess absorption 
profiles in this heterogeneous group. In order to improve drug therapy for patients with GI 
diseases, their medication should be tested under conditions specific to the particular 
pathophysiology. The ability to predict the in vivo performance of drug products in patients 
with GI diseases will be contingent on the development of appropriate biorelevant 
dissolution testing linked with PBPK models simulating pathophysiological conditions. 
Medication for concomitant diseases is seldom tested in GI disease patients. For these drugs, 
the development of more cost-effective and less time-consuming alternatives to expensive 
clinical trials would represent an opportunity to improve drug therapy. Predicting the 
probability that a drug will be affected by certain GI diseases depending on its 
physicochemical properties, would further limit the amount of experimental and 
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Gastrointestinal diseases and their impact on drug 




Biorelevant media representative of Crohn’s disease (CD) patients were developed using a 
Design of Experiment (DoE) approach to investigate differences in drug solubility and 
dissolution in luminal fluids of CD patients compared to healthy subjects. The CD media 
were characterised in terms of surface tension, osmolality, dynamic viscosity and buffer 
capacity and compared to healthy biorelevant media. To identify which drug characteristics 
are likely to present a high risk of altered drug solubility in CD, the solubility of six drugs 
was assessed in CD media and solubility differences were related to drug properties. 
Key findings 
Identified differences in CD patients compared to healthy subjects were a reduced 
concentration of bile salts, a higher gastric pH and an increased colonic osmolality. 
Differences in the properties of CD compared to healthy biorelevant media were mainly 
observed for surface tension and osmolality, suggesting differences in the wetting and 
swelling behaviour of drugs and formulations. Drug solubility of ionisable compounds was 
altered in gastric CD media compared to healthy biorelevant media. For drugs with moderate 
to high lipophilicity, a high risk of altered drug solubilisation in CD is expected, since a 
significant negative effect of log P and a positive effect of bile salts on drug solubility in 
colonic and fasted state intestinal CD media was observed. 
Conclusions  
Simulating the conditions in CD patients in vitro offers the possibility to identify relevant 
differences in drug solubilisation without conducting expensive clinical trials. To increase 
the confidence in the risk assessment tools, further studies investigating the composition of 




Inflammatory bowel disease (IBD) is an incurable autoinflammatory disorder that affects 
about 3.7 million people in Europe.1 While the aetiology of IBD is still unknown, a 
combination of factors (environment, genetics, microbiota) is expected to contribute to the 
disease.2 The two main types of IBD are Crohn’s disease (CD) and Ulcerative colitis. CD is 
characterised by transmural discontinuous ulcerations that can affect any part of the 
gastrointestinal (GI) tract. Typical symptoms that patients experience are abdominal pain 
and cramps, fatigue, fever, weight loss and diarrhoea with passage of blood and/or mucus.3 
Within the first 20 years after CD diagnosis, 50% of patients present complications such as 
strictures, fistulas, abscesses or obstructions.3 These complications often necessitate 
surgeries and bowel resections.4 Apart from the affected GI tract, extraintestinal symptoms 
are also common in CD patients including inflammations of the eyes such as uveitis or 
episcleritis, certain skin conditions such as pyoderma gangrenosum and joint diseases such 
as ankylosing spondylitis.5 Therefore, CD necessitates a long-term drug therapy adapted to 
the disease localisation and disease state (relapse or remission). 
Despite the location of the disease in the GI tract, drug therapy of CD patients relies highly 
on the oral route of drug administration. Recommended oral therapies for CD patients 
include 5-aminosalicylates (e.g., sulfasalazine, mesalamine), traditional corticosteroids (e.g., 
prednisone), budesonide, antibiotics (e.g., metronidazole) and immunosuppressive agents 
(e.g., azathioprine).6 To locally treat the disease in the GI tract, special drug delivery systems 
have been developed to deliver the drug to the affected GI compartment. Apart from 
medication for the GI condition, IBD patients also used other drug classes such as 
antidepressants, antibiotics and nonsteroidal anti-inflammatory analgesics more frequently 
compared to the general population.7  
Oral drug delivery depends highly on drug absorption. To reach the systemic circulation, the 
drug must be released from the pharmaceutical formulation, dissolve in the GI fluids, 
permeate the GI membrane and escape luminal degradation, gut wall and hepatic 
metabolism. These processes depend on the physiological conditions in the GI tract. 
Alterations of the physiological conditions due to disease states, can impact on drug product 
performance which has been observed for several drugs in GI disease patients.8 For poorly 
soluble compounds, classified according to the Biopharmaceutics Classification System 
(BCS) in class II or IV, drug absorption can be solubility- or dissolution rate-limited.9 
Differences in the composition of the GI fluids such as pH, osmolality, bile salt and lecithin 
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concentrations can impact on these rate-limiting steps, and thus, affect drug absorption.10, 11 
Pathophysiological changes in CD may alter the composition of the luminal fluids in the GI 
tract of CD patients and therefore, potentially result in altered drug product performance. 
Differences in drug product performance in GI disease patients compared to healthy subjects 
are rarely assessed in clinical trials due to high costs and small patient populations. The 
development of in vitro tools to assess the impact of CD on drug absorption could thus, 
improve the drug therapy of CD patients. 
For healthy subjects, biorelevant media closely simulating GI fluids of different GI 
compartments and prandial states have been developed to evaluate drug product performance 
in vitro using solubility or dissolution studies.12-16 This approach has previously been 
extended to special populations with the development of biorelevant media for paediatrics 
or hypochlorhydric and achlorhydric people.17, 18 Since drug product performance is 
influenced by a multitude of factors, the results from these in vitro studies can also be used 
as input in physiologically-based pharmacokinetic (PBPK) models taking into account all 
ADME (absorption, distribution, metabolism, and excretion) processes. 
The aim of this study was to develop biorelevant media representative of the stomach, 
intestine and colon of CD patients based on literature data and healthy biorelevant media, as 
a cost- and labour-effective tool to assess the risk of altered luminal drug solubility in 
patients with GI diseases in vitro. To take into account the interindividual variability in 
patients with CD, a Design of Experiment (DoE) approach was followed. The developed 
simulating GI fluids representing patients with CD were characterised according to their 
surface tension, osmolality, buffer capacity and dynamic viscosity. The solubility of six 
drugs, belonging to BCS class II or IV and possessing different physicochemical 
characteristics, was assessed in CD biorelevant media. The solubility results were analysed 
with partial least squares (PLS) regression to identify the impact of media-dependent factors 
on the solubility of the investigated drugs according to their physicochemical characteristics. 
2.2. Materials 
Acetic acid HPLC grade, methanol, pepsin from porcine gastric mucosa, sodium oleate, α-
D-glucose, budesonide, phosphoric acid and sodium hydroxide were purchased from Sigma-
Aldrich Company Ltd., Dorset, England. Sulfasalazine, loperamide hydrochloride, 
dipyridamole, celecoxib, azathioprine, methanol HPLC grade, acetonitrile HPLC grade and 
cholic acid sodium salt were purchased from VWR International Ltd, Lutterworth, UK. 
Tris(hydroxymethyl)aminomethane, hydrochloric acid 36.5–38%, sodium chloride, 
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trifluoroacetic acid (TFA), potassium dihydrogen orthophosphate and maleic acid were used 
from Fisher Scientific UK Ltd., Loughborough, England. Other chemicals used included 
sodium taurocholate (Prodotti Chimici Alimentari S.P.A., Basaluzzo, Italy), egg lecithin–
Lipoid EPCS (Lipoid GmbH, Ludwigshafen, Germany) and glyceryl monooleate–Rylo Mg 
19 (Danisco, Brabrand, Denmark). Water was ultra-pure (Milli-Q) laboratory grade. 
2.3. Methods 
2.3.1. Media development 
For the development of biorelevant media for CD patients, a DoE approach (Section 2.3.3) 
was followed to reflect interpatient variability. Briefly, relevant differences in CD patients 
compared to healthy subjects were identified in literature, a low and a high concentration 
level was defined based on the available data and the differences were integrated as factors 
with two levels in the DoE. Healthy biorelevant media were used as reference for all media 
properties and components that were not used as factors in the DoE. 
2.3.2. GI physiological differences in CD compared to healthy subjects 
A literature search was performed to identify differences in the GI fluid composition of CD 
patients compared to healthy subjects. Due to the low number of studies investigating the 
concentration of GI fluid components in CD, studies investigating parameters that are likely 
to impact on GI fluids were also considered (e.g., bile acid pool). For parameters that were 
directly measured in the GI fluids, the observed range was included in the experimental 
design with the minimum value observed representing the low level of the factor and the 
maximum value representing the high level of the factor. For parameters that were not 
directly measured in the GI fluids, an indirect percental approach was followed to determine 




∗ 𝑥𝐻−𝐵𝑀         (2.1) 
where 𝑥𝐶𝐷−𝐵𝑀 is the high or low level of the factor in CD media, 𝑦𝐶𝐷 and 𝑦𝐻 are the median 
of the corresponding parameter observed in studies of CD patients and healthy subjects, 
respectively and 𝑥𝐻−𝐵𝑀 is the level of the factor in healthy biorelevant media. In the case of 
a decrease of the factor in CD patients compared to healthy subjects, Equation 2.1 was used 
to set the low level and the high level was set to the level in healthy biorelevant media. The 
opposite was the case for an increase of the factor in CD. For the factor bile salt 
concentration, the bile acid pool was the corresponding parameter and for the factor colonic 
osmolality, the osmolality of the faecal fluid was the corresponding parameter. 
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2.3.2.1. Bile acid pool 
Bile acids, after being synthesised in the liver, are secreted into bile and further undergo a 
process of enterohepatic recirculation including reabsorption from the terminal ileum, return 
to the liver and again secretion into bile.19 The physiological function of bile salts includes 
e.g., the elimination of cholesterol, lipid transport due to micellar solubilisation and the 
stimulation of bile flow and biliary phospholipid secretion.19 The bile acid pool is the total 
amount of bile acids circulating in the enterohepatic circulation. CD can affect any part of 
the GI tract but most frequently the inflammation is localised in the terminal ileum, the main 
reabsorption area of bile salts. Several studies investigated the size of the bile acid pool in 
CD patients compared to healthy subjects, revealing a reduction to 38-58% of the size in 
healthy subjects (Table 2.1).20-22 An increased loss of bile salts can be compensated by higher 
production. However, constant bile salt loss during the day, when bile salts are released as 
response to meals, is expected to lower the bile salt concentrations in GI fluids. Bile salts are 
present in the luminal fluids of all GI compartments and thus, lower bile salt concentrations 
were integrated in the DoE of all CD media. 
  
Table 2.1: Bile acid pool in CD patients and controls. 
 
Bile acid pool 
healthy [g] 






 2.29 (0.33) 1.32 (0.17) 8/4 20 
 3.09 (0.27) 1.48 (0.16) 10/14 21 
 3.10 (0.27) 1.18 (0.2) 13/10 22 




2.3.2.2. pH in the stomach 
The pH profile in the stomach of CD patients was in the range of 1.5 to 4.1 as investigated 
in two studies.23, 24 A higher pH was also indicated by a reduced gastric acid secretion 
observed in CD patients, being especially strong if patients were malnourished with a mean 
basal acid output of 0.64±0.33 mEq/h (malnourished) and 2.12±0.88 mEq/h (after nutritional 
support) vs 3.85±0.93 mEq/h in controls and a maximal acid output of 7.36±1.38 mEq/h 




2.3.2.3. Osmolality in the colon 
The faecal osmolality in CD patients was increased by 32% to 52%, as observed in two 
studies (Table 2.2).26, 27 This observation was accompanied with a large osmotic gap 
indicating osmotic diarrhoea in CD patients from osmotic active agents other than 
electrolytes, for example undigested carbohydrates. Since these undigested components are 
already present in the large intestine, an increased osmolality in the colon is expected for 
patients with CD. Therefore, an increased osmolality in colonic luminal fluids was reflected 
by integrating the osmolality as factor in the DoE of colonic CD media. 
Table 2.2: Osmolality of the faecal fluids of CD patients and controls. 








 487 (87) 321 (254-464) 13/11 26 
 463 (21) 350 (20) 20/16 27 
Median 475 336   
 
2.3.3. Design of CD media with Design of Experiment 
The media development for CD patients followed a DoE approach. Biorelevant media 
developed for healthy subjects (Table 2.3) were used as reference and modifications were 
made to reflect the changes in the composition of luminal contents in patients with CD 
(Section 2.3.2). For the gastric medium in the fasted state, pH (p) and bile salt (b) 
concentration were included as factors in the DoE. For intestinal media, the bile salt (b) 
concentration was included as single factor. For colonic media, osmolality (o) and bile salt 
(b) concentration were included as factors. The DoE was performed using XLSTAT 
(Addinsoft, France) with a full factorial design in CD patients for stomach, intestine, colon 
in the fasted state and intestine and colon in the fed state. Each parameter changed in CD 
compared to healthy subjects was integrated in the DoE as factor with two levels, low (l) and 
high (h), resulting in 17 CD media (Figure 2.1): 
- CD- Fasted-State Simulated Gastric Fluid (FaSSGF): changed parameters pH, bile 
salts (lp-lb, hp-lb, lp-hb, hp-hb) 
- CD- Fasted-State Simulated Intestinal Fluid (FaSSIF): changed parameter bile salts 
(only one medium, high bile salt medium corresponds to FaSSIF-V2) 
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- CD- Fasted-State Simulated Colonic Fluid (FaSSCoF): changed parameters 
osmolality, bile salts (lb-lo, hb-lo, lb-ho, hb-ho) 
- CD- Fed-State Simulated Intestinal Fluid (FeSSIF): changed parameter bile salts 
(only one medium, high bile salt medium corresponds to FeSSIF-V2) 
- CD- Fed-State Simulated Colonic Fluid (FeSSCoF): changed parameters osmolality, 
bile salts (lb-lo, hb-lo, lb-ho, hb-ho) 
Additionally, a centre point with medium (m) levels of each parameter was included for CD-
FaSSGF (mp-mb), CD-FaSSCoF (mb-mo) and CD-FeSSCoF (mb-mo).  
In terms of the levels set for the factors in the DoE, the pH range observed in the stomach of 
CD patients was included with 1.5 as low level and 4.1 as high level for fasted state gastric 
CD media (Section 2.3.2.2). For the bile salt concentrations in all CD media, the low level 
was set based on the percental approach described in Section 2.3.2.1 corresponding to 43% 
of the concentration in the corresponding healthy biorelevant media. The ratio of bile salts 
to lecithin was kept constant in all CD media and set according to the ratio in healthy 
biorelevant media (Table 2.3), in order to reflect the mixed micelles in GI fluids. For the 
osmolality in the colonic CD media, the high level was based on the percental difference 
(Section 2.3.2.3) with 142% of the osmolality in corresponding healthy biorelevant media. 
Sodium chloride was used to adjust the osmolality in the respective colonic CD media. For 
all other CD media (osmolality not included as factor in the DoE), the osmolality was 
adjusted to the value of the corresponding healthy biorelevant medium.  
The method described by Jantratid et al was followed for the preparation of gastric and 
intestinal biorelevant media.14 Colonic biorelevant media were prepared according to 




Table 2.3: Biorelevant media representing conditions in healthy subjects. 
Medium FaSSGF FaSSIF-V2 FaSSCoF FeSSIF-V2 FeSSCoF 
Sodium chloride 
[mM] 
34.20 68.60  125.50 34.00 
1 M HCl qs pH 1.60     
Sodium taurocholate 
[mM] 
0.08 3.00  10.00  
Lecithin [mM] 0.02 0.20 0.36 2.00 0.50 
Pepsin [mg/mL] 0.10     
Maleic acid [mM]  19.10 75.80 71.90 30.15 
NaOH [mM]  34.80 120.00 102.40 16.50 
Sodium cholate [mM]   0.15   
Tris [mM]   45.40  30.50 
Sodium oleate [mM]   0.10 0.80 0.20 
Glycerol monooleate 
[mM] 
   5.00  
Glucose [mg/ml]     14.00 
Osmolality 
[mOsm/kg] 
121 180 196 390 207 






Figure 2.1: Design of Experiment for the development of biorelevant media for CD patients.
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2.3.4. Media characterisation  
Healthy biorelevant media and biorelevant media developed for CD were characterised 
according to their surface tension, osmolality, dynamic viscosity and buffer capacity. All 
experiments were performed in triplicate and results are presented as mean with standard 
deviation. 
2.3.4.1. Surface tension  
A Du Noüy ring tensiometer (Sigma 700 Force tensiometer, Attension, UK) was used to 
measure the surface tension of biorelevant media. Therefore, a platinum ring is lifted from 
the surface of the medium and the required force for the raising of the ring is measured. The 
surface tension of the medium can be related to the measured force according to  
𝐹 = 𝑤𝑟𝑖𝑛𝑔 + 2𝜋 ∗ (𝑟𝑖 + 𝑟𝑎) ∗ 𝛾       (2.2) 
where 𝐹 is the force, 𝛾 is the surface tension, 𝑤𝑟𝑖𝑛𝑔 is the weight of the ring and 𝑟𝑖 and 𝑟𝑎 
are the inner and outer radius of the ring, respectively.28 
2.3.4.2. Osmolality  
The osmolality of the media was determined with an Advanced Instruments Inc. micro-
osmometer Model 3300 (Norwood, MA, US) by measuring the freezing-point depression of 
a 20 µl sample. After the supercooling of the sample, crystallisation was induced by 
mechanical agitation and the temperature when the sample was in a solid/liquid equilibrium 
was measured. Osmolality was subsequently calculated since freezing-point depression is a 
colligative property (freezing point depression by 1.858 m°C corresponds to 1 mOsm/kg). 
2.3.4.3. Dynamic viscosity  
Dynamic viscosity was measured with a Bohlin Rheometer C-VOR (Malvern instruments, 
UK) using a cone-plate system (4°,40 mm). A range of shear stresses (20 points, 
logarithmically distributed between 0.05 and 0.15 Pa) were applied to the sample of the 
medium tempered at 37⁰C and the shear rate was measured. Dynamic viscosity was 
calculated as the ratio of shear stress to shear rate. 
2.3.4.4. Buffer capacity 
Buffer capacity was measured by subsequently adding volumes of 0.5 M hydrochloric acid 
to 10 mL sample until a change of one pH unit was recorded by a Mettler Toledo 
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SevenCompact S220 pH meter (Schwerzenbach, Switzerland). The buffer capacity (β) was 







       (2.3) 
where Macid is the molarity of the acid used, Vacid is the added volume of the acid, Vsample is 
the volume of the sample and ΔpH corresponds to the change in pH.29  
2.3.5. Compound selection 
For the solubility studies, poorly soluble compounds belonging to BCS class II (low 
solubility, high permeability) or IV (low solubility, low permeability) were selected. While 
drugs with an indication for GI diseases were preferred, the main selection criterion was to 
cover a range of different physicochemical properties. Therefore, the six drugs vary in their 




































477.0 8.6 (base)41 5.542 II40 Anti-diarrheal agent 
Sulfasalazine 
 
398.4 2.3, 7.9 
(acid) 43  
2.944 II/IV32 Anti-inflammatory 
agent in IBD 
 
2.3.6. Solubility studies 
The solubility studies of the investigated drugs were performed using the shake-flask 
method.45 Therefore, 5 mL of medium were transferred to a glass tube with an excess amount 
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of drug. The glass tube was placed for 24 h in a shaking water bath (Grant instruments, 
Royston, UK) (37°C, 200 strokes/min). Subsequently, the supernatant was filtered with 
GF/D membrane filters with a pore size of 2.7 μm (Whatman® Puradisc, diameter 13 mm) 
and analysed by HPLC-Ultraviolet (UV). Solubility studies were performed in triplicate in 
17 CD media and for comparison in 5 healthy media. Average solubility differences between 
CD media and healthy media were expressed as % Relative Effect on solubility [((SCD-
SHealthy)/ SHealthy) x 100)]. Positive values indicate that drug solubility in CD media exceeds 
the solubility in healthy media, whereas negative values indicate the opposite. HPLC 
analysis was performed with an Agilent Technologies 1200 series HPLC system (Santa 
Clara, CA, US): binary pump (G1212A), autosampler (G1329A), thermostatted column 
compartment (G1316A) and diode array detector (G1315D). HPLC-UV methods used for 
the quantitative analysis are presented in Table 2.5.  
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Table 2.5: HPLC-UV analytical methods used for the quantification of investigated drugs. 
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2.3.7. Statistical analysis 
One-way analysis of variance (ANOVA) with a post-hoc Tukey’s test was applied to identify 
statistically significant differences of media properties and drug solubility between healthy 
biorelevant media and various biorelevant media of CD patients. Therefore, the software 
XLSTAT (Addinsoft, France) was used with a significance level of p≤0.05. 
Multivariate statistical analysis was used to identify drugs at risk of altered drug 
solubilisation in CD according to their physicochemical properties. Hence, the % Relative 
Effect on drug solubility ((SCD-SHealthy)/ SHealthy) x 100) was correlated with media-dependent 
factors of the DoE and drug physicochemical properties by Partial Least Squares (PLS) 
regression using the software XLSTAT (Addinsoft, France). Media-dependent factors were 
for gastric fasted state CD media the bile salt concentration and pH, for intestinal CD media 
in the fasted and fed state only the bile salt concentration and for colonic CD media in both 
prandial states the bile salt concentration and osmolality. In terms of drug-dependent 
parameters, the n-octanol:water partition coefficient, log P, was included for all CD media. 
For media with pH as media-dependent factor (CD-FaSSGF), a categorical variable 
discriminating between weak acids, weak bases and neutral compounds was introduced. For 
the remaining CD media (CD-FaSSIF, CD-FaSSCoF, CD-FeSSIF, CD-FeSSCoF), the % 
Fraction ionised (calculated using Advanced Chemistry Development, Inc. (ACD/Labs) 
Software V11.02, Toronto, On, Canada and defined for anionic species as negative and 
cationic species as positive), was integrated as additional drug-dependent factor.51 
Interactions between media- and drug-dependent factors were included in the model. The 
quality of the obtained models was evaluated based on the square of coefficient of 
determination (r2) and goodness of prediction (q2), indicating when close to 1 a good fit of 
the data and a good predictive ability of the model, respectively. Highly disparate r2 and q2 
(difference higher than 0.3) indicate inappropriate models due to model over-fitting.52 
Models were selected based on the minimum predicted residual error sum of squares 
(PRESS) and the highest q2 representing optimum model predictability. A q2 higher than 0.5 
generally indicates good model predictability, but it should be noted that q2 is dependent on 
the properties of the data set, thereby impeding the setting of a general limit.53 The effect of 
media- and drug-dependent factors on the % Relative Effect on solubility is shown by their 
standardised coefficients with high values designating a considerable influence, positive 
values designating a positive effect and negative values a negative effect. Factors with a 
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Variable Importance in Projection (VIP) higher than or equal to 0.7 are the most influential 
factors in the model and were considered as statistically significant.52 
2.4. Results and discussion 
2.4.1. Media characterisation 
Surface tension of CD and healthy biorelevant media is presented in Figure 2.2. In gastric 
media, the surface tension was significantly higher in all CD-FaSSGF media (hp-hb +12%, 
mp-mb +13%, lp-lb +15%, hp-lb +24%,) except CD-FaSSGF lp-hb compared to FaSSGF 
(p<0.05). A higher surface tension of CD-FaSSGF media with low and medium bile salt and 
lecithin concentrations could be due to bile salt and lecithin concentrations being below the 
critical micellar concentration (CMC). For fasted state intestinal media, the surface tension 
of the CD medium was significantly increased by 9% compared to the corresponding healthy 
medium (p<0.05). This is in agreement with a previous study showing a higher surface 
tension for fasted state simulating fluids with reduced bile salt concentrations.54 Considering 
the surface tension of fasted state colonic media, only for CD-FaSSCoF lb-ho the surface 
tension was with 8% significantly decreased compared to FaSSCoF (p<0.05). In fed state 
intestinal media, the CD medium showed a significantly lower surface tension (-8%) 
compared to FeSSIF-V2. This slight decrease in surface tension with lower sodium 
taurocholate concentrations has previously been observed for fed state simulated intestinal 
fluids in a range of 1-7 mM, and could be related to the reduced concentration of surfactants 
being above the CMC.54 For fed state colonic media, the surface tension of CD-FeSSCoF 
mb-mo, lb-lo, lb-ho was significantly decreased by -11%, -22% and -28%, respectively 
compared to the corresponding healthy medium (p<0.05). 
Osmolality in CD fasted state gastric and intestinal media and fed state intestinal media was 
similar to the corresponding healthy biorelevant media as presented in Figure 2.2. 
Differences in osmolality were observed when osmolality was integrated as factor in the 
DoE according to the specified levels, which was the case for fasted and fed state colonic 
CD media. The altered osmolality in colonic media can have an impact on the dissolution 
rate of certain drugs due to a common ion effect and therefore, the conversion of the drug to 
another salt.55 Additionally, osmolality can affect the swelling behaviour of polymers 





Figure 2.2: Surface tension (blue, left y-axis) and osmolality (red, right y-axis) of CD 
biorelevant media according to the Design of Experiments (green: high level, yellow: 
medium level, red: low level, white: healthy level) and healthy media (H).  
 
The dynamic viscosity of CD biorelevant media at three different shear stresses is presented 
in Figure 2.3. All investigated biorelevant media showed pseudoplastic behaviour. With an 
applied shear stress of 0.06 Pa, the dynamic viscosity of CD biorelevant media was in the 
range of 4.23 mPas to 6.67 mPas. An increase of the shear stress to 0.08 Pa and 0.15 Pa, 
resulted in a reduced viscosity in the range of 3.36 mPas to 4.92 mPas and 2.86 mPas to 3.85 
mPas, respectively. Significant differences with application of the three different shear 
stresses were only observed for all CD-FaSSGF media, which possessed a significantly 




Figure 2.3: Dynamic viscosity of CD biorelevant media according to the Design of 
Experiments (green: high level, yellow: medium level, red: low level, white: healthy level) 
and the corresponding healthy biorelevant media (H) at different shear stress (0.06 Pa: blue, 
0.08 Pa: red, 0.15 Pa: black). 
 
Buffer capacity was not altered in intestinal and colonic CD media compared to the 
corresponding healthy media due to the use of the same buffer system and no changes in pH 
value (data not shown). 
2.4.2. Solubility of drugs in CD biorelevant media 
The solubility of six different drugs was investigated in CD and healthy biorelevant media 
simulating stomach, small intestine and colon in the fasted state and small intestine and colon 
in the fed state. Drug solubility of all investigated drugs in healthy biorelevant media is 




Table 2.6: Drug solubility of investigated drugs in healthy biorelevant media.  
  Solubility in healthy biorelevant media [μg/mL] 
Drug FaSSGF FaSSIF-V2 FaSSCoF FeSSIF-V2 FeSSCoF 
Azathioprine 242.9 (7.97) 242.53 (6.82) 316.27 
(11.09) 
254.33 (1.14) 252.82 
(8.41) 
Budesonide 17.83 (0.19) 22.72 (0.64) 18.43 (0.15) 43.75 (4.68) 17.48 (0.40) 
Celecoxib 2.94 (0.05) 14.77 (0.44) 12.34 (0.95) 97.98 (0.81) 22.50 (0.88) 
Dipyridamole 13.1 (4.4) x 
103 







29.31 (2.87) 241.13 (7.43) 231.19 
(30.06) 
Sulfasalazine a 1.28 (0.03) x 
103 
7.34 (0.11) x 
103 




aMeasurement value of 1.17 ug/mL (>Limit of Detection, <Limit of Quantification) was only 
used as reference value for comparative purposes 
 
In fasted state gastric media, differences in drug solubility between CD biorelevant media 
and healthy biorelevant media were observed (Figure 2.4). The solubility of the weak acid 
sulfasalazine was significantly increased in CD gastric media with high pH (p<0.05) as a 
higher fraction of the drug was ionised. For the weak base dipyridamole, the solubility was 
significantly decreased in CD gastric media with high and medium pH and increased in CD 
gastric media with low pH (p<0.05), indicating also a higher solubility with an increasing 
fraction of the drug being ionised. The solubility of loperamide hydrochloride, another weak 
base, was significantly increased in CD gastric media with high pH and low bile salt 
concentrations, most probably due to the common ion effect since less chloride ions are 
present in the gastric CD media with high pH (less hydrochloric acid), and decreased in CD 
gastric media with low pH and high bile salt concentrations (p<0.05). For neutral 
compounds, significant differences in drug solubility in CD gastric media were only 
observed for budesonide with a lower solubility in all CD gastric media compared to 




Figure 2.4: % Relative Effect (RE) on solubility of investigated drugs in CD gastric 
biorelevant media according to the Design of Experiments (green: high level, yellow: 
medium level, red: low level) in the fasted state compared to the corresponding healthy 
medium for ionisable drugs (a), and neutral drugs (b).  
 
The % Relative Effect of CD on drug solubility in fasted and fed state intestinal media is 
shown in Figure 2.5. In fasted state intestinal media, the solubility of celecoxib and the weak 
bases, loperamide hydrochloride and dipyridamole, was significantly lower in CD intestinal 
media (p<0.05). This is in accordance with another study showing an impact of bile salt and 
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lecithin concentration on the solubility of four weak bases and four neutral compounds in 
fasted state simulated intestinal fluids.11 Therefore, relevant differences in drug 
solubilisation in CD are expected for neutral lipophilic compounds and moderately lipophilic 
weak bases. The higher impact of reduced bile salt concentrations on weak bases could be 
explained by an interaction of the protonated drug with the charged head group of sodium 
taurocholate.56 
In fed state intestinal media, the solubility of sulfasalazine, dipyridamole, celecoxib and 
loperamide hydrochloride was significantly decreased in CD media (p<0.05). The solubility 
of budesonide was lower in CD-FeSSIF but the difference was not statistically significant 
(p=0.06). Drug solubilisation of hydrophilic drugs, such as azathioprine, is not expected to 
be altered in CD-FeSSIF. For moderately to highly lipophilic drugs, a decrease in drug 
solubilisation is expected in fed state intestinal CD media, irrespective of their ionisation 
properties. 
 
Figure 2.5: % Relative Effect (RE) on solubility of investigated drugs in CD intestinal 
biorelevant media in the fasted state and fed state compared to the corresponding healthy 
media. 
 
The % Relative Effect of CD on the solubility of investigated drugs in colonic biorelevant 
media in the fasted state and fed state is shown in Figure 2.6. In colonic media, the CD 
biorelevant medium with high bile salt concentration and low osmolality corresponds to 
FaSSCoF in the fasted state and FeSSCoF in the fed state, respectively. The solubility of 
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loperamide hydrochloride and budesonide was significantly decreased in all CD-FaSSCoF 
media compared to FaSSCoF (p<0.05). The solubility of dipyridamole was significantly 
decreased in CD-FaSSCoF with low bile salt concentrations and high osmolality (p<0.05). 
The solubility of celecoxib was significantly lower in CD-FaSSCoF media with low bile salt 
concentrations (p<0.05). As for CD-FaSSIF, the results suggest a lower solubility of 
moderately and highly lipophilic neutral and weakly basic compounds as a result of 
decreased bile salt and lecithin concentrations in CD fasted state colonic media. 
Additionally, increased osmolality had a negative impact on drug solubility of loperamide 
hydrochloride and budesonide. For loperamide, this can be attributed to a common ion effect. 
Since the higher osmolality in the faecal fluid of CD patients was related to a higher amount 
of insoluble carbohydrates instead of a higher chloride concentration, it is questionable if the 
solubility of loperamide hydrochloride would also be decreased in the colonic luminal fluid 
of CD patients. 
In fed state colonic media, the solubility of sulfasalazine was decreased in all CD media 
(p<0.05) suggesting a negative impact of decreased bile salt and lecithin concentrations and 
increased osmolality on the solubility of sulfasalazine. The solubility of loperamide 
hydrochloride and celecoxib was decreased in CD media with low or medium bile salt 
concentrations (p<0.05). For dipyridamole, the solubility was decreased in CD-FeSSCoF 
with low bile salt concentration and low osmolality (p<0.05). The results suggest a decreased 
solubility for neutral and weakly acidic drugs with high lipophilicity in media with lower 




Figure 2.6: % Relative Effect (RE) on solubility of investigated drugs in CD colonic biorelevant media in the fasted state (top) and fed state 
(bottom) according to the Design of Experiments (green: high level, yellow: medium level, red: low level) compared to the corresponding healthy 
media for neutral drugs (a, c), and ionisable drugs (c, d).
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2.4.3.  Multivariate statistical analysis 
The PLS models for the different GI compartments and prandial states are shown in Figure 
2.7 with the standardised coefficients and VIPs of the respective drug- and media-dependent 
factors and their interactions. For the fasted state gastric media, the developed PLS model 
for the % Relative Effect of CD on drug solubility showed a good fit of the experimental 
data (r2 0.89) and a high predictive power (q2 0.79). The model depicted a positive effect of 
the categorical variable weak acid, of the pH and of the interplay between pH and weak acid. 
In contrast, the categorical variable of neutral compounds had a negative effect on drug 
solubility.  
For fasted state intestinal media, the PLS model with good model quality (r2 0.78, q2 0.71) 
revealed a positive effect of bile salts and of the interplay between bile salts and log P, while 
the log P had a negative effect on the % Relative Effect of CD on drug solubility. This 
suggests that drug solubilisation of lipophilic compounds is at risk in patients with CD with 
low intestinal bile salt concentrations. 
For fasted state colonic media, a predictive PLS model was developed (r2 0.57, q2 0.50). 
According to the model, the % Relative Effect of CD on drug solubility was negatively 
influenced by % Fraction ionised and log P, while bile salts and the interplay between bile 
salts and % Fraction ionised showed a positive influence. The positive influence of the 
interplay between bile salts and % Fraction ionised can be explained by the interaction 
between the cationic fraction of the weak bases and the headgroup of sodium taurocholate. 
For fed state intestinal media, the PLS model (r2 0.60, q2 0.51) showed that bile salts had a 
positive effect on drug solubility. 
For fed state colonic media, the predictive power of the developed PLS model was low (q2 
0.37) and the model could only account for a low percentage of variability in the dependent 
variable (r2 0.42). Important variables of the model were bile salts and the interplay of bile 
salts and log P with a positive effect and log P with a negative effect on the % Relative Effect 




Figure 2.7: Standardised coefficients of factors and interactions in the PLS regression of 
drug solubility in CD simulated gastrointestinal fluids in the fasted state (left) and fed state 
(right) and different compartments of the GI tract (top: stomach, middle: small intestine, 




2.4.4. Drugs at risk of altered solubility in luminal fluids of CD patients 
In simulated gastric fluids of CD patients compared to healthy biorelevant media, differences 
of drug solubility were observed for a weak acid and weak bases. Therefore, an altered 
gastric pH in CD is expected to pose a risk for ionisable drugs. For weak acids, an increased 
gastric pH in CD patients is expected to result in a higher drug solubility. 
For drugs with moderate to high lipophilicity, a high risk of altered drug solubilisation is 
expected in the fasted state intestinal fluids of CD patients with low bile salt and lecithin 
concentrations. In contrast, hydrophilic drugs have a low risk of altered drug solubility in 
intestinal fluids of CD patients as shown by a similar drug solubility of azathioprine in CD 
and healthy intestinal biorelevant media. 
Considering colonic fluids of CD patients, a reduced drug solubility is expected with an 
increased log P in the fasted and fed state as indicated by the PLS models (Section 2.4.3), 
especially when low bile salt and lecithin concentrations are present in the colonic fluids of 
CD patients. Drugs that are at the same time also weak bases possess a higher risk for a 
reduced drug solubility in the fasted state colonic fluids, as indicated by the negative effect 
of the % Fraction ionised in the respective PLS model. 
Given the high number of CD media, solubility studies with six compounds were performed 
and resulted in appropriate statistical models. Further studies with a higher number of 
compounds would additionally increase the confidence in the risk assessment tools. 
 
2.5. Conclusion  
Based on current literature about pathophysiological changes in CD patients, simulated GI 
fluids of CD patients were developed for different GI compartments and prandial states. 
Differences in the properties of CD biorelevant media compared to healthy biorelevant 
media were mainly observed for surface tension and osmolality. Consequently, for example 
the common ion effect or differences in wetting behaviour could affect drug dissolution and 
drug release from pharmaceutical formulations in CD patients. Drug product performance, 
especially of drugs with solubility- or dissolution rate-limited absorption, may therefore be 
altered as a result of CD. 
Differences of drug solubility in simulated gastric fluids of CD patients compared to healthy 
biorelevant media were related to differences in media pH and drug ionisation as observed 
for a weak acid and a weak base in gastric CD media with high pH. At high risk of altered 
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drug solubilisation in CD are drugs with moderate to high lipophilicity, since the log P 
showed a significant negative effect on drug solubility for colonic and fasted state intestinal 
CD media. A lower drug solubility for lipophilic drugs is further expected in CD GI fluids 
with low bile salt and lecithin concentrations as a significant positive effect of bile 
salts/lecithin on drug solubility was observed in CD intestinal and colonic media. Further 
investigation of the luminal fluid composition of CD patients would increase the confidence 
in simulated biorelevant media of this patient population.  
Simulating the conditions in CD patients in vitro offers the possibility to identify relevant 
differences in drug solubilisation without conducting clinical trials. Especially for drugs for 
concomitant diseases, the high cost associated with clinical trials limits their conduction in 
CD patients. Apart from drug dissolution, drug product performance can also be affected by 
differences in permeability, distribution, gut wall/hepatic metabolism and elimination. 
Therefore, pathophysiological differences considering all ADME processes need to be 
considered to identify all drugs at risk of altered drug product performance in patients with 
CD. Results from solubility and dissolution experiments with CD media can be integrated 
in PBPK models offering the opportunity to integrate ADME processes mechanistically and 
to consider the special physiology of patient populations in order to predict a drug’s plasma 
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Gastrointestinal diseases and their impact on drug solubility. 




For poorly soluble compounds, drug product performance in patients with Ulcerative Colitis 
(UC) compared to healthy subjects can be affected due to differences in drug solubility in 
GI fluids. To assess this risk in vitro, biorelevant media for different prandial states and GI 
compartments were developed representative of UC patients based on pathophysiological 
changes in UC and with a Design of Experiment approach. The UC media were characterised 
and drug properties, posing a high risk of altered drug solubility in UC, were identified by 
assessing the solubility of six drugs in UC media and relating the results to their properties. 
Key findings 
The characterisation of UC biorelevant media showed differences in terms of surface 
tension, buffer capacity and osmolality compared to healthy biorelevant media. A lower drug 
solubility in UC intestinal media was observed for compounds with a high lipophilicity. For 
weak bases and weak acids, drug solubility was altered in UC colonic fasted state simulated 
fluids compared to healthy media. Additionally, a higher solubility of neutral lipophilic 
drugs was observed in UC media with increased concentrations of soluble proteins. In UC 
colonic fed state simulated fluids, differences in drug solubility of ionisable compounds were 
observed compared to the healthy medium and a lower solubility of neutral lipophilic drugs 
was observed in UC media with low lecithin concentration. 
Conclusions  
The developed UC biorelevant media offer the possibility to identify the risk of altered drug 
solubilisation in UC patients without conducting expensive clinical trials. A high risk was 
related to drug ionisation properties and lipophilicity in the current study with all 
investigated drugs showing differences in solubility between healthy and UC media. 
Therefore, drug product performance of drugs with dissolution rate- or solubility-limited 




Ulcerative Colitis (UC), a main type of inflammatory bowel disease (IBD), is an 
autoinflammatory disorder that affects approximately 2.1 million people in Europe.1 The 
inflammation manifests itself in ulcerations of the lining of the large intestine which are 
confined to the mucosa and submucosa. Typically, the first appearance of the disease is 
limited to the rectum and further disease progression leads to a proximal extension to the 
colon. According to the disease location, the Montreal classification system groups UC in 
Ulcerative proctitis (rectum is affected), left-sided UC (a proportion of the colorectum distal 
to the splenic flexure is affected) or extensive colitis (entire large intestine is affected).2 UC 
can also be grouped in four different disease states according to symptom severity: mild, 
moderate, severe or a state of clinical remission.2 
The different states and locations of UC necessitate different treatment options and drug 
formulation approaches. The classic step-up approach includes aminosalicylates as first 
treatment option in mild to moderate UC.3 For this treatment, different drug formulations 
can be used based on disease location with suppositories and enemas for distal UC and/or 
controlled-release or prodrug formulations of mesalamine, when more proximal parts of the 
colon are affected. Corticosteroids are used to induce remission in moderate to severe disease 
states. Drug formulations include immediate-release formulations of systemic 
corticosteroids or controlled-release formulations of the topical steroid budesonide (e.g., 
Uceris® [Santarus, San Diego, CA, USA]). For active UC, the next therapeutic option is a 
co-treatment with thiopurines such as azathioprine due to their slow onset of therapeutic 
action. Further treatment options are calcineurin inhibitors for severely active UC or 
monoclonal antibodies as last therapeutic option. 
Consequently, drug delivery via the oral route is commonly used in UC for locally-acting as 
well as systemic drug therapy. In addition, the use of several other drug classes, which are 
most often administered orally (e.g., antidepressants, antibiotics and nonsteroidal anti-
inflammatory analgesics), was increased in IBD patients compared to the general 
population.4 Successful drug delivery via the oral route is dependent on gastrointestinal (GI) 
physiology and drug/formulation properties. Various processes such as drug 
release/dissolution, permeation through the GI membrane and gut or hepatic metabolism can 
be influenced by an altered GI physiology in UC.5 Since clinical trials to assess drug product 
performance in UC patients are rarely performed due to high costs, a heterogenous patient 
population and a high time effort, possible effects on the drug therapy of UC patients are not 
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investigated in most cases. Therefore, alternative tools to predict drug product performance 
in UC patients are needed.   
In vitro release and dissolution testing can be used as surrogate for the in vivo performance 
of poorly soluble compounds with solubility- or dissolution rate-limited absorption.6 For this 
purpose, biorelevant media have been developed based on healthy subjects to simulate GI 
fluids of different GI compartments and prandial states and to evaluate drug products in 
vitro.7-11 Since UC can alter the GI fluid composition of patients, drug product performance 
could be affected for these drugs. The development of biorelevant media for UC patients 
allows to identify if differences in drug solubility or dissolution exist compared to the healthy 
biorelevant medium which would indicate a high risk of altered drug product performance 
in UC patients.  
This study aims to develop a risk assessment tool to identify compounds with a high risk of 
altered solubility in the GI fluids of UC patients. Therefore, pathophysiological changes 
impacting on the composition of GI fluids in UC patients are considered and UC biorelevant 
media representative of the stomach, intestine and colon were developed based on healthy 
biorelevant media and published data using a Design of Experiment (DoE) approach. 
Subsequently, the developed UC biorelevant media were characterised according to their 
surface tension, osmolality, buffer capacity and dynamic viscosity and the solubility of six 
poorly soluble compounds with different physicochemical properties was determined in UC 
biorelevant media. To identify if certain drug characteristics contribute to a higher risk of 
altered drug solubility in GI fluids of UC patients, Partial least Squares (PLS) regression was 
used to correlate drug properties and media-dependent factors with the Relative Effect on 
drug solubility. 
3.2. Materials 
Acetic acid High Performance Liquid Chromatography (HPLC) grade, pepsin from porcine 
gastric mucosa, sodium oleate, α-D-glucose, budesonide, phosphoric acid and sodium 
hydroxide were purchased from Sigma-Aldrich Company Ltd., Dorset, England. 
Sulfasalazine, loperamide hydrochloride, dipyridamole, celecoxib, azathioprine, methanol 
HPLC grade, cholic acid sodium salt and acetonitrile HPLC grade were purchased from 
VWR International Ltd, Lutterworth, UK. Tris(hydroxymethyl)aminomethane, hydrochloric 
acid 36.5–38%, sodium chloride, trifluoroacetic acid (TFA), potassium dihydrogen 
orthophosphate, bovine serum albumin (BSA) protease free powder fraction V, dimethyl 
sulfoxide and maleic acid were used from Fisher Scientific UK Ltd., Loughborough, 
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England. Other chemicals used included sodium taurocholate (Prodotti Chimici Alimentari 
S.P.A., Basaluzzo, Italy), egg lecithin–Lipoid EPCS (Lipoid GmbH, Ludwigshafen, 
Germany) and glyceryl monooleate–Rylo Mg 19 (Danisco, Brabrand, Denmark). Water was 
ultra-pure (Milli-Q) laboratory grade. 
3.3. Methods 
3.3.1. Media development 
3.3.1.1. GI pathophysiological changes in UC patients integrated in the 
experimental design 
Information from literature was collected to identify differences in the composition of GI 
fluids of UC patients compared to healthy subjects. For studies with graphically displayed 
data, the relevant information was extracted with WebPlotDigitizer (Ankit Rohatgi, USA).12 
Apart from components and properties directly measured in the GI fluids of UC patients, an 
additional factor, namely the lecithin levels measured in the GI mucosa, was considered as 
indirect factor due to the limited number of studies performed in UC patients. All factors 
were integrated with two levels in the experimental design. The low and the high level were 
selected based on the available information on the respective parameter as described in 
Sections 3.3.1.1.1 and 3.3.1.1.2. 
3.3.1.1.1. Indirect factor 
The lecithin concentration was included as indirect factor in the experimental design of 
gastric, intestinal and fed state colonic UC media. 
Lecithin is a constituent of the GI mucosa and essential to maintain the normal mucus barrier 
function. It has been shown that the lecithin concentration in the intestinal mucus barrier of 
patients with UC was decreased by over 70% compared to healthy subjects.13, 14 The lecithin 
in the colonic mucus barrier is likely to origin from secretions by jejunal and ileal enterocytes 
as investigated in rat intestinal perfusion studies.15 Therefore, decreased lecithin 
concentrations are likely to be present also in more proximal parts of the GI tract than the 
colon. The treatment of UC patients with a delayed-release oral formulation of lecithin has 
shown to increase the amount of lecithin in rectal mucus and reduce inflammatory activity.16 
Lecithin is also an essential constituent of bile and can emulsify hydrophobic molecules due 
to its amphiphilic structure. Hepatobiliary manifestations are common in UC patients and 
include primary sclerosing cholangitis (PSC), small duct PSC, chronic hepatitis, cryptogenic 
cirrhosis, cholangiocarcinoma and cholelithiasis.17 The most common of these conditions is 
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PSC with an incidence of 2.5 to 7.5% in patients with UC.17 PSC leads to the formation of 
bile duct strictures impeding the flow of bile to the intestine. Consequently, reduced bile salt 
and lecithin concentrations are likely to be present in the GI fluids of the affected patients 
with UC. Reduced concentrations of bile acids and lecithin were already observed in 
intrahepatic bile specimens of patients with PSC.18 Additionally, decreased lecithin 
concentrations in UC patients compared to healthy subjects were also observed in 
gallbladder bile in the fasted state obtained by cholecystokinin-stimulated, duodenal biliary 
drainage.19 
Apart from the ascending colon fluid, no studies investigated the concentration of lecithin in 
the remaining luminal fluids of UC patients. Therefore, the lecithin levels for the DoE were 
based on an indirect percental approach in all media except UC-Fasted-State Simulated 
Colonic Fluid (FaSSCoF) according to 
 
𝑥𝐶𝐷−𝐵𝑀 = 0.30 ∗ 𝑥𝐻−𝐵𝑀         (3.1) 
 
where 𝑥𝐶𝐷−𝐵𝑀 is the low level of the lecithin concentration in CD media, 𝑥𝐻−𝐵𝑀 is the 
lecithin concentration in healthy biorelevant media and the factor 0.30 represents the ratio 
of lecithin previously observed in the colonic mucus layer of CD patients compared to 
healthy subjects.13, 14 Hence, the low lecithin level in UC biorelevant media is set to 30% of 
the concentration in corresponding healthy biorelevant media and the high lecithin level 
corresponds to the concentration in healthy biorelevant media.  
3.3.1.1.2. Direct factors 
3.3.1.1.2.1. Fasted state ascending colon fluid 
The fasted state ascending colon fluid of UC patients in states of relapse and remission as 
defined based on the Clinical Rachmilewitz Index (CRI) has previously been characterised.20  
A higher osmolality was observed in patients with UC in remission 
(290.1±165.6 mOsmol/kg) compared to patients in relapse (199.6±127.4 mOsmol/kg) and 
healthy subjects (80.6±102.5 mOsmol/kg).20, 21 For the experimental design, the osmolality 
was integrated with a low level of 196.0 mOsmol/kg, corresponding to the osmolality of 
FaSSCoF and similar to the osmolality observed in UC patients in relapse, and a high level 
of 290.0 mOsmol/kg representative of UC patients in remission. 
The mean total bile acid concentration was lower in UC patients in relapse 
(75.83±42.96 μM) compared to patients in remission (115.15±100.20 μM) and healthy 
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subjects (115.20±119.30 μM), but the difference reached no statistical significance as the 
power of the test was very low.20, 21 For the experimental design, the bile salt concentration 
was integrated with a low level of 75.00 μM representative of UC patients in relapse and a 
high level of 150.00 μM (bile salt concentration of FaSSCoF, similar bile salt concentration 
in healthy and UC patients in remission). 
The concentration of soluble proteins was not significantly different between patients in 
relapse (18.9±8.1 mg/mL) and remission (19.0±10.8 mg/mL), but significantly higher 
compared to healthy subjects (9.8±4.6 mg/mL).20, 21 For the experimental design, the 
concentration of soluble proteins was integrated using BSA with a high level of 19.0 mg/mL 
representative of UC patients in relapse and remission and a low level of 0.0 mg/mL based 
on the concentration in FaSSCoF. 
The lecithin concentrations in the fasted state ascending colon fluid in UC patients in 
remission and relapse were in the range of 0.13 to 0.62 mM (graphically extracted).20 While 
the mean concentration of lecithin in the fasted state ascending colon fluid of UC patients 
was lower compared to healthy subjects, the difference did not reach statistical significance 
due to high data variability. For the experimental design, the lecithin concentration was 
included as factor with the observed range as low and high level. 
The pH in the fasted state colonic fluid of UC patients in remission and relapse was in the 
range of 6.1 to 7.3 with a median of 6.5 and in the range of 5.5 to 7.7 with a median of 6.6, 
respectively.20 For the experimental design, the pH was included as factor with a low level 
of 5.5 and a high level of 7.7 representative of the pH range observed in UC patients.  
The buffer capacity of the fasted state ascending colon fluid was higher in UC patients in 
relapse (32.0±18.1 mmol/L/ΔpH) and remission (37.7±15.4 mmol/L/ΔpH) compared to 
healthy subjects (21.4±7.9 mmol/L/ΔpH) as measured with hydrochloric acid. Due to the 
high number of factors integrated in the experimental design for the fasted state colonic UC 
media, the buffer capacity was not included. 
3.3.1.1.2.2. Fed state colon fluid  
Several studies investigated the pH in the colon of UC patients in the fed state.22-26 Very low 
pH values (pH 2.3-3.4), observed in one study were excluded due to analytical uncertainties 
(e.g., no confirmatory pH measurements, possibly artificial low pH values when a certain 
distance to antenna was exceeded).24, 27 The highest colonic pH value observed in UC 
patients in the fed state was 7.8 and the lowest was 4.7.24, 26 Therefore, the pH in the fed state 
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colonic medium was included as factor in the experimental design with a low level of 4.7 
and a high level of 7.8 representative of the pH range observed in UC patients.  
3.3.1.2. Development of UC media with DoE 
A DoE approach was followed to develop the UC biorelevant media with the aim to assess 
the impact of each of the factors and to reflect the interindividual variability in UC patients. 
The development of UC biorelevant media was based on observed differences in UC patients 
compared to healthy subjects identified in literature (Section 3.3.1.1) and previously 
developed biorelevant media for healthy subjects including Fasted-State Simulated Gastric 
Fluid (FaSSGF), Fasted-State Simulated Intestinal Fluid-Version 2 (FaSSIF-V2), FaSSCoF, 
Fed-State Simulated Intestinal Fluid-Version 2 (FeSSIF-V2) and Fed-State Simulated 
Colonic Fluid (FeSSCoF).8-11 
The DoE was performed using XLSTAT (Addinsoft, France) with a full factorial design in 
UC patients for stomach and intestine in the fasted state and intestine and colon in the fed 
state. For fasted state gastric and fasted and fed state intestinal media, the lecithin 
concentration was included as factor in the experimental design. Additionally, the ratio of 
bile salts to lecithin was integrated as factor and set to the ratio in the corresponding healthy 
biorelevant media for the low level. This approach was used to keep a similar composition 
of the mixed micelles to healthy biorelevant media in some UC media. For fed state colonic 
UC media, the pH and the concentration of lecithin and bile salts were the investigated 
factors. 
For fasted state colonic UC media, the factors investigated were bile salts, lecithin, pH, 
osmolality and soluble proteins. Due to the high number of factors, a fractional factorial 
design (2^(5-2)) was used for the UC fasted state colonic media using Dataplot (NIST, US).28 
Therefore, the main effects are confounded with the two-factor interaction in the case of UC-
FaSSCoF media, while permitting the exploration of the effects of many factors with a 
minimum number of media. The factor soluble proteins was represented in UC-FaSSCoF 
media by BSA. 
Each factor changed in UC compared to healthy subjects was integrated in the DoE with two 
levels (low and high). Additionally, centre points with medium levels of each parameter 
were included for gastric and intestinal media. An overview of the factors and levels of the 
DoE is given in Figure 3.1. For UC-FaSSCoF media with osmolality as factor in the DoE, 
sodium chloride was added to adjust the osmolality. For all other media, the osmolality was 
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set to the value in corresponding healthy biorelevant media by adjusting the concentration 
of sodium chloride.  
Biorelevant media were prepared according to the method described in Jantratid et al for 




Figure 3.1: Design of Experiments for the development of Ulcerative Colitis media.
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3.3.2. Media characterisation 
Surface tension, osmolality, dynamic viscosity and buffer capacity of biorelevant media 
previously developed based on healthy subjects and newly developed for UC patients were 
measured. All measurements were performed in triplicate. The results were reported as mean 
with standard deviation. 
3.3.2.1. Surface tension 
Surface tension measurements were performed with a ring tensiometer (Sigma 700 Force 
tensiometer, Attension, UK) and a glass vessel (diameter of 46 mm) filled with 10 mL of 
each medium. The force to pull a Du Noüy ring from the surface of the medium was 
measured and related to the medium’s surface tension.29 
3.3.2.2. Osmolality 
Osmolality was determined with an Advanced Instruments Inc. micro-osmometer Model 
3300 (Norwood, MA, US) by measuring the freezing-point depression of a 20 µl sample.  
3.3.2.3. Dynamic viscosity 
A Bohlin Rheometer C-VOR (Malvern instruments, UK) with a cone-plate system (4°, 
40 mm) was used to determine the dynamic viscosity of the media at a temperature of 37⁰C. 
A small amount of sample was placed between the plate and the cone, sheared with different 
shear stresses (20 points, logarithmically distributed between 0.05 and 0.15 Pa) and the shear 
rate was measured. Dynamic viscosity corresponds to the ratio of shear stress to shear rate.  
3.3.2.4. Buffer capacity 
To determine the buffer capacity of the media, small volumes of 0.5 M hydrochloric acid 
were added to 10 mL of medium until a change of one pH unit was measured with a Mettler 
Toledo SevenCompact S220 pH meter (Schwerzenbach, Switzerland). Subsequently, 







             (3.2) 
where β is the buffer capacity, Macid is the molarity, ΔpH is the change in pH, Vacid and Vsample 




3.3.3. Compound selection 
For the solubility studies, poorly soluble compounds belonging to class II (low solubility, 
high permeability) or IV (low solubility, low permeability) of the Biopharmaceutics 
Classification System (BCS) were selected as presented in Figure 3.2.31-45 Drug selection 
was based on different physicochemical characteristics of the drugs such as ionisation 




Figure 3.2: Physicochemical characteristics and indication of investigated drugs.31-45 
 
3.3.4. Solubility studies 
The shake-flask method was used to determine the solubility of the six selected drugs.46 
Therefore, 5 mL of medium were added to an excess amount of drug in a glass tube and 
placed in a shaking water bath (Grant instruments, Royston, UK) at 37°C with 
200 strokes/min. After 24 h, the supernatant was filtered with GF/D membrane filters with 
a pore size of 2.7 μm (Whatman® Puradisc, diameter 13 mm) and analysed by HPLC-
Ultraviolet (UV). HPLC analysis was performed with an Agilent Technologies 1200 series 
HPLC system (Santa Clara, CA, US) with a binary pump, autosampler, thermostatted 
column compartment and diode array detector. The details of the HPLC-UV methods used 
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for the quantitative analysis of the six compounds are presented in Gastrointestinal diseases 
and their impact on drug solubility. Part I. Crohn’s disease (Chapter 2). 
For biorelevant media including BSA, an additional treatment step for protein precipitation 
was added after sample filtration. 1 mL of protein precipitation reagent was added to 500 μL 
of sample, the mixture was vortexed for 30 s and centrifuged for 10 min at 12000 rpm and 
4°C (Eppendorf Heraeus Fresco 17 centrifuge, ThermoElectron LED GmbH, Germany). The 
protein precipitation reagent was methanol for all drugs except sulfasalazine, for which 
dimethyl sulfoxide was used due to the poor solubility of sulfasalazine in methanol. For the 
sulfasalazine samples with dimethyl sulfoxide, the ratio of the mobile phase used for the 
HPLC-UV analysis was modified to 60:40 MeOH: Acetic acid 3.3% in H2O. Solubility 
studies were performed in triplicate in UC media and healthy media. Average solubility 
differences between UC media and healthy media were expressed as a % Relative Effect on 
solubility [((SUC-SHealthy)/ SHealthy) x 100]. Positive values indicate that drug solubility in UC 
media exceeds the solubility in healthy media, whereas negative values indicate the opposite.  
3.3.5. Statistical analysis 
All statistical analysis was performed using XLSTAT (Addinsoft, France).  
To identify statistically significant differences of media properties and drug solubility 
between UC biorelevant media and the corresponding healthy media, one-way analysis of 
variance (ANOVA) with a post-hoc Tukey’s test was applied with a significance level of 
p ≤ 0.05. 
Multivariate statistical analysis was used to identify drug properties that present a high risk 
of altered drug solubility in UC. Therefore, the % Relative Effect on drug solubility was 
correlated with media-dependent factors of the DoE and drug physicochemical properties by 
Partial Least Squares (PLS) regression. Media-dependent factors were for gastric and 
intestinal UC media the bile salt and lecithin concentration. For fasted state colonic UC 
media, the media-dependent factors were osmolality, pH and the concentrations of bile salts, 
lecithin and soluble proteins. For fed state colonic UC media, media-dependent factors were 
pH and the concentration of bile salts and lecithin. In terms of drug-dependent parameters, 
the partition coefficient, log P, was included for all UC media. For media with pH as media-
dependent factor (colonic UC media), a categorical variable discriminating between weak 
acids, weak bases and neutral compounds was introduced. For the gastric and intestinal UC 
media, the % Fraction ionised (calculated using Advanced Chemistry Development, Inc. 
(ACD/Labs) Software V11.02, Toronto, On, Canada and defined for anionic species as 
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negative and cationic species as positive) was used as additional drug-dependent factor.47 
Interactions between media-dependent and drug-dependent factors were included in the 
model as shown in Table 3.1.  
The quality assessment of the PLS models was based on the square of coefficient of 
determination (r2) and goodness of prediction (q2), both indicating a good fit of the data and 
a good predictive ability of the model, respectively, when close to 1. A difference higher 
than 0.3 between r2 and q2 indicates model over-fitting and consequently an inappropriate 
model.48 Models were selected for optimum model predictive ability based on the lowest 
predicted residual error sum of squares (PRESS) and the highest q2. Usually good model 
predictability is given when q2 is higher than 0.5, in certain cases, however, lower limits can 
be accepted since q2 is dependent on the properties of the data set (e.g., number of 
observations).49 In our models, a high influence on the % Relative Effect on solubility is 
indicated for the media- and drug-dependent factors with high absolute value of the 
standardised coefficients. If the standardised coefficient is positive, this indicates a positive 
impact on the % Relative Effect on solubility, while a negative standardised coefficient 
indicates the opposite. The Variable Importance in Projection (VIP) of a factor summarizes 
the influence of each individual independent factor on the PLS model. In the current study, 
we considered factors with VIP ≥0.7 as influential to the model and factors with VIP >1 as 
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3.4. Results and discussion 
3.4.1. Media characterisation 
An overview of the surface tension and osmolality of healthy and UC biorelevant media is 
given in Figure 3.3. 
Surface tension in fasted state gastric media was significantly higher (+24%, p<0.05) in the 
UC medium with low lecithin and low bile salt concentrations compared to the healthy 
medium, possibly due to the low surfactant concentration being below the critical micellar 
concentration. In fasted state intestinal media, a significantly higher surface tension 
compared to the healthy medium was observed for both UC media with low lecithin 
concentrations (+4%, +15%, p<0.05). In fasted state simulated colonic media, the surface 
tension in three UC media with low pH (low lecithin/low bile salt/low osmolality/high 
soluble proteins -11%, low lecithin/high bile salt/high osmolality/low soluble proteins -26% 
and high lecithin/low bile salt/high osmolality/low soluble proteins -31%, p<0.05) was 
significantly lower compared to the healthy medium and the surface tension of one UC 
medium (low lecithin/low bile salt/high pH/high osmolality/high soluble proteins) was 
increased by 7% (p<0.05). The surface tension of UC-FaSSCoF media was in the range of 
29.3 mN/m to 46.0 mN/m, which is in accordance with the surface tension observed in the 
ascending colon fluid of UC patients in relapse (41.6±3.1 mN/m) and in remission (40.6±3.4 
mN/m).20 In the fed state, the surface tension of intestinal UC media was significantly 
decreased compared to the healthy medium (-7 to -12%, p<0.05). The surface tension of 
FeSSCoF was significantly higher compared to six of the UC media including the media 
with low pH and media with high pH/low lecithin concentrations (p<0.05). 
Osmolality in UC biorelevant media was only different according to the specified levels for 
fasted state colonic media when osmolality was included as factor in the experimental design 




Figure 3.3: Surface tension (blue, left y-axis) and osmolality (black, right y-axis) of UC 
biorelevant media according to the Design of Experiments (green: high level, yellow: 
medium level, red: low level, white: healthy level) and healthy media.  
 
The dynamic viscosity of the investigated biorelevant media is presented at three different 
shear stresses in Figure 3.4. All healthy and UC media showed pseudoplastic behaviour. The 
viscosity at an applied shear stress of 0.15 Pa was in the range of 3.23 to 3.50 mPas, at 
0.08 Pa in the range of 3.74 to 4.28 mPas and at 0.06 Pa in the range of 4.59 to 5.99 mPas, 
respectively. Significant differences between UC and healthy biorelevant media for all three 




Figure 3.4: Dynamic viscosity of UC biorelevant media and the corresponding healthy 
biorelevant media at different shear stress (0.06 Pa: blue, 0.08 Pa: red, 0.15 Pa: black) 
according to the Design of Experiments (green: high level, yellow: medium level, red: low 




Figure 3.5: % Relative Effect on buffer capacity in UC biorelevant media compared to the 
corresponding healthy biorelevant media according to the Design of Experiments (green: 
high level, yellow: medium level, red: low level). 
 
The buffer capacity was not significantly different in healthy fasted and fed state intestinal 
media compared to UC media (Figure 3.5). In fasted state colonic media, the healthy medium 
had a significantly lower buffer capacity compared to all UC media (p<0.05) and the increase 
was more pronounced for UC-FaSSCoF media with low pH compared to UC-FaSSCoF 
media with high pH. In contrast, in the fed state colonic media the buffer capacity was 
significantly lower in the UC media (p<0.05), whereby the decrease was more pronounced 
for UC-FeSSCoF media with low pH compared to UC-FeSSCoF media with high pH.  
3.4.2. Solubility of drugs in UC biorelevant media 
The % Relative Effect of UC on the solubility of six different drugs, as investigated with UC 
biorelevant media and healthy biorelevant media simulating stomach, small intestine and 




Figure 3.6: % Relative Effect on solubility of investigated drugs in UC biorelevant media compared to the corresponding healthy media according 










Figure 3.6: (followed). 
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3.4.2.1. Neutral drugs 
For the investigated neutral drugs, differences in drug solubility in gastric and intestinal 
media were observed due to decreased lecithin or bile salt concentrations. For budesonide, 
the decrease was significant in all gastric fasted state UC media, in the fasted state intestinal 
UC medium with low lecithin and high bile salt concentrations and in the fed state intestinal 
medium with low lecithin and low bile salt concentrations (p<0.05). For celecoxib, a 
significantly reduced solubility was observed in the fasted state gastric UC medium with low 
lecithin and low bile salt concentrations and in all fasted and fed state intestinal UC media 
(p<0.05). These findings are consistent with lower concentrations of bile salts and lecithin 
resulting in a decreased concentration of mixed micelles available for drug solubilisation of 
lipophilic compounds.51  
In fasted state colonic UC media, budesonide solubility was significantly higher in media 
with high pH, high osmolality and high soluble proteins (p<0.05). For celecoxib, the 
solubility was increased in all UC media with high concentrations of soluble proteins and 
one other UC medium (high bile salt and lecithin concentrations, high pH, low concentration 
of soluble proteins and a low osmolality), while the solubility was decreased in media with 
low concentrations of lecithin and soluble proteins (p<0.05). The positive effect of soluble 
proteins, represented by BSA, on the solubility of non-ionised compounds has previously 
been reported for danazol, felodipine and prednisolone.10, 52 Additionally, it has been shown 
that the octanol:water partition coefficient is positively correlated to the BSA:water partition 
coefficient for neutral compounds.53 In fed state colonic media, the solubility of budesonide 
and celecoxib was significantly decreased in UC media with low lecithin concentrations 
(p<0.05), indicating lower solubilisation due to decreased surfactant concentration. For 
celecoxib, this was also the case for UC media with low pH. This could be due to the low 
pH (4.7) resulting in more sodium cholate (pKa 5.13) being present in its unionised form 
and hindering the formation of micelles.54 
3.4.2.2. Weak bases 
For the investigated weak bases, no significant differences in drug solubilisation were 
observed in fasted state gastric UC media. The solubility of loperamide hydrochloride was 
decreased in all fasted state intestinal UC media (p<0.05), indicating a lower solubility with 
a lower concentration of surfactants. For dipyridamole, a lower solubility was observed in 
UC-FaSSIF with low lecithin and low bile salt concentrations, while the solubility was 
increased in UC-FaSSIF with high bile salt concentrations and either low or medium lecithin 
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concentration (p<0.05). For dipyridamole, lower lecithin concentrations seem to promote 
drug solubilisation, probably due to electrostatic interactions between dipyridamole and bile 
salts. In fed state intestinal media, the solubility of loperamide hydrochloride was decreased 
in UC-FeSSIF with low lecithin concentrations and medium lecithin and medium bile salt 
concentrations. For dipyridamole, the solubility was decreased in UC-FeSSIF with low and 
medium bile salt concentrations indicating again the importance of bile salts for the 
solubilisation of weak bases. In fasted state colonic media, the solubility of loperamide 
hydrochloride and dipyridamole was increased in media with low pH due to a higher fraction 
of the drug being ionised. Additionally, the solubility of dipyridamole was also increased in 
the UC-FaSSCoF media with high level of all factors. In fed state colonic media, loperamide 
hydrochloride had a lower solubility in all UC media with high pH due to a smaller 
protonated fraction of the drug. Similarly, the solubility of dipyridamole was increased in 
UC media with low pH due to a higher fraction of the drug being ionised. Additionally, 
loperamide hydrochloride had a higher solubility in UC-FeSSCoF with high bile salt and 
low lecithin concentrations and low pH. The solubility of dipyridamole was decreased in the 
UC-FeSSCoF media with high pH and low lecithin concentrations. 
3.4.2.3. Weak acids 
For the investigated weak acids, most differences were observed due to pH changes. For 
azathioprine, a hydrophilic compound with a log P of 0.1, the solubility was significantly 
decreased in UC-FaSSCoF with low pH, while the solubility was increased in UC-FeSSCoF 
with high pH. For sulfasalazine, the solubility in the fasted state gastric media was below 
the limit of quantification. In intestinal fasted and fed state media, the solubility of 
sulfasalazine was significantly decreased in UC media with low lecithin and low bile salt 
concentration and medium lecithin and medium bile salt concentration. In fasted state 
colonic media, sulfasalazine solubility was decreased in UC media with low pH and other 
media with high pH, low osmolality and low concentration of soluble proteins. In fed state 
colonic media, the solubility of sulfasalazine was increased in UC media with high pH and 
decreased in UC media with low pH.
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3.4.3. Multivariate statistical analysis 
Successful PLS models were developed for small intestinal and colonic UC media in the 
fasted and fed state. The plots of the standardised coefficients of the respective drug- and 
media-dependent factors are shown in Figure 3.7. For the fasted state gastric media, it was 
not possible to develop a predictive PLS model (q2 -0.04, r2 0.09).  
For fasted state intestinal media, the developed PLS model for the % Relative Effect of UC 
on drug solubility showed a good fit of the experimental data (r2 0.76) and a high predictive 
power (q2 0.70). The model depicted a positive effect of bile salts, lecithin and the interaction 
between lecithin and log P, while log P had a negative impact. Consequently, in the luminal 
fluids of UC patients with low bile salt and lecithin concentrations a high risk of reduced 
drug solubility is expected for compounds with a high lipophilicity. This is in accordance 
with another study, where a positive effect of bile salt and lecithin concentration on drug 
solubility in fasted state simulated fluids has previously been shown for seven out of twelve 
compounds with a clog P in the range of 1.43 to 6.15 (ACD/Labs) including three neutral 
compounds (felodipine clog P 4.83, griseofulvin clog P 3.53, fenofibrate clog P 4.80), three 
weak bases (tadalafil clog P 1.43, zafirlukast clog P 6.15, aprepitant clog P 4.80) and one 
weak acid (phenytoin clog P 2.52).47, 55 It should be noted that five drugs with a clog P of 
1.71-10.27 (ACD/Labs) (probucol clog P 10.27, carvedilol clog P 4.11, piroxicam clog P 
1.71, indomethacin clog P 3.1, naproxen clog P 3.0) did not follow this pattern in the 
respective study indicating drug-specific effects in certain cases.47, 55 Therefore, a difference 
in luminal drug solubility in UC patients may not be fully predicted for certain drugs by the 
sole use of drug properties employed in the current study. 
For fed state intestinal media, the model quality of the developed PLS model was accurate 
with a high predictability (r2 0.73, q2 0.66). As for the PLS model of the fasted state, bile 
salts and lecithin had a positive effect on the % Relative Effect on drug solubility with a 
higher impact of the bile salt concentration. The interaction between lecithin and log P had 
also a positive influence (VIP>0.7). In contrast, log P had a negative impact. In another 
study, a positive impact of higher bile salt concentration on drug solubility in fed state 
simulated intestinal media was observed for nine of thirteen compounds (itraconazole, 
probucol, felodipine, tadalafil, aprepitant, carvedilol, zafirlukast, indomethacin, phenytoin) 
with a clog P in the range of 1.43 to 10.27 (ACD/Labs).47, 56 In the same study, a positive 
effect of lecithin on the solubility of eight out of thirteen compounds was also observed 
(itraconazole, probucol, felodipine, fenofibrate, carvedilol, zafirlukast, indomethacin, 
phenytoin).56 However, bile salts or lecithin had a negative impact on drug solubility for 
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certain lipophilic drugs in the respective study indicating again drug-specific effects in some 
cases.56 
For fasted state colonic media, the good quality PLS model (r2 0.90, q2 0.82) revealed a 
positive effect of log P, weak base and the interplay between soluble proteins and neutral 
drugs, and a lower positive influence (VIP>0.7) of soluble proteins and the interplay between 
log P and neutral drugs. In contrast, the model showed a negative influence of pH, weak 
acids, the interplay between pH and log P and the interplay between pH and weak base. This 
indicates that differences in drug ionisation determine the drug solubility in the fasted state 
colonic fluid of UC patients. Additionally, a higher drug solubility of neutral lipophilic 
compounds is expected in the fasted state colonic fluids of UC patients. 
For fed state colonic media, the predictive power of the developed PLS model was 
acceptable (q2 0.49, r2 0.71). Most influential variables of the model with positive impact 
were the categorical variable weak acid and the interplay between pH/log P and pH/weak 
acid. Additionally, a positive effect of log P was influential to the model (VIP>0.7). A 
negative impact on the % Relative Effect on drug solubility was observed for the categorical 
variable neutral and the interplay between pH and weak base. Differences in ionisation are 
therefore, expected to be the major influence on drug solubility in the fed state colonic fluid 
of UC patients. 
Given the high number of UC media and the solubility studies of six compounds, the 
statistical models were acceptable. Further studies with more compounds would additionally 





Figure 3.7: Standardised coefficients of the PLS regression of drug solubility in UC 
simulated gastrointestinal fluids in the fasted state (left) and fed state (right) and different 
compartments of the GI tract (top: small intestine, bottom: colon). Red colour denotes 
coefficients of VIP values > 1 and blue > 0.7. 
 
3.4.4. Drugs at risk of altered solubility in luminal fluids of UC patients 
Considering intestinal fluids in the fasted and fed state, compounds with a higher 
lipophilicity are expected to show a lower drug solubility in UC patients compared to healthy 
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subjects. This is especially expected for UC patients with low concentrations of bile salts 
and lecithin in their intestinal fluids. 
In terms of fasted state colonic fluids of UC patients, a high risk of altered drug solubility is 
indicated for weak bases and weak acids. For weak acids, a lower drug solubility is expected 
in fasted state colonic fluids of UC patients compared to healthy subjects. For weak bases, a 
higher drug solubility is expected in UC patients with a low pH in their fasted state colonic 
fluids. Additionally, neutral moderately lipophilic drugs are expected to have a higher 
solubility in UC patients with increased concentrations of soluble proteins (relapse and 
remission) in their fasted state colonic fluids. 
Regarding the fed state colonic fluid of UC patients, the altered colonic pH in UC patients 
poses a risk for ionisable drugs. For weak acids, a higher drug solubility is expected in UC 
patients with increased pH in their fed state colonic fluids, whereas for weak bases a lower 
drug solubility is expected. In addition, a lower solubility of neutral moderately lipophilic 
drugs is expected in the fed state colonic fluids of UC patients with low lecithin 
concentration.  
3.5. Conclusion  
Biorelevant media were developed as in vitro tool to assess drug solubility and dissolution 
in UC patients for different GI compartments and prandial states based on literature data 
investigating pathophysiological changes in UC. The characterisation of UC biorelevant 
media showed differences in terms of surface tension, buffer capacity and osmolality 
compared to healthy biorelevant media. These findings suggest that drug product 
performance could be affected for certain drugs and formulations due to e.g., changes in the 
wetting behaviour or drug solubility due to the common ion effect or pH. 
A lower drug solubility in UC intestinal luminal fluids is expected for compounds with high 
lipophilicity, especially in patients with low concentrations of bile salts and lecithin. In the 
fasted state colonic fluid of UC patients, weak bases and weak acids are at high risk of altered 
drug solubility compared to healthy subjects. Additionally, neutral drugs are likely to have 
a higher solubility due to increased concentrations of soluble proteins. In the fed state colonic 
fluids of UC patients, ionisable drugs have a high risk of altered drug solubility. Furthermore, 
a lower solubility of neutral drugs is expected in the fed state colonic fluids in UC patients 
with low lecithin concentration.  
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To increase the confidence in the predictions of drug solubility in UC patients, further studies 
assessing the luminal fluid composition in UC patients are needed. Furthermore, the 
confidence in the presented statistical models can be increased by investigating additional 
compounds. 
Differences in drug solubility in luminal fluids of UC patients compared to healthy subjects 
can be identified using biorelevant UC media, without the need to conduct expensive clinical 
trials. Apart from differences in drug solubility and dissolution, UC can affect a drug’s 
permeability, distribution, gut wall/hepatic metabolism and elimination. Therefore, in vitro 
solubility or dissolution tests can be used as input for physiologically-based pharmacokinetic 
models that offers the possibility to predict drug product performance considering all ADME 
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Gastrointestinal diseases and their impact on drug solubility. 
Part III. Coeliac disease 
Abstract 
Objectives 
The aim of this study was to develop biorelevant media for patients with Coeliac disease 
(CED) using a Design of Experiment (DoE) approach as in vitro tool for predicting drug 
solubility and dissolution in their intestinal fluids. The CED biorelevant media were 
characterised according to their surface tension, osmolality, dynamic viscosity and buffer 
capacity. By performing solubility studies of six drugs with different physicochemical 
properties in CED media, we aimed to identify drugs at high risk of altered luminal solubility 
in CED patients.  
Key findings 
Identified published differences in CED patients compared to healthy subjects were related 
to a higher concentration of bile salts, lecithin and cholesterol and included as factors in the 
DoE resulting in 8 CED biorelevant media. Differences in media properties were observed 
for the surface tension between CED and healthy biorelevant media. In terms of solubility, 
only a minimal effect of CED on the solubility of the hydrophilic neutral compound 
azathioprine was observed. For neutral moderately lipophilic compounds (budesonide, 
celecoxib), a higher surfactant concentration resulted in most cases in a higher drug 
solubility, while it was specific to each drug whether this was driven majorly by bile salts or 
lecithin. In comparison, drug solubilisation of ionisable compounds with moderate to high 
lipophilicity was less impacted by CED differences. 
Conclusions 
The developed biorelevant CED media serve as in vitro tool to identify the main media 
factors impacting on drug solubility in CED. Further studies assessing the luminal fluid 
composition in patients with CED are needed to increase the confidence in the developed in 




Coeliac disease (CED) is a chronic auto-inflammatory disease induced by an intolerance to 
dietary gluten, a storage protein of wheat, rye, barley and oats. Approximately 1% of the 
population is affected by CED and its aetiology is a combination of genetic predisposition 
and environmental factors (e.g., breastfeeding, time of gluten introduction and the 
microbiota).1 CED mainly affects the small intestine resulting in gastrointestinal (GI) 
symptoms such as bloating, diarrhoea, malabsorptive symptoms and weight loss. 
Additionally, CED patients can present extra-intestinal symptoms such as dermatitis 
herpetiformis, anaemia or osteoporosis.2 The diagnosis involves serological testing for 
autoantibodies (anti-tTG, anti-EMA) and an endoscopic biopsy.3 Depending on the damage 
of the small intestine, the disease can be classified in different disease grades based on 
histological findings such as crypt hyperplasia, the constitution of the villi and the intra-
epithelial lymphocytes in the jejunum and duodenum.4 For the treatment of CED, patients 
need to adhere to a gluten-free diet, the only known effective treatment to date, since the 
reintroduction of dietary gluten results in a relapse of the disease.5 More treatment options 
are expected to emerge in the near future, since several new active pharmaceutical 
ingredients have reached clinical phases of drug development in recent years.5 
Oral administration is due to patient convenience the preferred route of drug administration 
for most drugs. Consequently, patients with CED are likely to be treated with orally 
administered drug products for concomitant conditions or extra-intestinal manifestations of 
CED. Since oral drug administration is, apart from drug and formulation properties, 
dependent on GI physiology, pathophysiological changes in CED could affect drug safety 
and efficacy. GI diseases can affect various processes involved in oral drug delivery e.g., 
drug release from the formulation, drug dissolution, permeation through the GI membrane 
and gut or hepatic metabolism.6 Altered drug absorption in CED patients compared to 
healthy subjects has previously been attributed to a reduced small intestinal surface area, a 
different intestinal CYP enzyme abundance, a higher jejunal permeability and differences in 
gastric emptying.7 
So far, there is only a small number of drugs for which drug product performance has been 
investigated in CED patients and these studies included only a small number of patients.7 
Due to the high costs of clinical trials, it is expected that in the future investigations in CED 
patients will remain rare.  
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For poorly soluble drugs, drug absorption can be limited by the dissolution rate or the 
solubility of the drug in GI fluids.8 If this is the case, in vitro release and dissolution testing 
can be used as surrogate for a drug’s in vivo performance.8 In vitro setups with a close 
representation of in vivo conditions are expected to result in better predictions. To simulate 
closely the conditions present in the GI tract, biorelevant media have been developed 
mimicking the composition of the GI fluids of healthy subjects.9-13 The composition of the 
GI fluids can be altered in patients with GI disease and therefore, in vitro dissolution and 
solubility studies with biorelevant media adapted to pathophysiological conditions could 
result in better predictions of drug product performance in patient populations. 6 
This study aims to identify drugs at risk of altered solubility in GI fluids of patients with 
CED by developing biorelevant media for patients with CED representative of the small 
intestinal fluid in the fasted and fed state. Therefore, information from literature was 
collected to identify differences in the composition of luminal contents of patients with CED 
compared to healthy subjects. Biorelevant media for patients with CED were developed 
based on biorelevant media for healthy subjects and a Design of Experiment (DoE) approach 
by integrating the identified differences as factors with two levels. Subsequently, the CED 
biorelevant media were characterised in terms of surface tension, osmolality, buffer capacity 
and dynamic viscosity. Additionally, the solubility of six compounds with different 
physicochemical properties in the developed CED and healthy biorelevant media was 
determined. 
4.2. Materials 
Acetic acid High Performance Liquid Chromatography (HPLC) grade, chloroform, sodium 
oleate, budesonide, phosphoric acid and sodium hydroxide were purchased from Sigma-
Aldrich Company Ltd., Dorset, England. Sulfasalazine, loperamide hydrochloride, 
dipyridamole, celecoxib, azathioprine, methanol HPLC grade and acetonitrile HPLC grade 
were purchased from VWR International Ltd, Lutterworth, UK. Sodium chloride, 
trifluoroacetic acid (TFA), potassium dihydrogen orthophosphate, dimethyl sulfoxide and 
maleic acid were used from Fisher Scientific UK Ltd., Loughborough, England. Other 
chemicals used included sodium taurocholate (Prodotti Chimici Alimentari S.P.A., 
Basaluzzo, Italy), egg lecithin–Lipoid EPCS (Lipoid GmbH, Ludwigshafen, Germany), 
glyceryl monooleate–Rylo Mg 19 (Danisco, Brabrand, Denmark) and cholesterol (95%, 





4.3.1. Media development 
4.3.1.1. GI physiological differences in CED compared to healthy subjects 
To identify differences in the composition of GI fluids of CED patients compared to healthy 
subjects, a literature search was performed. Since to date the GI fluids of CED patients have 
not been directly characterised, studies investigating parameters that most likely impact on 
GI fluids were considered. 
The bile flow and biliary lipid output was previously investigated in CED patients and 
healthy subjects using a duodenal intubation technique with a constant infusion of a liquid 
formula diet.14 Biliary lipid outputs such as cholesterol, bile acids and phospholipids could 
then be estimated by the dilution of a marker, polyethylene glycol 4000. The bile flow was 
with 232±29 mL/h (mean ± SD) significantly higher in CED patients compared to 
132±24 mL/h in healthy subjects (Student’s t-test, p<0.05). The biliary cholesterol output 
normalised to the body weight was significantly increased in CED patients (0.82±0.10 vs 
0.43±0.06 mg/kg*h, p<0.02). Similarly, the biliary output of phospholipids was also highly 
increased in CED patients compared to healthy subjects (0.26±0.05 vs 0.08±0.02 mg/kg*h, 
p<0.02). Additionally, a higher bile acid output was observed in CED patients (9.28±1.65 vs 
4.64±0.45 mg/kg*h). In accordance, it was observed that the bile salt pool is three times 
higher in CED patients compared to healthy subjects which could be related to a very 
effective ileal reabsorption of bile acids or a sluggish contraction of the gall bladder.15 
4.3.1.2. Development of CED media with Design of Experiment 
The development of biorelevant media for CED patients followed a DoE approach and CED 
biorelevant media representative of the small intestinal fluid in the fasted and fed state were 
developed. Biorelevant media previously developed based on healthy subjects were used as 
the basis for CED biorelevant media and included Fasted-State Simulated Intestinal Fluid-
Version 2 (FaSSIF-V2) and Fed-State Simulated Intestinal Fluid-Version 2 (FeSSIF-V2).11 
According to the identified differences described in Section 4.3.1.1, healthy biorelevant 
media were modified by including the respective differences as factors in the experimental 
design. For both prandial states, the integrated factors were the concentration of bile salts, 
lecithin and cholesterol. Since the biliary secretion is the main source of bile salts, lecithin 
and cholesterol present in the intestinal fluids, a direct correlation between biliary output and 
intestinal concentration was assumed. Due to the three parameters not being directly 
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measured in the GI fluids, an indirect percental approach was followed to determine the level 




∗ 𝑥𝐻−𝐵𝑀         (4.1) 
where 𝑥𝐶𝐷−𝐵𝑀 is the high level of the factor in CD media, 𝑦𝐶𝐷 and 𝑦𝐻 are the median of the 
corresponding biliary output observed in CD patients and healthy subjects, respectively and 
𝑥𝐻−𝐵𝑀 is the level of the factor in healthy biorelevant media. 
The three factors were integrated with two levels in the experimental design, a low and a 
high level. The low level was based on the concentration in healthy biorelevant media (Table 
2.3) and the high level corresponded to the median percentage of the respective 
concentration in the healthy medium. For cholesterol, the low level concentration was based 
on the median concentration of cholesterol observed in human intestinal fluid as observed 
previously (fasted state: 0.08 mM, fed state: 0.57 mM), since cholesterol is not a component 
of FaSSIF-V2 and FeSSIF-V2.16  
The DoE was performed with Statgraphics Centurion 18 (Statpoint Technologies Inc., VA, 
US) with a full factorial design for CED intestinal biorelevant media for the fasted and fed 
state. An overview of the DoE is given in Figure 4.1. Biorelevant media were prepared as 
previously described with an additional step of adding cholesterol.11 The cholesterol solution 
(50 mg/mL in chloroform) was mixed with a lecithin solution (100 mg/mL in 
dichloromethane) using a magnetic stirrer, before being added to the bile salt/buffer mixture 
and driven off using a rotary evaporator Büchi Rotovapor R-114 (Büchi Labotechnik, Flawil, 
Switzerland) according to the published protocol. The osmolality of CED media was set to 






Figure 4.1: Design of Experiments for the development of Coeliac disease intestinal 
biorelevant media (*value observed in human intestinal fluids16). 
 
4.3.1.3. Media characterisation 
Surface tension, osmolality, dynamic viscosity and buffer capacity of biorelevant media 
previously developed based on healthy subjects and newly developed for CED patients were 
measured in triplicate. The results are reported as mean with standard deviation. 
4.3.1.3.1. Surface tension 
Surface tension measurements were performed with a ring tensiometer (Sigma 700 Force 
tensiometer, Attension, UK) using approximately 10 mL of each medium, placed in a glass 
vessel with a diameter of 46 mm. A platinum Du Noüy ring was lowered below the meniscus 
of the medium. Subsequently, by pushing and pulling the ring through the surface of the 
medium, the force exerted by the meniscus was measured and related to the surface tension 
of the medium.17 
4.3.1.3.2. Osmolality 
Osmolality was determined with an Advanced Instruments Inc. micro-osmometer Model 
3300 (Norwood, MA, US). Therefore, the freezing-point depression of a 20 µl sample was 
measured with a high-precision thermistor following the supercooling and induced 





4.3.1.3.3. Dynamic viscosity 
The dynamic viscosity at 37⁰C was measured with a Bohlin Rheometer C-VOR (Malvern 
instruments, UK). Therefore, a cone-plate measuring system, including a rotating upper cone 
(4°, 40 mm) and a fixed lower plate with the medium contained between them, was used. 
The shear rate was measured while twenty different shear stresses, logarithmically 
distributed in the range of 0.05 to 0.15 Pa, were exerted on the sample of the medium. The 
ratio of shear stress to shear rate corresponds to the dynamic viscosity. 
4.3.1.3.4. Buffer capacity 
Buffer capacity was determined using a potentiometric titration method. Therefore, small 
volumes of 0.5 M hydrochloric acid were added to 10 mL of sample until a change of one 
pH unit was recorded by a Mettler Toledo SevenCompact S220 pH meter (Schwerzenbach, 








                   (4.2) 
 
where Vacid is the volume of the acid added and ΔpH corresponds to the change in pH.
18 
4.3.1.4. Compound selection 
For the solubility studies, poorly soluble compounds belonging to Biopharmaceutics 
Classification System (BCS) class II (low solubility, high permeability) or IV (low 
solubility, low permeability) were selected as shown in Table 4.1. Additionally, the selected 
drugs varied in their ionisation properties (pKa) and lipophilicity (log P). Drugs with an 




Table 4.1: Overview over physicochemical characteristics and indication of selected 
compounds for solubility studies. 
Neutral drugs Weak bases Weak acid 
Azathioprine: 
• pKa 7.9 (acid)19 
• log P 0.120 




• pKa 6.4 (base)22 
• log P 2.223 
• BCS class II24 




• pKa 2.3 (acid), 7.925 
• log P 2.926 
• BCS class II or IV21 
• Anti-inflammatory 
agent in IBD 
 
Budesonide 
• pKa 12.0 (acid)27 
• log P 2.628 
• BCS class II29 





• pKa 8.6 (base)30 
• log P 5.531 
• BCS class II24 




• pKa 11.1 (acid)32 
• log P 3.532 






4.3.1.5. Solubility studies 
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The shake-flask method was used to determine the solubility of the investigated 
compounds.34 Therefore, an excess amount of drug was added to 5 mL of the respective 
medium in a glass tube, which was placed in a shaking water bath (Grant instruments, 
Royston, UK) and maintained at 37 °C and 200 strokes/min for 24 h. Subsequently, GF/D 
membrane filters with a pore size of 2.7 μm (Whatman® Puradisc, diameter 13 mm) were 
used to filter, followed by the quantitative analysis of the supernatant with HPLC-Ultraviolet 
(UV). The solubility studies were performed in triplicate in CED disease media and healthy 
media and average solubility differences between CED media and healthy media were 
expressed as a % Relative Effect on solubility [((SCED-SHealthy)/ SHealthy) x 100]. A higher drug 
solubility in CED media compared to healthy media is indicated by a positive value, whereas 
the opposite is indicated for negative values. HPLC analysis was performed with an Agilent 
Technologies 1200 series HPLC system (Santa Clara, CA, US) including a binary pump 
(G1212A), an autosampler (G1329A), a thermostatted column compartment (G1316A) and 
a diode array detector (G1315D). The methods used for the HPLC-UV analysis of the six 
drugs were modifications of previously published methods (presented in Gastrointestinal 
diseases and their impact on drug solubility. Part I. Crohn’s disease [Chapter 2]). 
4.3.1.6. Statistical analysis 
Differences between media properties and drug solubility in CED disease biorelevant media 
compared to healthy biorelevant media were identified with the software XLSTAT 
(Addinsoft, France) using one-way analysis of variance (ANOVA) with a post-hoc Tukey’s 
test and a significance level of p≤0.05. 
A multifactorial ANOVA performed in Statgraphics Centurion 18 (Statpoint Technologies 
Inc., VA, US) was used to estimate the effects of the three categorical variables (bile salts, 
lecithin, cholesterol) and two-factor interactions in the DoE on the solubility of each of the 
six investigated compounds. Factors were considered statistically significant if the p-value 
was less than 0.05, indicating an effect on drug solubility at the 95.00% confidence level.  
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4.4. Results and discussion 
4.4.1. Media characterisation  
Figure 4.2: Surface tension (blue, left y-axis) and osmolality (rose, right y-axis) of Coeliac 
disease biorelevant media according to the Design of Experiment (green: high level, red: low 
level, white: healthy level) and healthy media (H).  
 
The surface tension of fasted and fed state intestinal CED biorelevant media is shown in 
Figure 4.2. In the fasted state, the surface tension of all media with low bile salt concentration 
was increased compared to the healthy medium (p<0.05). This finding is consistent with 
another study, where a higher surface tension was observed for reduced bile salt 
concentrations in fasted state simulating fluids without cholesterol.35 Additionally, media 
with at the same time high bile salt and lecithin concentrations possessed a significantly 
higher surface tension compared to the healthy medium but a lower surface tension 
compared to all CED media with low bile salt concentrations (p<0.05). In the fed state, the 
surface tension of all CED media with low lecithin concentrations, except for the medium 
with at the same time low bile salt and cholesterol concentrations, was significantly 
decreased (p<0.05).  
The osmolality of CED and healthy biorelevant media was not significantly different. 
The measured dynamic viscosities of CED biorelevant media at a shear stress of 0.06 Pa, 
0.08 Pa and 0.15 Pa are presented in Figure 4.3. All healthy and CED media showed shear 
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thinning behaviour. The viscosity of CED biorelevant media at an applied shear stress of 
0.15 Pa was in the range of 3.26 to 3.56 mPas, at 0.08 Pa in the range of 3.70 to 4.56 mPas 
and at 0.06 Pa in the range of 4.28 to 6.42 mPas. No significant differences between CED 
and healthy biorelevant media were observed considering all three different shear stresses 
(p<0.05). 
 
Figure 4.3: Dynamic viscosity of Coeliac disease biorelevant media and the corresponding 
healthy biorelevant media (H) at different shear stress (0.06 Pa: blue, 0.08 Pa: red, 0.15 Pa: 
black) according to the Design of Experiments (green: high level, red: low level, white: 
healthy level). 
 
The buffer capacity was not significantly different in healthy fasted and fed state intestinal 
media compared to CED media, since the same buffer composition was used and no changes 
to the media pH were applied (data not shown).  
4.4.2. Solubility of drugs in CED biorelevant media 
4.4.2.1. Neutral drugs 
The results of the solubility studies with neutral compounds in CED fasted and fed state 
intestinal media are illustrated in Figure 4.4.  
For azathioprine, the solubility in the fasted state was not significantly different in CED 
media compared to healthy media. In the fed state, the solubility of azathioprine was 
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significantly higher in CED biorelevant media with high concentrations of bile salts but the 
relative increase was for all media below 15%. 
For budesonide, the solubility in all fasted state CED biorelevant media was significantly 
higher compared to the healthy medium (p<0.05), whereby the solubility of budesonide was 
highest in CED media with high bile salt concentrations. The positive effect of bile salts is 
in accordance with a previous study showing that an increase of the concentration of bile 
salts in a fixed 4:1 ratio of bile salts to lecithin resulted in an increase in budesonide 
solubility.36 Additionally, the positive effect of cholesterol on budesonide solubilisation 
indicates a drug-cholesterol interaction or a positive solubilisation effect of more complex 
vesicles (sodium taurocholate-lecithin-cholesterol) as previously reported for fenofibrate.37 
In the fed state, the solubility of budesonide in the CED media with at the same time low 
concentrations of bile salts and lecithin was significantly decreased compared to the healthy 
medium (p<0.05), indicating a competition for solubilisation between cholesterol and 
budesonide possibly due to the similarity of their chemical structure. In contrast, a 
significantly higher solubility was observed in CED media with high concentrations of bile 
salts and lecithin and CED media with either a high concentration of bile salts or lecithin 
and a low concentration of cholesterol (p<0.05), indicating a positive effect of higher 
surfactant concentration and a negative effect of cholesterol on budesonide solubility. 
For celecoxib, the solubility in fasted state CED media with a high concentration of lecithin 
and a low concentration of cholesterol was significantly higher compared to the healthy 
medium. In contrast, in all other CED fasted state media, the solubility of celecoxib was 
significantly lower (p<0.05). The positive effect of lecithin on celecoxib solubility is in 
accordance with previous results revealing a higher solubility of celecoxib in FaSSIF (higher 
concentration of lecithin) compared to FaSSIF-V2.38   
In the fed state, the solubility of celecoxib was significantly higher in CED media with at 
the same time high concentrations of bile salts and lecithin (p<0.05), suggesting a positive 





Figure 4.4: % Relative Effect (RE) on the solubility of neutral (at pH 5.8-6.5) investigated 
drugs in Coeliac disease intestinal biorelevant media compared to the corresponding healthy 
media according to Design of Experiment (red lines: low concentration of cholesterol, blue 




4.4.2.2. Weak acid 
The results of the solubility studies in CED fasted and fed state intestinal media with 
compounds possessing different ionisation properties are presented in Figure 4.5.  
For the weak acid sulfasalazine, the solubility in fasted state CED media with at the same 
time high concentrations of lecithin and low concentrations of cholesterol is significantly 
lower compared to the healthy medium (p<0.05). In fed state intestinal media, the solubility 
of sulfasalazine was significantly higher in CED media with high bile salt concentrations 
and in the medium with a low concentration of bile salts and lecithin and a high concentration 
of cholesterol. 
4.4.2.3. Weak bases 
For the weak base dipyridamole, the solubility was significantly higher in fasted state CED 
media with high bile salt concentrations and to a lower extent also in the medium with a high 
concentration of lecithin and low concentrations of bile salts and cholesterol (p<0.05). The 
positive effect of bile salts on the solubility of dipyridamole is most likely the result of 
electrostatic interactions of the weak base with sodium taurocholate. In the fed state, the 
solubility of dipyridamole in the CED medium with a high concentration of lecithin and low 
concentrations of bile salts and cholesterol was significantly lower compared to the 
corresponding healthy medium (p<0.05). 
For loperamide hydrochloride, the solubility in the fasted state CED media with high 
concentrations of lecithin and cholesterol and a low concentration of bile salts was 
significantly lower compared to the corresponding healthy medium (p<0.05). This is 
possibly due to less bile salts being available for drug solubilisation due to the need for 
lecithin and cholesterol solubilisation. In the fed state, the solubility of loperamide 
hydrochloride was not significantly different in CED media compared to the corresponding 




Figure 4.5: % Relative Effect (RE) on the solubility of weak acids and bases in Coeliac 
disease intestinal biorelevant media compared to the corresponding healthy media according 
to Design of Experiment (red lines: low concentration of cholesterol, blue lines: high 
concentration of cholesterol).  
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4.4.3. Multifactorial statistical analysis of solubility in CED media 
For CED fasted state intestinal media, the significant effects and two-factor interactions 
affecting the drug solubility of the six investigated drugs are presented in Table 4.2.  
For azathioprine and budesonide, only the bile salt concentration had a positive impact on 
their solubility. For celecoxib, the highest positive effect on solubility had the lecithin 
concentration, followed by a negative effect of cholesterol. Additionally, all two-factor 
interactions were significant for the solubility of celecoxib but less influential in comparison 
to both main effects. For dipyridamole, the highest positive impact on its solubility was 
observed for bile salts. Other significant effects for dipyridamole were a positive effect of 
lecithin, a negative effect of cholesterol and the interaction between bile salts and cholesterol 
was significant. Considering loperamide, bile salts showed a positive and cholesterol a 
negative impact on solubility. For sulfasalazine solubility, a positive effect of cholesterol 
was observed, followed by a significant interaction of bile salts and cholesterol and a positive 
effect of the bile salt concentration. 





AZA BUD CEL DIP LOP SSZ 
BS + (9.07) + (32.52)  + 
(1165.22) 
+ (10.11) + (4.64) 
Lec   + 
(908.98) 
+ (4.70)   
Chol   - (199.47) - (5.43) - (4.92) + (37.77) 
BS/Lec   - (15.79)    
BS/Chol   + (19.59) + (4.82)  + (6.74) 
Lec/Chol   - (141.76)    
+: positive effect, -: negative effect, (F-ratio), BS: bile salts, Lec: lecithin, Chol: cholesterol, 
AZA: azathioprine, BUD: budesonide, CEL: celecoxib, DIP: dipyridamole, LOP: 
loperamide, SSZ: sulfasalazine 
For CED fed state intestinal media, the significant effects and two-factor interactions with 
an impact on the drug solubility of all six drugs are shown in Table 4.3.  
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For azathioprine, the bile salt concentration had the highest positive impact on solubility, 
followed by a positive impact of cholesterol. Considering budesonide solubility, all three 
main effects were significant with the highest positive impact of bile salts, followed by a 
positive impact of lecithin and a negative impact of cholesterol. The two-factor interactions 
bile salts/cholesterol and lecithin/cholesterol were also significant but less influential 
compared to the main effects. For celecoxib, the lecithin concentration had the highest 
positive impact on its solubility, followed by a positive effect of the bile salt concentration. 
For dipyridamole, bile salts and cholesterol had a positive impact on solubility. Additionally, 
the interaction of bile salts and cholesterol was significant. Considering loperamide 
solubility, a negative impact of cholesterol was observed and a smaller positive effect of the 
lecithin concentration. For sulfasalazine, only the bile salt concentration had a positive 
impact on its solubility. 




AZA BUD CEL DIP LOP SSZ 
BS + (24.83) + 
(328.11) 
+ (6.56) + (78.90)  + (17.47) 
Lec  + 
(309.56) 
+ (62.68)  + (8.09)  
Chol + (6.44) - (125.57)  + (23.48) - (12.55)  
BS/Lec       
BS/Chol  - (6.51)  + (6.18)   
Lec/Chol  - (4.97)     
+: positive effect, -: negative effect, (F-ratio), BS: bile salts, Lec: lecithin, Chol: cholesterol, 
AZA: azathioprine, BUD: budesonide, CEL: celecoxib, DIP: dipyridamole, LOP: 
loperamide, SSZ: sulfasalazine  
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4.4.4. Drugs at risk of altered solubility in luminal fluids of CED patients 
For hydrophilic compounds, only small differences in drug solubility are expected between 
intestinal fluids of CED patients and healthy subjects as shown by the low impact of CED 
alterations on azathioprine solubility.  
A higher impact of CED on drug solubility is expected for neutral compounds with moderate 
to high lipophilicity. For these drugs, a higher luminal surfactant concentration (bile salts, 
lecithin) is expected to result in a higher solubility. It seems to be specific to each drug 
whether this increase in solubility is mainly driven by bile salts as in the case of budesonide 
or lecithin as in the case of celecoxib.  
A lower risk of altered intestinal solubility in CED is expected for ionisable compounds with 
moderate to high lipophilicity since drug solubilisation was less impacted by CED changes 
integrated in the DoE compared to neutral lipophilic compounds. 
4.5. Conclusion  
In the current study, biorelevant media developed representative for the small intestinal fluid 
in fasted and fed state of patients with CED showed differences in media properties and drug 
solubilisation compared to biorelevant media developed based on healthy subjects. In terms 
of media properties, CED biorelevant media showed different surface tensions with some 
CED media possessing a higher surface tension in the fasted state, whereas a lower surface 
tension was observed in some CED media in the fed state. Most likely, this is the result of 
different concentrations of sodium taurocholate, lecithin and cholesterol resulting in self-
assembled structures with a different composition. The different surface tension indicates 
that the wetting of the surface of a drug or formulation could be altered in CED patients 
compared to healthy subjects.  
In terms of solubility, hydrophilic neutral compounds possess a minimal risk of altered drug 
solubility in intestinal fluids of patients with CED. Considering neutral compounds with 
moderate to high lipophilicity, a higher impact of CED on drug solubility is expected with a 
higher surfactant concentration (bile salts, lecithin) resulting in most cases in a higher drug 
solubility. The driving factor behind the increase in drug solubility, either the higher bile salt 
or lecithin concentration, seems to be specific to each drug. For ionisable compounds with 
moderate to high lipophilicity, drug solubilisation was less impacted by CED differences 
compared to neutral lipophilic compounds.  
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To increase the confidence in the developed in vitro tool, further studies assessing the 
luminal fluid composition in patients with CED are needed. Additionally, drug product 
performance in patients with CED can also be affected by other pathophysiological changes 
in terms of GI transit time, enzyme and transporter abundance or available absorptive surface 
area. To also account for these differences in patients with CED compared to healthy 
subjects, physiologically-based pharmacokinetic (PBPK) models can be used. PBPK models 
are complex mechanistic models that predict the absorption, distribution, metabolism and 
elimination of a drug using various physiological information, experimental data and drug 
characteristics. By using a trial population adapted to the physiology of patients with CED, 
PBPK models can be used to predict the plasma concentration profile of the investigated 
drugs in patients with CED. To account for differences in drug dissolution in CED, the 
results from in vitro solubility and dissolution studies using the developed CED biorelevant 
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Predicting budesonide performance in healthy subjects and 
patients with Crohn’s disease using biorelevant in vitro 
dissolution testing and PBPK modelling 
Abstract 
Objectives 
Drug product performance might be affected in Crohn’s disease (CD) patients compared to 
healthy subjects due to pathophysiological changes. Since a low number of clinical studies 
is performed in this patient population, physiologically-based pharmacokinetic (PBPK) 
models with integrated results from biorelevant in vitro dissolution studies could be used to 
assess differences in the bioavailability of drugs. Using this approach, budesonide was used 
as model drug and its performance in healthy subjects and patients with CD was predicted 
and compared against observed pharmacokinetic (PK) data. 
Key findings 
The in vitro release tests revealed a similar extent of drug release from a controlled-release 
budesonide formulation in the fasted state, whereas in the fed state a lower extent was 
observed. Differences in the physiology of patients with CD were identified in literature and 
their impact on budesonide performance was investigated with a PBPK model, revealing the 
highest impact on the simulated bioavailability for the reduced hepatic CYP3A4 enzyme 
abundance and lower human serum albumin concentration. For patients with CD, a higher 
budesonide exposure compared to healthy subjects was predicted with a PBPK population 
adapted to CD physiology and in agreement with observed PK data. 
Conclusions  
Budesonide performance in the fasted and fed state was successfully predicted in healthy 
subjects and patients with CD using PBPK modelling and in vitro release testing. Following 
this approach, predictions of the direction and magnitude of changes in bioavailability due 
to CD could be made for other drugs and guide prescribers to adjust dosage regimens for CD 




Crohn’s disease (CD) is, along with ulcerative colitis (UC), one of the main types of 
inflammatory bowel disease (IBD). It is estimated that 3.7 million persons in Europe are 
affected by IBD, whereof CD is estimated to affect 1.6 million people.1 CD is to date a non-
curable disease and therefore, lifelong medical treatment adapted to the disease state (relapse 
or remission) is required.2 Apart from the treatment for CD, it has been shown that the use 
of various other medications such as antidepressants, cardiovascular medication or non-
steroidal analgesics was increased in IBD patients compared to control subjects.3  
The oral drug delivery route is important for IBD patients not only for local drug therapy, 
but also for the medical treatment of concomitant conditions. Since oral drug delivery relies 
on the physiological conditions in the gastrointestinal (GI) tract, pathophysiological changes 
could affect drug product performance in patients with CD. In the worst case, the drug 
release from a formulation can be impeded and the formulation can accumulate in the GI 
tract, as recently reported for mesalamine pills in the medium ileum of a patient with CD.4 
Reported changes in patients with CD with potential impact on drug product performance 
include differences in GI transit time, in the composition of GI fluids and in the abundance 
of metabolizing enzymes.5 Apart from the GI tract, CD also presents systemic symptoms 
with potential to alter a drug’s pharmacokinetics. Moreover, pharmacodynamic effects can 
differ between healthy subjects and patients with CD as suggested in the cases of alfentanil 
and verapamil.6, 7 This highlights the need to test medications in patients with CD. However, 
expensive clinical trials are rarely performed in this patient population, especially for drugs 
for the treatment of concomitant diseases. Hence, the use of in vitro and in silico tools to 
identify drugs at risk of altered performance in patients with CD could be a less expensive 
and time-saving alternative. 
Drug release from pharmaceutical formulations and drug dissolution in the GI fluids has 
been successfully simulated using in vitro dissolution testing with the USP IV apparatus 
(flow-through cell).8-10 For poorly-soluble compounds, the use of biorelevant dissolution 
media, simulating closely the GI fluid composition of healthy subjects, resulted in successful 
predictions of drug absorption.11-14 This approach has previously been extended by 
considering pathophysiological differences in patients with CD for the development of CD 
biorelevant media, which can be used for solubility or dissolution studies (Chapter 2). 
The experimentally obtained dissolution profiles can be integrated in physiologically-based 
pharmacokinetic (PBPK) models. PBPK models are mathematical models that predict a 
drug’s pharmacokinetic plasma profile by integrating various ADME (absorption, 
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distribution, metabolism, excretion) processes and considering the physiology of the study 
subject, the physicochemical properties of the drug, in vitro or in silico ADME information 
and the trial design. In terms of the physiology of the subjects, it can be accounted for 
pathophysiological differences by developing a virtual patient population in the PBPK 
model. This approach has resulted in improved predictions of drug product performance in 
patients with liver cirrhosis15, critically septic patients16, chronic kidney disease17 and 
patients after post-bariatric surgery18, 19 or in the perioperative setting20. 
Budesonide is a locally-acting corticosteroid due to its high ratio of topical to systemic 
activity and is indicated for the treatment of asthma after pulmonary administration or for 
the treatment of IBD after oral administration.21 To deliver budesonide to the affected 
regions in the GI tract of patients with IBD, available formulations on the market include 
multi-particulate controlled-release formulations such as Entocort® (Tillotts Pharma UK 
Ltd., Wellingore, UK) with a triggering pH of 5.5 or Budenofalk (Dr. Falk Pharma, Freiburg, 
Germany) with a triggering pH of 6.4 and a multimatrix monolithic formulation with time-
dependent release (Uceris, Santarus, San Diego, CA, USA).22 Both multi-particulate 
formulations aim to deliver budesonide to the terminal ileum and ascending colon, the region 
most often affected in patients with CD. Budesonide can be grouped as drug with 
intermediary hepatic extraction ratio (0.3 < EH < 0.7), due to its high intestinal extraction 
ratio of at least 0.50 contributing to the low bioavailability in healthy subjects in the range 
of 9% in the fasted state and 12% in the fed state.23, 24 In patients with CD, a higher 
bioavailability after oral budesonide administration has been reported in several studies.24-26 
The aim of the present study was to develop a biorelevant in vitro dissolution method and a 
PBPK model to predict the performance of budesonide in healthy subjects and patients with 
CD. Therefore, the release of budesonide from the controlled-release formulation Entocort® 
was simulated with the USP IV dissolution apparatus in healthy and CD conditions. A PBPK 
model for budesonide was developed for healthy subjects considering intravenous and oral 
administration. The effect of pathophysiological differences in patients with CD on 
budesonide performance was investigated with parameter sensitivity analysis (PSA) and a 
population representative of patients with CD was developed and used to predict budesonide 
performance in this patient population. 
 
5.2. Materials 
Acetic acid High Performance Liquid Chromatography (HPLC) grade, pepsin from porcine 
gastric mucosa, sodium oleate, α-D-glucose, budesonide and sodium hydroxide were 
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purchased from Sigma-Aldrich Company Ltd., Dorset, England. Methanol HPLC grade, 
acetonitrile HPLC grade and cholic acid sodium salt were purchased from VWR 
International Ltd, Lutterworth, UK. Tris(hydroxymethyl)aminomethane, hydrochloric acid 
36.5–38.0%, sodium chloride, trifluoroacetic acid (TFA), potassium dihydrogen 
orthophosphate and maleic acid were used from Fisher Scientific UK Ltd., Loughborough, 
England. Other chemicals used included sodium taurocholate (Prodotti Chimici Alimentari 
S.P.A., Basaluzzo, Italy), egg lecithin–Lipoid EPCS (Lipoid GmbH, Ludwigshafen, 
Germany) and glyceryl monooleate–Rylo Mg 19 (Danisco, Brabrand, Denmark). Water was 
ultra-pure (Milli-Q) laboratory grade. Entocort® CR 3 mg capsules were used from Tillotts 
Pharma UK Ltd., Wellingore, UK. 
5.3. Methods 
5.3.1. In vitro release tests 
A flow-through cell dissolution apparatus (Sotax CE7 smart, Sotax, Aesch, Switzerland), 
equipped with cells with a diameter of 22.6 mm and connected to a piston pump (Sotax CP7, 
Sotax, Aesch, Switzerland), was used in open mode and maintained at a temperature of 37⁰C. 
A 5 mm rubi bead was placed at the bottom of the cell, followed by 6 g glass beads with a 
diameter of 1 mm to fill the conical part of the cell. The investigated capsules were placed 
on top of the glass beads and a tablet holder was reversely positioned to avoid the floating 
of the capsules. Glass fibre filters (GF/D with a diameter of 2.7 μm and GF/F with a diameter 
of 0.7 μm) were placed on top of the cell. Different setups were used to simulate the fasted 
and fed state and healthy and CD conditions (Sections 5.3.1.1 and 5.3.1.2). Samples were 
collected every 30 min and analysed by HPLC-Ultraviolet (UV). All experiments were 
performed in triplicate. 
5.3.1.1. Healthy conditions 
5.3.1.1.1. Biorelevant media 
For healthy subjects, the passage through the GI tract was simulated with biorelevant media 
in the fasted state [Fasted-State Simulated Gastric Fluid (FaSSGF), Fasted-State Simulated 
Intestinal Fluid-Version 2 (FaSSIF-V2) and Fasted-State Simulated Colonic Fluid 
(FaSSCoF)] and fed state [Fed-State Simulated Gastric Fluid (FeSSGF), Fed-State 
Simulated Intestinal Fluid-Version 2 (FeSSIF-V2) and Fed-State Simulated Colonic Fluid 
(FeSSCoF)], mimicking closely the composition and properties of the gastric fluid, the small 
intestinal fluid and the ascending colon fluid, respectively.27-30 Biorelevant media were 




GI hydrodynamics are expressed in the USP IV apparatus by the flow rate and the duration 
of exposure to the specific dissolution medium. For healthy conditions, the hydrodynamics 
were defined based on a previously published method, confirmed with literature data of the 
GI passage of Entocort® (measured with scintigraphy) and modified according to recent 
literature data on gastric fluid volumes.8, 9, 24, 31, 32 An overview of the experimental setup is 
given in Table 5.1. 
Table 5.1: Healthy experimental conditions for in vitro release tests with the USP IV 
dissolution apparatus. 























Colon FaSSCoF 270-420 4 FeSSCoF 330-450 4 
 
5.3.1.2. CD conditions 
5.3.1.2.1. Biorelevant media 
To reflect the differences in the composition of the GI fluids of patients with CD compared 
to healthy subjects, previously developed biorelevant media adapted to CD conditions were 
used for the in vitro release tests and prepared using the same method as for healthy 
biorelevant media (Chapter 2). Since the development of CD biorelevant media followed a 
Design of Experiment (DoE) approach to reflect interindividual variability, several media 
have been developed for one prandial state and GI compartment with different levels of the 
investigated factors in the DoE. For the gastric fasted state CD media, the integrated factors 
were the pH and bile salt/lecithin concentration. For the fasted and fed state intestinal CD 
media, only the bile salt/lecithin concentration was used as factor. Considering the fasted 
and fed state colonic CD media, the osmolality and bile salt/lecithin concentration were 
integrated in the DoE. Details of the CD biorelevant media with integrated factors and their 
two levels, low and high, are presented in Table 5.2. For the current study, two different 
approaches were selected with one approach including all CD media with the low level of 
all factors and one approach with the high level of all factors. 
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Table 5.2: CD biorelevant media used for in vitro release studies. 
  Factor Low level High level 
Fasted state Stomach Bile salt/lecithin 
concentration [mM] 
0.035/0.008 0.08/0.02 
pH 1.5 4.1 
Intestine Bile salt/lecithin 
concentration [mM] 
1.29/0.09 3.00/0.20 






Fed state Intestine Bile salt/lecithin 
concentration [mM] 
4.30/0.86 10.00/2.00 








The experimental setup simulating conditions in patients with CD in the fasted and fed state 
is described in Table 5.3. In the fasted state, the time in the gastric compartment was reduced 
to 0.5 h as reported in vivo and the flow rate was increased to 12 mL/min, since no difference 
in gastric volume has been reported.34 The small intestinal phase was increased by 0.5 h in 
CD conditions compared to healthy conditions as indicated for active disease state.33 For the 
colonic phase, no adjustments to the healthy setup were made considering the 
hydrodynamics. 
In the fed state, the time in the gastric compartment was prolonged by 1.0 h according to in 
vivo data and the flow rate was reduced to 4 mL/min, since no difference in gastric fluid 
volume is expected.24 For the small intestinal phase, the time was reduced by 0.5 h as 





Table 5.3: Crohn’s disease experimental conditions for in vitro release tests with the USP 
IV apparatus. 
 Fasted state 
GI 
compartment 




In vivo transit times [h] 
Stomach CD-FaSSGF 
1) Low level 
2) High level 




1) Low level 
2) High level 
30 - 300 4 




1) Low level 
2) High level 
300 - 450 4 -  
 Fed state 
GI 
compartment 




In vivo transit times [h] 





1) Low level 
2) High level 
180 - 360 6 2.4 [Healthy 3.0]24 
Colon CD-FeSSCoF 
1) Low level 
2) High level 
360 - 480 4 8.1 [Healthy 15.5]24 
 
5.3.1.3. HPLC-UV analysis of budesonide 
The HPLC-UV analysis was performed with an Agilent Technologies 1200 series equipped 
with a binary pump (G1312A), a diode-array detector (G1315D), an autosampler (G1329A) 
and a controller (G1316A) [Agilent Technologies, Santa Clara, US]. A Waters Spherisorb 
ODS2 C18 column (250 mm x 4.6 mm, 5 µm) was used and set to a temperature of 25⁰C. 
An isocratic method with a mobile phase consisting of 0.1% acetic acid in water:methanol 
(25:75, V/V) and a flow rate of 1 mL/min was applied. The injection volume was 100 μL 
and the detection wavelength was set to 245 nm. The limit of detection and quantification 
were 46 ng/mL and 138 ng/mL, respectively. 
 
5.3.2. PBPK model development 
A PBPK model for budesonide was developed for healthy subjects and CD patients 




Figure 5.1: Schematic workflow for the development of a PBPK model for budesonide in 




5.3.2.1. PBPK model development in healthy subjects 
The Simcyp® Simulator Version 17 (Certara, Sheffield, UK) was used to develop a PBPK 
model for budesonide using drug-specific, anatomic and physiological information. Table 
5.4 gives an overview of the input parameters derived from literature. 
Budesonide-specific information includes drug physicochemical properties, plasma protein 
binding and blood plasma ratio. For the disposition model of budesonide, a minimal PBPK 
model with a single non-physiological adjusting compartment, representing all tissues 
except the liver and portal vein, was used. The disposition model for healthy subjects was 
developed based on fitting of parameters (intravenous clearance, volume of distribution at 
steady state (VSS), volume of single adjusting compartment (VSAC), input rate (kin) and output 
rate (kout)) to previously published pharmacokinetic data after intravenous administration of 
budesonide.35 The intravenous clearance was further integrated mechanistically as intrinsic 
enzymatic clearance using the retrograde model within the Simcyp® simulator and literature 
data from CYP phenotyping experiments.36 Due to the high contribution of CYP3A4 to the 
budesonide clearance, the gender differences for the hepatic CYP3A4 abundance were taken 
into account in Simcyp®. For oral budesonide administration, the advanced dissolution, 
absorption and metabolism (ADAM) model was used. To account for transit time differences 
between different types of formulations, the segregated transit time model was selected. For 
the simulations for Entocort®, even though the formulation is composed of multiparticulate 
units, the GI transit time for a controlled-release monolithic formulations was selected due 
to a software issue and the similarity of these transit times to previously published transit 
times for Entocort®.24 For the input of dissolution/release data, the experimental data was 
fitted to the following Weibull function using DDSolver  
 
F=100*(1-Exp((t-tlag)^β/α))        (5.1) 
 
where F is the percentage of drug released, t is time, tlag is lag time, β is a shape parameter 
and α is a scale parameter.37 Two different dissolution input options were evaluated: Option 
1. The input of the release profile as Weibull function with substitution of the lag time with 
a triggering pH; Option 2. The input of the release profile as discrete in vitro dissolution 
profile (after the last experimental time point extrapolation up to 15 h was performed based 
on the fitted Weibull function). 
Considering the permeability input, budesonide permeability was calculated in a previous 
study based on pharmacokinetic data after regional budesonide administration in the gut 
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(jejunum, ileum, colon) with concomitant administration of ketoconazole to inhibit gut wall 
metabolism, deconvolution of pharmacokinetic data after intravenous budesonide 
administration and information about intestinal surface area.23, 38 The retrieved data was 
integrated in the ADAM model as regional permeability (Table 5.4).  
In terms of physiology, all simulations for healthy subjects were performed with the healthy 
volunteer population model of the Simcyp® simulator. For the trial design, all simulations 
were performed with 10 trials and 10 subjects in each trial. The minimum and maximum age 
of the trial population and the percentage of females was adjusted according to the study 
population in the pharmacokinetic trials used for validation. Based on a correlated Monte-
Carlo approach, realistic virtual subjects were generated within the Simcyp® simulator based 
on demographic information (e.g., age is linked to height, body weight and body surface area 
and organ volumes are correlated with body size).  
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Table 5.4: Input parameters for budesonide PBPK model. 
Parameter Unit Input Reference 
Compound type  Neutral  
B/P   0.80 21 
Fraction unbound (PPB%)   0.15 (85-90%) 21 
log P   2.62 39 
Mw  g/mol 430.50  
Compound type   neutral  
Kin  1/h 10.491 35 
Kout  1/h 1.651 
Vss L/kg 3.201 
Vsac L/kg 3.011 
CL IV L/h 63.001 
CLint CYP1A2 μL/min/pmol of 
isoform 
1.182 36 
CLint CYP2C9 μL/min/pmol of 
isoform 
0.212 
CLint CYP3A4 μL/min/pmol of 
isoform 
4.422 
Additional CL, human 
liver microsomes 
μL/min/mg protein 84.262 
Degradation rate constant 
in colon 
1/h 0.65 40 
Difference in male/female 
CYP3A4 abundance 
 Option activated  
Permeability: Peff, man    
Duodenum 10-4 cm/s 1.90 38 
 
Jejunum I 10-4 cm/s 1.90 
Jejunum II 10-4 cm/s 1.90 
Ileum I 10-4 cm/s 3.40 
Ileum II 10-4 cm/s 3.40 
Ileum III 10-4 cm/s 3.40 
Ileum IV 10-4 cm/s 3.40 
Colon 10-4 cm/s 0.59 
1Parameter fitted to observed PK data 
2Calculated with retrograde model enzyme kinetics using the percentage of enzymatic 
contribution from published reactive CYP 450 phenotyping experiments and the clearance 
after intravenous administration of budesonide  
 
5.3.2.2. Pathophysiological differences in CD patients 
A literature search was carried out to quantify major physiological and anatomical changes 
in patients with CD compared to healthy subjects. In the following sections, the identified 




5.3.2.2.1. Hepatic and intestinal CYP3A4 
Differences in hepatic and intestinal CYP3A4 activity were observed in patients with CD 
compared to healthy subjects by comparison of the hepatic and intestinal extraction ratio of 
midazolam, a CYP3A4 substrate.25 Since no direct control group was included in the study 
with CD patients, the hepatic and intestinal extraction ratio (ER) of midazolam in CD 
patients (hepatic ER 0.11, intestinal ER 0.64) was compared to several published studies in 
healthy subjects (hepatic ER 0.36-0.44, intestinal ER 0.43-0.70).25, 41-44 The relative 
difference of the ER in CD patients compared to healthy subjects varies depending on the 
chosen reference study. Therefore, a range (comparison to study with healthy subjects with 
lowest and highest value) was used to reflect the lowest and highest impact. Hence, the 
hepatic CYP3A4 activity is estimated to be decreased in patients with CD to 25 to 31% of 
the healthy value and the intestinal activity to be in the range of 91 to 149%. For the 
simulations, this ratio was used to adjust the enzyme abundance by multiplying the ratio with 
the healthy enzyme abundance given in the Simcyp® simulator according to ERCD/ERHealthy 
x Enzyme abundanceHealthy (hepatic CYP3A4 in females 183 pmol/mg protein, hepatic 
CYP3A4 in males 126 pmol/mg protein, intestinal CYP3A4 66.2 nmol/small intestine).  
Limitations of this approach are firstly, that it is assumed that the ratio of intestinal or hepatic 
ER in CD patients compared to healthy subjects is similar to the proportion of their intestinal 
or hepatic CYP3A4 abundance, respectively. Secondly, the intestinal ER is determined 
based on intravenous and oral administration of midazolam. Therefore, it is assumed that the 
extrahepatic metabolism has a negligible contribution to the overall clearance after 
intravenous administration of midazolam and other factors contributing to differential 
estimates of the fraction metabolised in the gut (e.g, differences in fraction absorbed, 
blood:plasma ratio, hepatic blood flow) are not considered.45 
5.3.2.2.2. Human serum albumin 
The concentration of human serum albumin (HSA) in patients with CD has been reported 
between 28.0 g/L and 41.0 g/L as shown in Table 5.5. The normal range of HSA is 35.0-
55.0 g/L and therefore, some CD patients are hypoalbuminemic.46 In 17.6% of inflammatory 
bowel disease patients the HSA concentration was below the normal range and median 
serum levels of albumin were significantly lower in patients with active disease compared 
to patients in remission.47 Reduced HSA concentrations are likely to be the result of the 
inflammation processes during which albumin synthesis is decreased, albumin catabolism is 
increased and albumin is lost from the vascular compartment due to an increased vascular 
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permeability.48 Additionally, an increased amount of albumin can be lost through the 
damaged tissue in the GI tract in IBD patients and malnutrition can contribute to a lower 
HSA concentration.49 
 
Table 5.5: Human serum albumin concentrations in CD patients (mean ± SD). 
 Female CD patients Male CD patients Reference 
Human serum 
albumin [g/L] 
27.7 ± 6.0 31.7 ± 4.6 50 
38.1 ± 5.1 47 
41.0 ± 5.0 (low-grade inflammation) 
33.0 ± 6.0 (severe inflammation) 
51 
40.0 ± 8.0 52 
 
5.3.2.2.3. Gastric pH 
The pH range in CD patients has been reported between pH 1.5 to 4.1, as observed in two 
studies.53, 54 Additionally, gastric acid secretion (mean basal acid output and maximal acid 
output) was lower in CD patients compared to healthy subjects, especially when patients 
were in a malnourished state.55 Gastric acid-reducing agents such as proton pump inhibitors 
are an additional risk factor for increased gastric pH and are commonly prescribed in patients 
with IBD.56  
5.3.2.2.4. GI transit time 
Considering GI transit times, only a limited amount of studies has investigated the GI transit 
time in the fasted and fed state in patients with CD.5 It has previously been shown that small 
intestinal transit time in patients with CD varied according to disease state.33 Additionally, 
diarrhoea caused by inflammatory and non-inflammatory mechanisms is a frequent 
symptom in patients with CD.57 
5.3.2.2.5. Absorptive surface area in the ileum 
The available absorptive surface area is likely to be reduced in CD due to ulcerated and 
inflamed parts of the GI wall. The extent will be highly dependent on the location of the 
disease in the individual patient and the disease severity. In CD patients, the terminal ileum 
is the most commonly affected area.58 For individual patients, the Simple Endoscopic Score 
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for Crohn's Disease (SES-CD) can give an indication about the affected area since the extent 
of ulcerated surface (none = 0; <10% =1; 10%–30% =2; >30% =3) and the extent of affected 
surface (none = 0; <50% =1; 50–75% =2; >75% =3) are two of four endoscopic variables 
considered for the classification in each bowel segment separately (ileum, 
right/transverse/left colon, and rectum).59 
5.3.2.3. Parameter sensitivity analysis 
Automated PSA was used to estimate the impact of the identified pathophysiological 
differences in patients with CD compared to healthy subjects (Section 5.3.2.2) on the 
predicted PK parameters Cmax and AUC. As basis for the PSAs, the simulation after oral 
administration of Entocort® in the fasted state in healthy subjects using dissolution input 
option 1 with triggering pH and Weibull function was used. Considering hepatic CYP3A4 
abundance, the investigated range for PSA included the abundance in the healthy volunteer 
population as highest value and the lowest value was based on the percental approach (25%) 
described in Section 5.3.2.2.1. The percental approach was also used to define the 
investigated range for the intestinal CYP3A4 abundance (91-149%). For the human serum 
albumin concentration, the investigated range included the lowest value observed in patients 
with CD up to the value in the healthy volunteer population. Additional parameters were 
investigated, when literature information was limited in patients with CD with the aim to 
identify their risk of altering the performance of budesonide. Therefore, the gastric pH in the 
range of 1.0 to 7.5, the gastric residence time in the range of 0.5 to 2.5 h, the small intestinal 
transit time in the range of 3.0 to 6.0 h and the ileal surface area in the range of 16% to 100% 
were investigated. PSA served to identify the most relevant pathophysiological differences 
in CD impacting on budesonide pharmacokinetics. 
To investigate the effect of a reduced available absorptive surface area in the ileum on the 
simulation results, the permeability input was changed to the MechPeff model and the 
intrinsic transcellular permeability was adjusted to 22*10-6 cm/s in order to match the 
regional effective permeability of the jejunum I defined for the initial PBPK model. 
Subsequently, the plicae circulares fold expansion was adjusted to match the regional 
effective permeability values of the initial model in the remaining GI compartments 
(duodenum and jejunum: 1.97, ileum: 6.4, colon: 1.6). A reduction in available absorptive 
surface area was subsequently investigated with PSA by stepwise reducing the plicae 




5.3.2.4. Development of budesonide PBPK model for CD patients 
The pathophysiological key differences in CD patients compared to healthy subjects were 
used to define a CD population for the PBPK model. The healthy volunteer population was 
used as basis and modifications were made to reflect the main differences as identified with 
PSA. The considered differences in the CD population were a reduced hepatic CYP3A4 
abundance, an altered intestinal CYP3A4 abundance, a reduced human serum albumin 
concentration and a different dissolution/release input according to the CD conditions 
described in Section 5.3.1.2. To account for the variability observed in CD patients, two 
different CD populations were defined with the CD low level population reflecting the low 
level for each parameter and the CD high level population reflecting the high level for each 
parameter, respectively. An overview of the CD populations and the defined range for each 
parameter is presented in Table 5.6.  
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45.75 55.91 183.00 
Intestinal CYP3A4 
[nmol/SI] 
60.53 98.53 66.20 
HSA, male [g/L]  
31.72 41.00 50.34 
HSA, female [g/L]  
27.70 41.00 49.38 
Dissolution input Profile in CD 
biorelevant media 
with low levels of 
all factors 
Profile in CD 
biorelevant media 
with high levels of 
all factors 
 
HSA: Human serum albumin 
 
5.3.2.5. Validation of budesonide PBPK model 
5.3.2.5.1. Treatment of in vivo PK data 
For the evaluation of the simulations, data from various PK studies was extracted graphically 
using WebPlotDigitizer Version 4.260 and PK parameters were derived from non-
compartmental analysis (NCA) using PKsolver.61 An overview of the PK literature data is 
given in Table 5.7. For studies where the budesonide plasma concentration-time profile was 
not presented, reported parameters were only used for discussion but excluded from the PK 
parameter mean values used for simulation validation. For Entocort® simulations, several 
published PK studies with different doses were used for model validation and therefore, PK 
parameters were normalised to a dose of 3 mg. In order to compare the simulations against 
observed PK data, the mean values of all studies with PK profiles weighed according to the 
number of subjects in each study were used. The mean Cmax, AUC0-inf and Tmax used for the 
validation of Entocort® administration in healthy subjects and CD patients in the fasted state 




5.3.2.5.1.1. External validation 
Predicted plasma concentration profiles were visually assessed against observed PK profiles. 
In addition, the predictive performance of the simulations was assessed using the ratio of 
predicted to observed Cmax and AUC0-inf. For external validation (PK data not used in the 
model building process), simulations were considered successful when the ratio was within 
a 2-fold range.  
5.3.2.5.1.2. Internal validation 
For internal validation (observed PK data used for model development), a tighter criterion 
was set for the ratio of predicted to observed Cmax and AUC0-inf corresponding to the 
bioequivalence range of 0.8-1.25.    
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0.1 4 (4/0) 2.23/22.3 1.54 1.69/16.9 0.08 35 
Healthy subjects, 
oral solution 
3.0 12 (6/6) 0.92/0.31 2.82 (12 
h) 




18.3 8 (8/0) 2.55/0.14 28.16 32.68/1.79 2.95 24 
9.0 13 (6/7) 1.80/0.20 11.37 (12 
h) 
13.03/1.45 3.02 63 
4.5 6 (6/0) 0.95/0.21 8.06 8.38/1.86 2.74 31 
9.0 12 (6/6) 1.33/0.15 14.46 15.26/1.70 4.90 64 
3.0 8 (8/0) 0.50/0.17 5.27 5.57/1.86 5.00 65 
4.5 20 (0/20) 0.60/0.13 5.66 5.95/1.32 6.10 66 
3.0 8 (8/0) 0.55/0.18 5.06 5.91/1.97 5.02 67 
3.0 13 (5/8) 0.76/0.25 5.59 6.21/2.07 1.50 68 
9.0 13 (5/8) 1.61/0.18 16.64 17.34/1.93 1.50 68 
15.0 13 (5/8) 3.05/0.20 25.56 27.01/1.80 3.00 68 




4.5 6 (6/0) 1.09/0.24 7.95 (24 
h) 
8.27/1.84 4.64 31 
17.9 8 (8/0) 3.49/0.19 29.65 (30 
h) 
33.85/1.89 6.04 24 
Mean 0.21  1.87 5.34  
CD, Entocort®, 
fasted state 
various 8 (1/7) /0.24 /1.90 /2.30 2.95 25 
9.0 8 (4/4) 1.86/0.21 11.74 12.86/1.43 3.95 69 
9.0 6 (5/1) 1.38/0.15 16.01 18.34/2.04 4.00 70 
Mean 0.20  1.91 3.63  
CD, Entocort®, 
fed state 
9.0 8 (4/4) 1.30/0.14 9.97 (12 
h) 
16.66/1.85 6.96 69 
18.0 8 (8/0) 6.99/0.39 54.47 54.54/3.03 6.06 24 
Mean 0.27  2.44 6.51  
CD, Entocort®, -, 
single 
administration* 
4.5 18 (-) 1.77/0.39 - 12.27/2.73 - 26 
CD, Entocort®, -, 
repeated 
administration* 
4.5 18 (-) 1.38/0.31 - 9.08/2.02 - 26 
M: male, F; female  
*No budesonide plasma concentration profiles, PK values are reported as in publication and data was only 
used for discussion 
1Normalised to a dose of 3 mg  
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5.4. Results and discussion 
5.4.1. In vitro release studies 
The in vitro release profiles of Entocort® in healthy and CD conditions in the fasted and fed 
state are shown in Figure 5.2. As expected, no drug release was observed in both prandial 
states, when Entocort® was exposed to the gastric media due to the formulation’s triggering 
pH of 5.5 exceeding the pH of all gastric media. 
In the fasted state, the onset of drug release in healthy conditions was delayed by 0.5 h 
compared to CD conditions due to the prolonged time of the formulation being exposed to 
FaSSGF. For CD low level and high level conditions, similar in vitro release profiles were 
observed. After the onset of drug release, the dissolution rate in CD conditions was slightly 
lower compared to healthy conditions resulting in a similar drug release between healthy and 
CD conditions starting from 2 h until the end of the experiment. 
In the fed state, the longer gastric residence time resulted in a delayed release of budesonide 
in CD conditions. After the media change to small intestinal conditions, the rate of drug 
release was similar between healthy and CD conditions with high level media, while a lower 
rate was observed for CD conditions with low level media. In contrast, when changing to 
the colonic media, the budesonide release was faster in CD conditions with low level media 
compared to both other setups. This could be due to the high percentage of budesonide 
already released in the other two setups (healthy conditions 88%, CD high level 75% 
compared to 63% CD low level) or the different media composition. At the end of the 
dissolution experiment, 94% of the budesonide dose were released after 7.5 h in healthy 
conditions, while only 76% and 82% of budesonide were released after 8.0 h in CD low level 
and high level conditions, respectively. By comparing fasted and fed state conditions, a 
longer lag time due to the prolonged time in stomach conditions was observed but the 




Figure 5.2: In vitro release of Entocort® in healthy and CD conditions in (a) the fasted state 
and (b) the fed state (Red arrows indicate the media change in healthy conditions and blue 




5.4.2. PBPK predictions for healthy subjects  
5.4.2.1. Intravenous administration  
The performance of the PBPK model considering the disposition of budesonide was assessed 
by simulating the administration of 100 μg budesonide given as intravenous infusion over 
5 min. The disposition of budesonide was successfully simulated as shown in Figure 5.3 and 
predicted PK parameters were within the predefined range set for internal model verification.  
 
Figure 5.3: Prediction of systemic budesonide concentration in healthy subjects and 
observed PK profiles (a) after intravenous administration of 0.1 mg budesonide, and (b) after 




5.4.2.2. Oral administration in the fasted state 
Considering oral administration, the PBPK model was first used to simulate budesonide 
exposure after administration of an oral solution and externally validated against observed 
PK data as illustrated in Figure 5.3.62 Despite a slight overprediction of Cmax, AUC and Tmax, 
the predicted PK parameters were within the 2-fold criterion set for model verification as 
shown in Table 5.8. Since budesonide exposure after administration of an oral solution is 
independent of drug release and dissolution, intestinal permeability and gut metabolism were 
adequately reflected in the PBPK model. The prediction revealed an apparent fraction 
absorbed of 95%, whereof the main part (49%) was absorbed in the jejunum, which was 
consistent with complete budesonide absorption reported in literature.71 Additionally, the 
predicted fraction of budesonide metabolised in the gut was 43%, whereof the metabolism 
in the jejunum contributed to 53%. A slightly higher gut extraction ratio of at least 0.50 has 
previously been indicated by the pre-systemic elimination of budesonide after local 
administration in the intestine with and without the local inhibition of gut wall metabolism.23 
For simulations for the controlled-release formulation Entocort®, the results of the in vitro 
release studies were integrated in the PBPK model to predict the dissolved budesonide 
available for intestinal absorption. Simulations of Entocort® administration (3 mg dose) in 
healthy subjects using two different dissolution input options (option 1 and 2) are shown in 
Figure 5.4 and were compared against PK studies presented in Table 5.7. The PK parameters 
of both simulations met the 2-fold criterion set for external validation (Table 5.8) and both 
simulations were similar in their performance. 
When comparing the two dissolution input options, the main difference relates to a 41% 
higher Cmax for option 2 compared to option 1, while AUC0-inf was only 2% higher. The mean 
observed Cmax was approximately in the middle of both simulated Cmax. The limitation of the 
discrete dissolution input (option 2) is that it only accounts for experimental variability in 
the in vitro release experiment. In contrast, intersubject variability in terms of GI pH is 
considered when option 1 is used. In this case, the onset of drug release from the Entocort® 
formulation depends on the virtual subject’s GI pH and indirectly also on its GI transit times. 
This is reflected in the 5th and 95th percentiles of the simulations with option 1 showing a 
higher variability for the onset of budesonide absorption. 
In comparison to the simulation for the oral solution, the apparent fraction absorbed of 
budesonide is lower with 68-70% for Entocort® compared to 95% for the oral solution, 
whereof a higher percentage of 63-64% vs 39% is absorbed in the ileum. This is in agreement 
189 
 
with a previous study showing an increased budesonide delivery to the ileo-colonic region 
for Entocort® compared to an immediate-release formulation.24 
Intersubject variability was evaluated based on the comparison of the simulation with 
observed single subject PK profiles (Figure 5.4).64 Considering the 90% confidence interval 
of the Entocort® simulation, only one out of 12 subjects fell outside the 5th and 95th 
percentiles (dissolution option 1) indicating that interpatient variability is satisfactorily 
captured. 
Figure 5.4: Simulation of budesonide plasma concentration for healthy subjects after 
administration of 3 mg Entocort® in the fasted state with dissolution input option 1 (a) 
compared to observed mean profiles (Table 5.7), and (c) compared to individual PK 
profiles64, and (b) with dissolution input option 2 compared to observed mean profiles (Table 
5.7). 
5.4.2.3. Oral administration in the fed state 
Entocort® administration in the fed state was simulated using the fed state parameters within 
the Simcyp® PBPK model and by integrating the results of the in vitro dissolution profile in 
healthy conditions of the fed state (Section 5.3.1.1). As for the fasted state, two different 
dissolution options (option 1 and 2) are shown in Figure 5.5 and compared against observed 
PK data (Table 5.7). Both simulations successfully predicted budesonide exposure by 
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meeting the external validation criterion (Table 5.8). The simulations with both dissolution 
options performed similar in terms of the prediction of AUC0-inf, but the simulation with 
option 2 was superior in predicting Cmax.  
Compared to the fasted state, the observed Tmax was 1.77 h higher in the fed state which was 
also reflected in the predictions with an increase in Tmax of 1.98 h and 3.72 h between fasted 
and fed state simulations with option 2 and option 1, respectively. Additionally, the observed 
Cmax and AUC0-inf were slightly higher in the fed state compared to the fasted state. This was 
also reflected in both simulations and could relate to the higher drug release rate in the fed 
state (Section 5.4.1) or increased GI transit times resulting in a longer time frame available 
for absorption.  
 
Figure 5.5: Simulation of budesonide plasma concentration for healthy subjects after 
administration of 3 mg Entocort® in the fed state with dissolution input (a) option 1 
(triggering pH and a Weibull function), and (b) option 2 (discrete dissolution input) 




Table 5.8: Overview of predicted and observed PK parameters and calculated fold error.  
 Predicted Observedf Ratio 
 Cmax [μg/L] AUC0-inf 
[μg/L*h] 

















2.50 1.61 0.12 2.23 1.69 0.08 1.12 0.95 1.50 
Oral solution 1.18 3.94 1.09 0.92 2.84 0.68 1.28 1.39 1.60 
Entocort®, fasted 
state 
0.44a/0.62b 3.47a/3.54b 3.00a/3.00b 0.54 5.19 3.57 0.81a/1.15b 0.67a/0.68b 0.84a/0.84b 
Entocort®, fed 
state 


























a Dissolution input option 1: Triggering pH with Weibull function, b Dissolution input option 2: Discrete profile, c Low level CD population, d High level CD 




5.4.3. Impact of pathophysiological differences in CD on budesonide 
performance investigated with PSA 
Figure 5.6 depicts the effect of hepatic CYP3A4 abundance in female and male subjects, 
intestinal CYP3A4 abundance and human serum albumin concentration in female and male 
subjects on Cmax and AUC of budesonide after Entocort® administration in the fasted state 
as investigated with PSA.  
The reduction of hepatic CYP3A4 abundance had a substantial impact on Cmax and AUC 
with an enzyme reduction of 75% resulting in an increase of Cmax by approximately 250% 
or 222% and of AUC by 267% or 239% in females and males, respectively. Since CYP3A4 
contributes to 79% to the hepatic metabolism of budesonide and the hepatic extraction ratio 
is approximately 0.60, the lower CYP3A4 enzyme abundance results in a reduced hepatic 
clearance.36, 72  
The intestinal CYP3A4 abundance investigated in the range of 91-149% of healthy intestinal 
CYP3A4 abundance had a lower impact on Cmax and AUC with 84-103% and 85-103% of 
the parameters in the healthy simulation, respectively. 
A reduced concentration of human serum albumin by up to -44% and -37% is expected to 
result in a reduction of budesonide Cmax by up to 40% and 32% and of AUC by up to 40% 
and 34% in female and male subjects, respectively. 
 
Figure 5.6: Parameter sensitivity analysis of the hepatic CYP3A4 abundance in male and 
female subjects, the intestinal CYP3A4 abundance and the human serum albumin 
concentration in male and female subjects on (a) Cmax and (b) AUC. 
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The effect of gastric pH on the Cmax and AUC of budesonide after Entocort
® administration 
in the fasted state as investigated with PSA is illustrated in Figure 7. An increased gastric 
pH was shown to only impact on Cmax and AUC when exceeding the triggering pH of the 
formulation (pH 5.5). The impact of a pH >5 was shown to be very limited with a decrease 
of Cmax by 3.6%, an increase in AUC by 5.0% and a decrease of Tmax from 4.1 h to 3.7 h. 
Therefore, the risk of altered budesonide performance from Entocort® in CD patients with 
increased gastric pH, either due to their co-treatment (e.g., proton pump inhibitors) or 
condition, is expected to be very low.  
The GI transit time determines the time during which the drug is exposed to the intestinal 
membrane and therefore, available for absorption. A difference in GI transit times due to CD 
can consequently have an impact on drug product performance. The impact of gastric 
residence time and small intestinal transit time on Cmax and AUC of budesonide after 
Entocort® administration in the fasted state as investigated with PSA is shown in Figure 5.7. 
Changes in gastric residence time from 0.5 h to 2.5 h showed no impact on the Cmax and 
AUC of budesonide, while the Tmax increased from 3.36 h to 5.40 h when increasing the 
gastric residence time from 0.5 h to 2.5 h. Since Entocort® has a triggering pH of 5.5 which 
is usually not exceeded by gastric pH, the gastric residence time mainly determines the onset 
of drug release rather than the extent.  
The small intestinal transit time (SITT) had a very low impact on Cmax but an increase in 
SITT from 3.0 h to 6.5 h resulted in an increase in AUC by 27% due to the longer 
presentation of budesonide to the absorptive GI membranes.  
Consequently, gastric and intestinal transit times are expected to have only a limited effect 
on budesonide performance in comparison to the previously investigated factors. Due to the 
regional permeability differences of budesonide in the intestine, differences in transit times 
of specific compartments of the small intestine (opposed to the total SITT) could influence 
budesonide performance. These differences are expected to be in the same range as the 




Figure 5.7: Parameter sensitivity analysis of the gastric mean residence time and the small 
intestinal transit time on (a) Cmax and (b) AUC. 
 
As shown in Figure 5.8, the lower available surface area had a very limited effect on 
budesonide performance. A reduction of the plicae circulares fold expansion by 84% resulted 
in a reduction of Cmax in the range of 3-11% and AUC in the range of 3-7% in the different 
parts of the ileum. Only when reducing the plicae circulares fold expansion in all parts of 
the ileum by 84%, the impact would be higher with a reduction of Cmax by 54% and AUC 
by 34%.  
Due to the high permeability of budesonide, even profound changes in surface area are not 
representing a major risk for budesonide absorption. Additionally, CD affects the GI tract in 
a discontinuous manner, and it is unclear whether inflamed and ulcerated parts of the GI 





Figure 5.8: Parameter sensitivity analysis of the plicae circulares fold expansion in the four 
different parts of the ileum on (a) Cmax and (b) AUC. 
5.4.4. PBPK predictions for CD patients 
Predicted and observed budesonide plasma concentration profiles after Entocort® 
administration in CD patients in the fasted and fed state are shown in Figure 5.9 and the 
respective PK parameters are presented in Table 5.8.  
 
Figure 5.9: Simulation of budesonide plasma concentration in CD patients after 
administration of 3 mg Entocort® in the fasted state with dissolution input option 1 (a), and 
in the fed state with dissolution input option 2 (b) compared to observed mean profiles (Table 
5.7). 
 
In the fasted state, the highest exposure of budesonide was predicted for the CD low level 
population followed by the CD high level population and the simulation for healthy 
volunteers. Compared to the simulation for healthy volunteers and the observed PK 
parameters, the CD low level simulation improved the prediction of Cmax by 25% and AUC 
by 32% and the CD high level simulation improved the prediction of Cmax by 23% and AUC 
by 30%. It should be noted that a similar budesonide bioavailability in CD patients compared 
to healthy subjects after Entocort® administration in the fasted state was observed in one of 
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four studies, while all other studies showed an increased exposure of budesonide compared 
to healthy subjects (Table 5.7).  
In the fed state, the exposure of budesonide was highest for the CD high level simulation 
followed by the CD low level simulation and the simulation for healthy volunteers. 
Compared to the simulation with the healthy volunteer population, simulations with the CD 
populations were closer to the observed AUC and improved the prediction by 17% and 24% 
for the low and high level population, respectively. In terms of Cmax, the prediction of all 
three simulations was close to the observed value with the CD simulations being slightly 
higher (9-27%) and the healthy simulation being slightly lower (-6%). Also in the fed state, 
differences in the exposure of budesonide in CD patients in different studies were reported 
with one study showing a similar exposure compared to healthy subjects, while others show 
a substantial increase (Table 5.7).  
The discrepancies between the PK studies in CD patients could be related to a different 
disease states of the patients or their concomitant medication. The inflammation process has 
been shown to decrease CYP3A4 activity in different inflammatory conditions such as 
rheumatoid arthritis and in haemodialysis patients.73, 74 A higher budesonide exposure 
related to reduced buccal CYP3A activity has also been observed in patients with oral 
chronic graft-versus-host disease.62 This can be explained by the inflammation process, 
which induces the production of pro-inflammatory cytokines leading to a down-regulation 
of CYP3A4.75 When patients are treated with medication preventing cytokine production, 
this effect could be reversed.75 For example, it has been shown that the repeated 
administration of budesonide in patients with active CD resulted in a reduction of the initial 
budesonide Cmax and AUC by 22% and 26%, respectively.
26 
5.5. Conclusion 
The budesonide exposure was successfully predicted after intravenous and oral 
administration using the developed PBPK model. By using in vitro biorelevant 
dissolution/release tests with PBPK modelling successful PK simulations were achieved for 
a controlled-release formulation of budesonide (Entocort®) in healthy subjects in the fasted 
and fed state. Pathophysiological differences in CD patients were identified in literature and 
their impact on budesonide performance was investigated revealing the highest impact on 
the simulations for hepatic CYP3A4 enzyme abundance and HSA concentration. A higher 
budesonide exposure in CD patients compared to healthy subjects was reported in literature 
and successfully predicted with a PBPK population adapted to CD physiology. 
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Apart from patients with CD, the workflow presented in the current study can be used to 
predict drug product performance in patients with other GI diseases. Therefore, the following 
steps should be followed: i. Development of an in vitro dissolution methodology 
representative of the GI fluid composition and hydrodynamics in the investigated population; 
ii. Development and validation of a PBPK model in healthy subjects; iii. Identification of 
pathophysiological differences in the respective GI disease patients compared to healthy 
subjects; iv. Investigation of the impact of the identified differences on the PBPK 
simulations; v. Development of a population representative of the investigated population 
according to relevant differences; vi. Prediction of drug exposure in the GI disease 
population and when applicable validation with PK data. 
A mechanistic modelling approach allows to consider pathophysiological differences in 
patients with GI diseases and can therefore, be used to predict the effect of GI diseases on 
drug product performance. This is especially helpful due to the sparse clinical data available 
for this patient population. PBPK models could indicate when GI diseases pose a risk for 
safety and efficacy and dose adjustments are needed. Further studies investigating the 
physiology of patients with GI diseases and the drug product performance of additional drugs 
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Investigating the impact of Crohn’s disease on the 
bioaccessibility of a lipid-based formulation with an in vitro 
dynamic gastrointestinal model 
Abstract 
Objectives 
The aim of the study was to investigate the impact of Crohn’s disease (CD) on the 
performance of a lipid-based formulation of ciprofloxacin in a complex gastrointestinal 
simulator (TIM-1, TNO) and to compare the luminal environment in terms of bile salt and 
lipid composition in CD and healthy conditions. 
Key findings 
CD conditions were simulated with a reduced concentration of porcine pancreatin and 
decreased amount of porcine bile in the TIM-1 system. The bioaccessibility of ciprofloxacin 
was similar in CD and healthy conditions considering its extent as well as its time course in 
the jejunum and ileum filtrate. Differences were observed in terms of the luminal 
concentration of triglycerides, monoglycerides and fatty acids in the different TIM-1 
compartments, indicating a reduction and delay in the lipolysis of formulation excipients in 
CD. Quantitative analysis of bile salts revealed higher concentrations for healthy conditions 
(standard TIM-1 fasted state protocol) in the duodenum and jejunum TIM-1 compartment 
compared to published data in human intestinal fluids of healthy subjects, while bile salt 
concentration in CD conditions were similar to these. A lipidomics approach with UPLC-
MS has proven to be a time-efficient method to semi-quantitatively analyse differences in 
fatty acids and bile salts levels between healthy and CD conditions. 
Conclusions  
The dynamic luminal environment in CD and healthy conditions after administration of a 
lipid-based formulation can be simulated using the TIM-1 system. For ciprofloxacin, an 
altered luminal lipid composition had no impact on its performance indicating a low risk of 
altered performance in CD patients. Human duodenal and jejunal bile salt levels are lower 
than the levels in corresponding TIM-1 compartments when using the standard TIM-1 fasted 




Crohn’s disease (CD), affecting approximately 1.6 million people in Europe, is a chronic 
auto-inflammatory disorder and one of the main types of inflammatory bowel disease 
(IBD).1 CD commonly affects the terminal ileum but can be localised in any part of the 
gastrointestinal (GI) tract. The disease manifests as transmural ulcerations that are 
discontinuously spread in the GI tract. Additionally, CD patients often present extra-
intestinal manifestations such as inflammations of the eyes (uveitis, episcleritis), skin 
diseases (erythema nodosum, pyoderma gangrenosum), spondyloarthritis or hepato-
pancreato-biliary diseases.2 For the patients, CD results in a lifelong treatment with anti-
inflammatory drugs (e.g., mesalamine, steroids, azathioprine, cyclosporine). Additional to 
this treatment, IBD patients have shown a higher use of antidepressants, anxiolytics, oral 
bisphosphonates, cardiovascular medication, antibiotics, proton pump inhibitors and 
nonsteroidal anti-inflammatory analgesics compared to the general population.3 The use of 
antibiotics to treat CD was not investigated in large clinical trials and therefore, a therapeutic 
effect could only be observed in studies with a small number of subjects.4 However, 
antibiotics are often used for CD patients experiencing complications such as fistulas or 
abscesses.5 In this case, ciprofloxacin is one of the treatment options and has been shown to 
be beneficial for the treatment of perianal fistulas.6 
To exert its pharmacodynamic effect, a drug must overcome many challenges to reach its 
target site in the body including drug release from the formulation, dissolution in the GI 
fluids, permeation of the GI membrane and escaping gut and hepatic metabolism. All these 
processes are dependent on the physiology of the treated subject. For patients with CD, 
pathophysiological differences with possible impact on drug product performance were 
observed in terms of the composition of luminal contents, the abundance of metabolising 
enzymes, GI transit times and the microbiota.7 
Most candidates from contemporary drug discovery programs are poorly water-soluble with 
dissolution rate-limited absorption and typically belong to BCS class II or IV.8 Therefore, 
formulation scientists are challenged to use more complex formulation approaches. For 
example, a higher bioavailability can be achieved with a lipid-based formulation (LBF) 
approach by e.g., circumventing at least partially the drug dissolution step due to the higher 
drug solubility in the formulation vehicle or the promotion of lymphatic drug uptake. Several 
LBFs are already commercially available and the ever-increasing number of poorly soluble 
compounds might further increase their number in the future.9  
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Upon entering the GI tract, LBFs are subject to a dynamic environment with dispersion and 
digestion processes. Various excipients of LBFs such as acylglycerols, phospholipids, 
polysorbates (Tweens), polyethyleneglycol mono- and di-esters can be digested along the 
GI tract.10 The enzymes involved in their hydrolysis include gastric lipase and classical 
colipase-dependent pancreatic lipase, hydrolysing mainly triacylglycerols and 
diacylglycerols.10 Additionally, several other pancreatic enzymes such as pancreatic 
carboxyl ester hydrolase, pancreatic lipase-related protein 2 and pancreatic phospholipase 
A2 act on micellar substrates and possess a phospholipase activity.10 For the drug, the 
continuous reorganisation of colloidal structures composed of luminal bile acids, cholesterol, 
phosphatidylcholine, on the one hand, and excipients and their digestion products, on the 
other hand, can induce a supersaturated state or precipitation of a drug.10 This complexity 
highlights the need for in vitro systems considering these dynamic processes to evaluate the 
formulation performance of LBFs. 
The digestion and dispersion process of LBF is most often investigated in pH-stat lipolysis 
models focusing only on the small intestine, the main absorption and digestion area, and 
using porcine pancreatin as enzymatic source.11 Therefore, the contribution of gastric lipase, 
estimated to around 3-37% of triglyceride (TG) digestion, is often neglected.12-16 This is 
especially a limitation for the simulation of pathological conditions with a deficiency of 
exocrine pancreatic enzymes, where gastric lipase is assumed to have a significant role in fat 
digestion.15, 17 In recent years, modifications of the pH-stat lipolysis models have been 
developed to address this issue with a two-step one-compartment or a two-step two-
compartment model.11, 18 
The complex GI simulator TIM-1 (TNO, Zeist, Netherlands) mimics closely the GI tract by 
simulating biliary and pancreatic secretion, controlling luminal pH with bicarbonate 
secretion, removing drug/micellar components via ultrafiltration and simulating gastric lipid 
digestion. The in vivo predictive ability of TIM-1 has previously been shown in nutritional 
sciences and in pharmaceutical formulation performance.19-24 Due to the high level of 
biorelevance of the TIM-1 system, its suitability for the evaluation of LBFs has been 
suggested.11 However, the high lipophilicity of drugs in LBFs might limit its use due to drug 
binding to the TIM-1 membranes and filters possibly resulting in a low recovery of the 




Ciprofloxacin is used for the treatment of bacterial infections and belongs to the antibiotic 
group fluoroquinolones. In terms of physicochemical characteristics, ciprofloxacin 
possesses a log P of 0.28, poor aqueous solubility and is a zwitterionic molecule (high 
solubility at pH<5, pH>10).25, 26 Apart from tablets, it is available as lipid-based oral 
suspension for reconstitution and marketed as Ciproxin® 250 mg/ 5ml granules and solvent 
for oral suspension (Bayer plc, Reading, UK). Ciprofloxacin tablets have previously been 
tested in the TIM-1 simulator and shown high levels of drug recovery.27 
The aim of this study was to investigate the performance of ciprofloxacin from an oral lipid-
based suspension in a complex dynamic simulator of the upper GI tract, TIM-1, in healthy 
conditions and conditions representative of CD. In addition, differences in the digestion 
process of excipients of the LBF between healthy and CD conditions were investigated and 
relevant components (bile acids, cholesterol) of the mixed micelles in the TIM-1 matrix were 
measured. 
6.2. Materials 
The formulation Ciproxin® 250 mg/5 mL granules and solvent for oral suspension from 
Bayer Plc, Reading, UK was used. The water used was Milli-Q grade. 
For the TIM-1 experiments, potassium chloride, acetic acid and sodium chloride were used 
from Fisher Scientific, Loughborough, UK. Calcium chloride di-hydrate, hydrochloric acid 
(37%), pancreatin from porcine pancreas, sodium acetate trihydrate, pepsin from porcine 
gastric mucosa, sodium citrate, lipase from Rhizopus oryzae, amylase from Bacillus sp., 
(hydroxypropyl)methyl cellulose (HPMC) (2%) in water, porcine bile extract, sodium 
bicarbonate (1.14 mol/L) in water and trypsin were purchased from Sigma-Aldrich, 
Gillingham, UK. Sodium hydroxide (1 M) in water was used from Merck KGaA, Darmstadt, 
Germany. Porcine bile was purchased from Triskelion (Hendrix Slaughter House, Druten, 
Netherlands). 
For the High-Performance Liquid Chromatography (HPLC) analysis of ciprofloxacin, 
formic acid and sodium hydroxide were purchased from Fisher Scientific, Loughborough, 
UK and ciprofloxacin from USP, Rockville, MD, US.  
For the Gas Chromatography-Flame Ionisation Detector (GC-FID) analysis, chloroform, 
octanoic acid, decanoic acid, cholesterol and a Lipid Standard, Mono-, Di-, & Triglyceride 
Mix containing 1,3-Diolein 10 mg, 1,2-Dioleoyl-rac-glycerol 10 mg, Glyceryl trioleate 
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10 mg, Monoolein 10 mg were purchased from Sigma Aldrich, Gillingham, UK. 
Hydrochloric acid 1 M was purchased from Fisher Scientific, Loughborough, UK.   
For the HPLC-Charged Aerosol Detector (CAD) analysis, HPLC grade methanol, 
ammonium formate and formic acid were used from Fisher Scientific, Loughborough, UK. 
Triethylamine, glycochenodeoxycholic acid (GCDC) sodium salt, glycocholic acid (GC), 
taurodeoxycholic acid (TDC) sodium salt, taurochenodeoxycholic acid (TCDC) sodium salt 
and taurocholic acid (TC) sodium salt were purchased from Sigma-Aldrich, Gillingham, UK. 
For Ultra-Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) analysis, 
HPLC grade acetonitrile and acetic acid were used from Fisher Scientific, Loughborough, 
UK and ammonium acetate from Sigma-Aldrich, Gillingham, UK, respectively. 
6.3. Methods 
6.3.1. TIM-1 experiments 
To investigate the effect of CD on the performance of a LBF, a complex in vitro GI model 
TIM-1 (TNO, Zeist, Netherlands) was used, which has previously been described.22, 23, 28 
The system has been used in a pharmaceutical context to predict drug product performance 
of formulations 22-24 and in food sciences to investigate e.g., the digestion of lipids.19-21 An 
overview of the TIM-1 system is given in Figure 6.1. The human upper GI tract is simulated 
with four serial compartments representing the stomach, duodenum, jejunum and ileum. 
These compartments consist of two connected equal basic units with a glass jacket and a 
flexible silicone membrane inside. Mixing of the chyme and control of the luminal 
temperature is achieved by pumping tempered water around the flexible membranes. 
Peristaltic valve-pumps connect the different TIM-1 compartments and allow the control of 
the chyme’s flow rate between the different compartments. The volume of the luminal 
contents is controlled with level sensors and the secretion of buffers. A predetermined pH 
curve can be programmed for each compartment, monitored with a pH probe in each TIM-
1 compartment and controlled by secretion of either water, 1 M hydrochloric acid (only 
gastric compartment) or 1 M sodium bicarbonate solution. Additionally, secretions of gastric 




Figure 6.1: Overview of TIM-1 system. [A: Gastric compartment, B: Duodenum 
compartment, C: Jejunum compartment, D: Ileum compartment, E: Peristaltic valve, F: 
Dosing port, G: Pressure sensor, H: Gastric secretions, I: Level sensors, K: Filter system, L: 
prefilter, M: Filtrate (jejunum and ileum), N: pH-electrode, O: Jejunum secretions, P: Ileum 
secretions, Q: Ileum efflux, S: Sampling points]. 
6.3.1.1. Preparation of solutions, reagents and starting residues 
Various solutions were prepared to perform the experiments with the TIM-1 system 
including 0.1 M sodium citrate buffer (pH 7.0) and 1 M sodium acetate buffer (pH 5.0). 
Gastric electrolyte solution (GES) was prepared by dissolving 8 g/L sodium chloride, 1.7 g/L 
potassium chloride and 0.16 g/L calcium chloride di-hydrate in water. HPMC 0.4% & bile 
0.04% gastric solution was prepared by dissolving 0.4 g/L bile extract in water, subsequently 
adding 4.0 g/L HPMC and stirring the solution overnight. Gastric enzymes solution 
contained 1 mL 1 M sodium acetate buffer, 6000 units lipase, 1440000 units pepsin, 
42000 units amylase and 299 mL GES. Small intestinal electrolyte solution (SIES) was 
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prepared by dissolving 7 g/L sodium chloride, 0.35 g/L potassium chloride and 0.1 g/L 
calcium chloride di-hydrate in water and adjusting the pH to 7.0 with 1 M sodium hydroxide 
solution. Pancreatic solution was prepared by dissolving pancreatin powder in water, 
centrifuging the solution for 20 min at 12.500 G at 4⁰C and using the supernatant for the 
experiment. The bile solution used consisted of prefiltered pig bile in SIES. The 
concentration of the pancreatic and bile solution varied according to the experimental 
conditions as detailed below (Section 6.3.1.2).  
At the beginning of the experiments, the gastric compartment was filled with 30 g gastric 
start residue, consisting of 15 g gastric enzyme solution and 15 g HPMC 0.4% & bile 0.04% 
gastric solution. The duodenum compartment was filled with 60 g of a solution consisting 
of 15 g SIES, 15 g pancreatin solution, 30 g bile solution and 2 mg trypsin in 1 mL SIES. 
The jejunum compartment was filled with a mixture of 35 g SIES, 35 g pancreatin solution 
and 70 g bile solution. The ileum compartment was filled with 140 g SIES. 
6.3.1.2. Experimental conditions 
Ciprofloxacin was selected as model drug for the studies with its lipid-based formulation 
Ciproxin® oral suspension, since another more lipophilic compound was tested initially but 
failed in pretesting experiments due to binding to membranes and filters of the TIM-1 
system. This limitation may restrict the use of TIM-1 for the evaluation of LBFs of more 
lipophilic compounds.22 
The Ciproxin® suspension was prepared according to the patient leaflet (brown bottle with 
granules was emptied into a large white bottle with diluent, turned horizontally and shaken 
for 15 s) and stored in a refrigerator until further use. At the start of each experiment, the 
bottle with the formulation was turned horizontally, shaken for 15 s, and 10 mL of the 
formulation were added with a syringe to the dosing port of the gastric compartment. 
According to the patient leaflet, a drink of water may be taken after Ciproxin® administration 
and therefore, water was added to the gastric compartment according to the experimental 
conditions shown in Table 6.1. 
The Ciproxin® oral suspension consists of granules dispersed in an oily diluent consisting of 
miglyol 575, lecithin, sucrose and strawberry flavouring.29 The medium chain TGs in 
Miglyol 575 are a mixture of octanoyl and decanoylglycerides. In this study, we selected the 
fasted state protocol for the TIM-1 experiments since it has been shown that a small quantity 
of medium chain TGs does not lead to substantial gallbladder contraction and therefore, does 
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not induce concentrations of biliary components representative of a fed state in the intestinal 
lumen.30 Therefore, average physiological conditions of the GI tract in the fasted state were 
simulated in terms of pH, temperature, GI transit times and hydrodynamics, GI volumes, 
electrolyte concentrations and secretions of enzymes, biliary and pancreatic juice. 
The pH in the gastric compartment was set to drop from 3.0 to 1.7 within 30 min.27 The pH 
of the duodenum, the jejunum and the ileum compartment were 6.3±0.2, 6.5±0.2 and 
7.4±0.2, respectively. The volume of bicarbonate solution secreted to maintain the specified 
luminal pH in the intestinal compartments was automatically reported by the TIM-1 system. 
The temperature was maintained at 37 ⁰C. 
Gastric emptying was set according to the equation of Elashoff with a halftime of 20 min 
and a b-value (shape factor) of 1.0.31 To simulate the house keeper wave, the total content 
of the gastric compartment was manually emptied and introduced into the duodenum 
compartment after the first 60 min. GI volumes were 55 mL, 130 mL and 130 mL for the 
duodenum, jejunum and ileum compartment, respectively.  
The secretions to the gastric compartment included gastric enzyme solution, hydrochloric 
acid and water at a total secretion rate of 1.0 mL/min. The duodenal secretion consisted of 
bile solution, pancreatin solution and SIES. The jejunal secretion consisted of 10% V/V bile 
solution in SIES and the ileal secretion was only SIES. 
To mimic the absorption of the dissolved or solubilised drug and digestion products, the 
“lipid membrane configuration” mode was selected.23 Therefore, two hollow fibre 
polysulfone filtration units with a cut-off size of 50 nm and a surface area of 0.3 m3 (Plasma 
Flux P1 dry, Fresenius Medical Care, Bad Homburg, Germany) were used. Before the 
experiment, the filters were saturated with 10 L of water and subsequently preconditioned 
by filtering a mixture of 50 mL porcine bile, 25 mL SIES and 25 mL pancreatic solution. As 
a next step, the filters were connected to the jejunum and ileum compartment. The drug 
analysed in both filtrates was considered the bioaccessible fraction of the drug within a given 
time period. The bioaccessibile fraction refers to the drug available for absorption through 
the gut wall.32 Due to the use of a syringe instead of the supplied measuring spoon to 
administer the Ciproxin® formulation, the ciprofloxacin dose was slightly higher and the 
bioaccessible amount of ciprofloxacin was therefore, normalised to the total amount of 
ciprofloxacin recovered from the TIM-1 system (luminal samples, filtrates, ileal efflux, 
residues, washing solution). 
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Considering the lipolysis in the TIM-1 system, lipase from Rhizopus oryzae was used to 
simulate human gastric lipase, since human gastric lipase is not commercially available. In 
vitro experiments with lipase from Rhizopus oryzae showed a significantly higher lipid 
digestion compared to the in vivo lipid digestion by human gastric lipase.33 Currently, there 
is still a lack of suitable substitutes for human gastric lipase due to differences in terms of 
the pH-optimum, the substrate affinity and the stereo selectivity of microbial and animal 
lipases.11, 33 To simulate pancreatic lipases, porcine pancreatin was used as enzymatic source, 
which has previously been shown to be a good substitute for human pancreatic juice.34 
Three different experimental conditions were used including healthy, CD and healthy blank 
TIM-1 experiments as shown in Table 6.1. In healthy conditions, the bile solution consisted 
of 20.0% v/v pig bile in SIES and the pancreatin solution of 7.0% w/v porcine pancreatin 
extract in water. The healthy blank run was performed without any formulation and with the 
same conditions as defined for healthy subjects. 
In CD, pathophysiological changes can affect the composition of the GI fluids and 
hepatobiliary manifestations are common extraintestinal symptoms.7 In terms of LBFs, 
differences in lipase activity and bile concentration could impact drug product performance. 
In CD patients, the pancreatic lipase activity was decreased to 28-80% of the activity in 
healthy subjects.35-37 Additionally, the bile acid pool in CD patients was reduced to 38-58% 
of the size in healthy subjects.38-40 To investigate the impact of these differences, CD 
conditions were simulated in the TIM-1 system (Table 6.1). The amount of porcine 
pancreatin was reduced to 28% of the concentration in healthy conditions, assuming a worst-
case scenario. The bile concentration was reduced to 43% of the porcine bile concentration 
in healthy conditions, corresponding to an indirect approach by using the median reduction 
in studies investigating the bile acid pool.38-40  
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Healthy (n=2) CD (n=2) Healthy blank 
(n=1) 
Setup Lipid setup – ultrafiltration 
Prandial state Fasted state 
Drug product Ciproxin® oral suspension (10 mL) - 
c (porcine bile) 20.0% v/v pig bile in 
SIES 
8.6% v/v pig bile 
in SIES 




7.0% w/v in water 2.0% w/v in water 7.0% w/v in water 
Experimental time 
[h] 
5.0 5.0 4.0 
Water added to the 
gastric 
compartment [mL] 
230 230 240 
SIES: Small intestinal electrolyte solution 
 
6.3.1.3. Sampling and drug analysis 
Samples were collected every 30 min for 5 h from the jejunal and ileal filtrate (drug available 
to permeate the intestinal membrane) and the ileal effluent (drug entering the colon). 
Additionally, 5 mL samples were taken directly from the gastric compartments at three 
different time points (0, 30, 60 min) and from the duodenal compartment every 30 min for 
5 h. The collected samples were subsampled and stored at -18⁰C for further analysis. After 
completion of the experiment, the residues were collected, the system was cleaned with 
0.1 M sodium hydroxide solution and residues in the compartments and washing solution 
were analysed for remaining ciprofloxacin quantification.  
For the HPLC analysis, all TIM-1 samples were diluted with 0.1 M sodium hydroxide 
solution and filtered through 1.0 μm PTFE syringe filters (Sigma-Aldrich, Gillingham, UK). 
Ciprofloxacin was quantified according to a published method with a Waters Acquity UPLC 
equipped with a Waters Xevo Triple Quadrupole Mass Spectrometer (Waters Corporation, 
Milford, MA, US).27 A Waters Acquity UPLC BEH300 C18 column (2.1 x 200 mm, 1.7 μm) 
was used and set to a temperature of 40°C. The flow rate was 0.6 mL/min and 3 µL of sample 
were injected. The mobile phase A consisted of 0.1% Formic acid in water and the mobile 
phase B of 0.1% Formic acid in acetonitrile. A gradient elution mode was used as shown in 
Table 6.2. The Triple Quadrupole mass spectrometer was operated with a cone voltage of 
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45⁰C, a source temperature of 500⁰C, a desolvation gas flow rate of 800 L/h and a cone gas 
flow rate of 80 L/h. All samples were measured in positive ion electrospray mode and 
photodiode array detection was set to 210-400 nm (4.8 nm resolution). Multiple reaction 
monitoring was used for the parent and daughter m/z of 332.2 and 288.2, respectively. 
Table 6.2: Mobile phase gradients used for HPLC-MS analysis of ciprofloxacin, HPLC-
CAD analysis of bile salts and UPLC-MS analysis of lipids and bile salts.  




0.00 100 0 
12.00 0 100 
12.01 100 0 
15.00 100 0 
HPLC-CAD 
analysis of bile 
salts 
0.00 40 60 
25.00 10 90 
25.10 40 60 
30.00 40 60 
UPLC-MS 
analysis of lipids 
and bile salts  
0.00 65 35 
9.00 5 95 
10.00 5 95 
10.01 65 35 
12.00 65 35 
 
6.3.2. Analysis of formulation and matrix components  
6.3.2.1. GC-FID for lipid analysis 
Lipid components were extracted as previously described.20 Briefly, 900 μl chloroform and 
100 μl of 0.1 M hydrochloric acid were added to 100 μl of sample in a vial, the mixture was 
vortexed for 1 min and the bottom layer was directly analysed by GC-FID. The analysis was 
performed on an Agilent 6890N network gas chromatograph (Agilent Technologies, Santa 
Clara, CA, US) equipped with an injector series 7683B and a flame ionisation detector. The 
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column used for the separation was a TG-5MT (Thermo Fisher Scientific, Loughborough, 
UK) with a length of 15 m, a diameter of 0.25 mm and a film thickness of 0.10 μm. Helium 
was used as carrier gas. The column was set to a constant pressure of 30.00 psi. Sample 
injection (1 μl) was performed from the bottom layer of the sample with a split ratio of 5:1 
(split/splitless) on the column with an injector temperature of 300°C. The initial oven 
temperature was set to 60°C for 2 min, followed by an increase of 10°C/min during 34 min 
and a hold time of 2 min at 400°C resulting in a total run time of 38 min. The detector 
temperature was kept constant at 350°C. Empower® 3 (Waters Corporation, Milford, MA, 
US) was used for data collection.  
For fatty acids (FA) and cholesterol, chromatographic peaks were identified by comparing 
retention time with those of known standards, resulting in a retention time of 3.6 min for 
octanoic acid, 6.0 min for decanoic acid and 20.6 min for cholesterol. For monoglycerides 
(MG) and TGs, chromatographic peaks were identified with an Agilent 5975 MS (Santa 
Clara, CA, US) [data not shown] with retention times of 20.0 min, 21.2 min, 22.3 min and 
23.4 min for TGs and 9.2 min, 9.5 min and 11.3 min for MGs. Quantification of TGs was 
performed against Glyceryltrioleate, MGs against monoolein and for cholesterol, octanoic 
acid and decanoic acid against their standards. 
6.3.2.2. HPLC-CAD for bile salt analysis 
For the bile salt analysis, an Agilent 1200 Series (Agilent Technologies, Santa Clara, CA, 
US) with a degasser (G1379B), binary pumps system (G1312B), autosampler (G1367C), 
thermostatted column compartment (G1316B) with a Corona Charged Aerosol Detector 
(CAD) (ESA Biosciences Inc., Chelmsford, MA, US) was used. A modification of a 
previously published method was used.41 A Waters Halo C18 column (150 mm × 3 mm, 
2.7 μm) was maintained at 30°C. The mobile phase A consisted of 20 mM ammonium 
formate with 0.5% formic acid and 0.2% triethylamine. The mobile phase B was methanol. 
A gradient method was used according to Table 6.2 with a flow rate of 0.5 mL/min. The 
TIM-1 samples were appropriately diluted with mobile phase (mobile phase A: mobile phase 
B 40:60 V/V) and a volume of 20 µL was injected. The CAD was used with a response range 
of 100 pA full scale. The retention time of TC, GC, TCDC acid and GCDC were 7.4 min, 
10.2 min, 10.8 min and 14.0 min, respectively. Bile acids were quantified against their 
known standards (TC, GC, TCDC, GCDC) except for the bile acid with a retention time of 
8.1 min which was quantified against GCDC due to having the same molecular weight, 
which had previously been determined by HPLC-MS (data not shown). 
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6.3.2.3. UPLC-MS for lipid and bile salt analysis 
A lipidomics approach with UPLC-MS was used as semi-quantitative tool to identify the 
magnitude of changes considering FAs and bile salts in CD compared to healthy conditions 
in a time-efficient way. Therefore, TIM-1 samples from healthy conditions (n=1) and CD 
conditions (n=1) after administration of the Ciproxin® suspension were analysed. The 
samples were diluted with acetonitrile in a ratio of 1:3 (sample:acetonitrile). Additionally, a 
quality control (QC) sample was prepared by mixing 50 µL of each sample and diluting the 
mixture with acetonitrile in a ratio of 1:3 (sample:acetonitrile). The injection of a QC sample 
after every 6 TIM-1 samples was used to assure reproducibility. Three dilutions of the 
resulting QC sample with acetonitrile (2x, 5x and 10x) served to confirm the linearity of the 
peaks of interest over the respective range. TIM-1 samples were randomised for the UPLC-
MS analysis. 
The analysis was performed with a G6550A Agilent Q-TOF LC/MS System (Agilent 
Technologies, Santa Clara, CA, US) with a 6550 iFunnel Q-TOF equipped with a HiP-ALS 
autosampler (G4226A), a binary pump (G4220A) and a thermostatted column compartment 
(G1316C). A previously published method was used with an Acquity UPLC BEH C8 
column (2.1 mm x 100 mm, 1.7 μm) maintained at 60°C.42 The mobile phase A consisted of 
50 mM ammonium acetate (pH 5.0) and acetonitrile was used as mobile phase B. A gradient 
according to Table 6.2 was applied with a flow rate of 0.6 mL/min. 
All samples were measured in negative ion electrospray mode with Dual Agilent Jet Stream 
Electrospray Ionisation (Dual AJS ESI). The gas temperature was set to 250°C with a flow 
rate of drying gas of 15 L/min, a sheath gas temperature of 220°C and a sheath gas flow rate 
of 10 L/min. The nebulizer was set to 40 psig, the fragmentor to 400 V, the collision energy 
to 5 V and capillary voltage to 4000 V. A nozzle voltage of 1000 V was applied. Two 
different reference masses were used for the negative ESI (112.99 and 1033.99). 
For the data analysis, the data was processed using XCMS online platform 
(https://xcmsonline.scripps.edu) with a metabolomics workflow including feature detection, 
retention time correction and alignment.43 The following parameters were used for data 
processing. For feature detection, the centWave method was used with a maximal tolerated 
m/z deviation in consecutive scans of 10 ppm, a signal to noise ratio cut-off of 6, a peak 
width in the range of 10 to 60 s, a minimum m/z difference for peaks with overlapping 
retention times set to 0.01, a prefilter intensity of 10000, the prefilter peaks set to 3 and noise 
to 100. To align the retention time across samples, the method obiwarp was used with a prof 
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step of 1. For the grouping, density was used as method with a bandwidth of 5, a width of 
overlapping m/z slices of 0.015 and the minimum fraction and minimum number of samples 
necessary in at least one of the sample groups for it to be considered as a valid group were 
set to 0.5 and 1, respectively. 
6.3.3. Light microscopy 
Microscopic images of the TIM-1 samples from the different compartments of the model 
and at different time points were taken with a Nikon Labophot 2 microscope (Nikon, Tokyo, 
Japan) equipped with an Olympus DP12 camera (Olympus, Tokyo, Japan) and a TV lens C-
0.45x (Nikon, Tokyo, Japan). After mixing each sample with a pipette, several drops of the 
TIM-1 sample were transferred onto microscopy slide and a cover slip was placed on top of 
the preparation. A 40x objective lens was used resulting in a total magnification of 400x. Z-
Stacking was used to get a greater depth of field for the resulting images by taking 
approximately five pictures at different focus distances. 
6.4. Results and discussion 
6.4.1. Bioaccessibility of ciprofloxacin 
The bioaccessibility of ciprofloxacin after administration of the Ciproxin® suspension in the 
TIM-1 system in healthy and CD conditions is presented in Figure 6.2. 
The total bioaccessibility of ciprofloxacin was 82.6% and 86.4% in healthy and CD 
conditions, respectively, suggesting a similar drug product performance in CD patients 
compared to healthy subjects. The reduced levels of pancreatic enzymes and bile in CD 
conditions are therefore, not expected to impact on the performance of Ciproxin® oral 
suspension, most likely due to the hydrophilic nature of ciprofloxacin. Furthermore, the lipid 
excipients in the Ciproxin® formulation are most likely not needed for solubility 
enhancement and intended for another purpose (e.g., taste masking, dispersant, stability). 
The high ciprofloxacin bioaccessibility was in accordance with previous TIM-1 studies with 
other formulations of this drug (immediate-release and extended-release tablets) and a high 
human bioavailability of 70-80%.27, 29 The maximum amount of bioaccessible ciprofloxacin 
per time period was observed at 0.5-1.0 h with 25.7% in healthy conditions and 23.7% in 
CD conditions, respectively. Pharmacokinetic studies with the Ciproxin® suspension showed 
a slightly higher time to maximum plasma concentration (Tmax) of 1.1-1.5 h.
29 For the first 
2.0 h after administration of the formulation, the cumulative bioaccessible amount of 
ciprofloxacin was high, with 68.4% for the oral suspension in healthy conditions and 84.4% 
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for the previously investigated immediate-release tablet.27 A similar performance of the oral 
suspension compared to the immediate-release tablets has been shown in a clinical study 
demonstrating their bioequivalence.29 
Ciprofloxacin behaves as a BCS class I drug in vivo as indicated by a study using 
physiologically-based pharmacokinetic (PBPK) modelling despite its common classification 
as BCS class II/IV compound.25 Additionally, a limited effect of differences in simulated GI 





Figure 6.2: Bioaccessibility of ciprofloxacin in the jejunum and ileum compartment of TIM-
1 in healthy and CD conditions (a), and ciprofloxacin concentration in the gastric 




6.4.2. Formulation and matrix components 
6.4.2.1. Lipids 
The digestion of excipients from a LBF can be followed in the different compartments of 
TIM-1, as shown in Figure 6.3, by the reduction of TGs and the increase of MGs and FAs 
over time as measured with GC-FID. 
For triglycerides, a higher concentration in the gastric compartment was observed at time 
point 0.0 h in CD compared to healthy conditions. Since the concentration of gastric lipase 
is similar in healthy and CD conditions, no difference was expected. The observed difference 
could possibly be attributed to the gastric content not being well mixed at the start of the 
experiment and the low number of replicates (n=2). While at 0.5 h the TG concentration is 
higher in CD compared to healthy conditions, at 1.0 h the opposite is the case. This could be 
due to variations in the emptying of the gastric content and mixing as suggested by the high 
variability observed (coefficients of variation between 12-57%). In the duodenum, higher 
TG concentrations were observed for CD conditions after 0.5 h and 1.0 h, indicating a slower 
TG hydrolysis due to the reduced concentration of porcine pancreatin. After 2.0 h, no TGs 
were detected for both experimental conditions in all TIM-1 compartments. 
For monoglycerides, the concentration in CD conditions reached only approximately one 
fifth of the concentrations observed for healthy conditions during the first 2.0 h considering 
all TIM-1 compartments. In both experimental setups the duodenum compartment showed 
the highest MG concentrations, followed by the jejunum and ileum. While in healthy 
conditions no MGs were detected after 3.0 h, in CD conditions MGs in the jejunum and 
ileum compartment were observed from 2.0-2.5 h until the end of the experiment. This 
indicates that the lipid hydrolysis in healthy conditions is complete after 3.0 h. In contrast, 
this process is slowed down in CD conditions and not complete within the 5.0 h of the 
experiment. 
In terms of fatty acids, during the first 2.0 h, the total FA concentration in all TIM-1 
compartments was approximately 5-times higher in healthy conditions compared to CD 
conditions. Similarly to MGs, the highest FA concentrations were observed in the duodenum 
followed by the jejunum and ileum for both setups. In the healthy setup, no FAs were 
observed after 3.5 h. Considering CD conditions, FAs in the jejunum and ileum compartment 
were observed starting from 1.5 h until the end of the experiment. Therefore, in healthy 
conditions the lipid hydrolysis of the TGs of the formulation is mainly located in the 
duodenum and jejunum and expected to be complete within 3.5 h. In CD conditions, the 
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lower FA concentrations and their delayed observation indicate a slower and unfinished 
digestion process. 
Consequently, the different concentrations of lipids in CD compared to healthy conditions 
indicate that the drug is exposed to a different GI luminal environment in CD patients 






Figure 6.3: Analysis of lipid components in different compartments of TIM-1 in healthy 
(left) and CD conditions (right) including triglycerides (top), monoglycerides (middle) and 
fatty acids (bottom). 
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The ratio of the intensity of the FAs (octanoic and decanoic acid) in CD to healthy 
conditions, in the different compartments of the TIM-1, as assessed with semi-quantitative 
analysis using UPLC-MS is shown in Figure 6.4.  
For both FAs, a lower concentration was observed in CD conditions compared to healthy 
conditions in the first two hours, with approximately one half of the FA concentration in the 
duodenum compartment and one quarter in the jejunum and ileum compartment. For 
octanoic acid, the concentration in CD conditions was higher compared to healthy conditions 
after 2.5 h in the duodenum compartment and after 3.0 h in the jejunum and ileum 
compartment. For decanoic acid, higher concentrations in CD conditions were observed after 
2.5 h in the duodenum compartment, after 3.5 h in the ileum compartment and after 4.0 h in 
the jejunum compartment. Consequently, the UPLC-MS results are consistent with a delayed 
hydrolysis of TGs in CD conditions. Considering the total intensity of the FAs over all time 
points, in CD conditions only 65% and 61% of the intensity in healthy conditions was 
observed for octanoic acid and decanoic acid, respectively. This again suggests a lower 
extent of TG hydrolysis in CD. Therefore, the semi-quantitative UPLC-MS lipidomics 




Figure 6.4: UPLC-MS intensity of fatty acids (n=1) illustrated as ratio of intensity in CD to 
healthy conditions for octanoic acid (a) and decanoic acid (b). 
 
Cholesterol is an excipient of the Ciproxin® suspension but also a biliary component and 
therefore, present in the TIM-1 matrix. Since no cholesterol was observed in the gastric 
compartment, the observed cholesterol in the small intestinal TIM-1 compartments is 
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expected to be mainly from the biliary secretions (porcine bile). In Figure 6.5a, the mean 
cholesterol concentration over the 5.0 h time course of the experiment is shown in the 
different TIM-1 compartments and experimental setups. For the CD conditions, the 
cholesterol concentration is less than half of the concentration observed for healthy 
conditions, as expected due to the lower concentration of porcine bile in CD conditions. In 
terms of the biorelevance of the TIM-1 conditions, the mean duodenal and jejunal cholesterol 
concentrations in healthy conditions correspond to the range observed in human intestinal 
fluids that has been reported between 0.08 mM and 1.80 mM (mean cholesterol 
concentration).30, 44-47 The time course of the cholesterol concentration in the different TIM-
1 compartments is shown in Figure 6.5b. In the duodenum compartment, a lower 
concentration of cholesterol is observed in the first hour of the experiment, most likely due 
to the transfer of the gastric content to the duodenum compartment in the first hour until the 
housekeeper wave. In contrast, higher concentrations of cholesterol are observed for the first 
hour in the jejunum and ileum compartment, indicating a higher cholesterol concentration 
due to the preconditioning of the filter with a solution containing porcine bile or a higher 




Figure 6.5: Concentration of cholesterol in different TIM-1 compartments in healthy and CD conditions shown as mean value over 5 h (a) and time 
course (b). [H: Healthy, CD: Crohn’s disease].
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6.4.2.2. Secretion of bicarbonate solution 
The volume of bicarbonate solution secreted in the different TIM-1 compartments to 
maintain the pre-set pH in the different experimental conditions is shown in Figure 6.6. In 
healthy and CD conditions, more bicarbonate solution was secreted compared to the blank 
TIM-1 run in all compartments, indicating an impact of formulation components on pH. The 
digestion of TGs results in a release of FAs, which in turn provokes a pH reduction and, 
consequently, can trigger the secretion of bicarbonate solution. In the duodenum and 
jejunum compartment, more bicarbonate solution was secreted in healthy compared to CD 
conditions, possibly due to more FAs being released in healthy conditions (Section 6.3.2.1). 
In the jejunum compartment, the bicarbonate secretion slightly increased after 3 h in CD 
conditions, which agreed with increased FA concentrations observed at later time points 
(Section 6.3.2.1). Another point for consideration is that there is no direct relationship 
between the volume of bicarbonate solution secreted and the amount of FAs released in the 
compartments. For example, the concentration of FAs in the duodenal samples was higher 
compared to the jejunal samples in healthy conditions, while the total bicarbonate secretion 
was slightly higher in the jejunum. This highlights that other formulation factors and TIM-1 
matrix components are also influential to the bicarbonate secretion.  
The control of the bicarbonate secretion in TIM-1 is comparable to the use of sodium 
hydroxide in the pH stat method, another in vitro method for the evaluation of LBFs. For the 
pH stat method, the degree of lipid digestion is determined by the sodium hydroxide 
necessary for the neutralization of the FAs released by enzymatic lipid hydrolysis.11 In 
comparison to the pH stat method, additional factors including various secretions and the 
compartmental transfer of formulation and matrix components can influence the pH in TIM-
1 and therefore, the bicarbonate secretion. Additionally, it is difficult to assess the total 
digestion of the formulation in TIM-1 due to the constant removal of lipids e.g., MGs via 
filtration. It should be considered that in the case of formulations with long chain FAs 
possessing a higher pKa, the bicarbonate secretion might not be indicative of their release 





Figure 6.6: Secretion of bicarbonate solution in the duodenum compartment (a), the jejunum 
compartment (b) and the ileum compartment (c) in healthy and CD conditions with 
Ciproxin® suspension and healthy blank conditions. 
 
6.4.2.3. Bile salts 
The total bile salt concentrations over time in the different TIM-1 compartments and 
experimental conditions are shown in Figure 6.7. 
Apart from the first two time points (0.5 h and 1.0 h), the bile salt concentration in the 
different TIM-1 compartments was stable over the remaining run time of 4 h. For the 
duodenum compartment, the difference in the beginning is most likely due to initial transfer 
of luminal content from the stomach to the duodenum compartment until the housekeeper 
wave after the first hour. In contrast, the higher bile salt concentration in the beginning in 
the jejunum and ileum compartment is likely due to the starting residues or initial 
preconditioning of the filters. Similar bile salt concentrations were observed in the different 




For the healthy conditions, the average duodenal total bile salt concentration was 7.43 mM, 
the jejunal total bile salt concentration was 6.00 mM and the ileal total bile salt concentration 
was 3.14 mM. For the CD conditions, the average duodenal total bile salt concentration was 
3.27 mM, the jejunal total bile salt concentration was 3.10 mM and the ileal total bile salt 
concentration was 2.28 mM. As expected, the reduced bile salt concentration in CD 
conditions (lower concentration of porcine bile) was reflected in all compartments with a 
reduced total bile acid concentration.  
In comparison to human intestinal fluids, the duodenal bile salt concentration of the healthy 
experimental setup was significantly higher with 187% of the mean observed value in 13 
different studies in healthy subjects.16, 44, 47, 49-58 In contrast, the total bile salt concentration 
of the CD experimental setup was much closer to the concentration in human duodenal fluid 
(82% of value observed in healthy subjects). Similarly in the jejunum compartment, the total 
bile salt concentration in the healthy experimental setup was doubled the mean concentration 
in human jejunal fluid, as observed in 10 different studies, while the total bile salt 
concentration in CD conditions was similar (103% of the concentration in human jejunal 
fluids).44, 45, 57, 59-67 Considering the ileum compartment, in both experimental setups the total 
bile salt concentration was 28- to 46-fold higher compared to the mean concentration in the 
human distal ileum in the fasted state as investigated in one study.68 It should be taken into 
account that the high bile salt concentrations during the first hour have a high impact on the 
mean value of the ileum compartment. For example, when only the last two hours of the 
experiment are considered, the ileal total bile salt concentration in CD conditions was only 




Figure 6.7: Overview of total bile salt concentration in TIM-1 in healthy and CD conditions 
with mean concentrations over time plus range in different compartments of the TIM-1 in 
comparison to human intestinal fluids (left), and total bile acid concentrations at different 
time points during TIM-1 run (right). [H: healthy conditions with Ciproxin®, H blank: 
healthy conditions without formulation, CD: CD conditions with Ciproxin®, HIF: Human 
Intestinal Fluids].16, 44, 45, 47, 49-67 
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In terms of the specific bile salt concentrations, Figure 6.8 gives an overview of the 
percentage of specific bile acids in the TIM-1 duodenum and jejunum samples in healthy 
conditions in comparison to human intestinal fluids.44, 46, 49-52, 57, 59, 60 The bile salt with the 
retention time of 8.3 min and the molecular weight of 449.6 g/mol (data not shown, same 
molecular weight as GCDC) is in the following assumed to be Glycohyodeoxycholate 
(GHDC), which has been reported as a major component of porcine bile.69 
Due to the similar source of bile salts (porcine bile), the duodenum and jejunum 
compartment showed similar percentages of the specific bile salts, with GHDC as most 
prominent component followed by GCDC and TC. TCDC and GC had the lowest 
percentages, both accounting for less than 6% of the total bile salt concentration. 
In comparison to human duodenal fluids, a similar percentage of TC and GCDC was present 
in the duodenal TIM-1 samples compared to the percentage observed in human duodenal 
fluids. For TCDC and GC, the percentage in the TIM-1 samples of the duodenum 
compartment is lower compared to human duodenal fluids. GHDC, which accounted for 
approximately one third of the bile salt concentration in TIM-1 samples of the duodenum 
compartment, was not present in human duodenal fluids, instead another glycine conjugate, 
GDC, was present in human duodenal fluid. Considering the proportion of glycine to taurine 
conjugates, glycine conjugated bile salts are slightly more prevalent in TIM-1 samples with 
71% to 29% compared to 59% to 40% in human duodenal fluids. Similar differences were 
observed when comparing the specific bile salt composition of TIM-1 samples of the 




Figure 6.8: Mean bile salt composition of TIM-1 in the duodenum compartment (a) and the jejunum compartment (c) in comparison to the bile acid 
composition of human intestinal fluids from the duodenum (b) and the jejunum (d) as reported in literature.44, 46, 49-52, 57, 59, 60 
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The ratio of the intensity of specific bile salts in CD to healthy conditions in the different 
compartments of the TIM-1 as assessed with UPLC-MS is shown in Figure 6.9. 
In the duodenum and jejunum compartment, the ratio of bile salts in CD to healthy conditions 
is stable after 1.5 h, with CD conditions showing approximately 50% of the bile salt intensity 
of healthy conditions. During the first hour of the experiment, the concentration of bile salts 
in CD conditions is closer to the bile salt concentration in healthy conditions, most likely 
due to the starting residues or preconditioning of the filters. In the ileum compartment, the 
bile salt concentration in CD conditions compared to healthy conditions was initially lower 
than in the duodenum and ileum. However, the overall bile salt concentration in CD 
conditions in the ileum was also approximately half of the concentration in healthy 
conditions. The lower concentration of porcine bile in the CD conditions (43% of healthy 
conditions) was therefore, approximately reflected in the bile salt concentrations in all TIM-
1 compartments. The presented semi-quantitative UPLC-MS analysis of luminal bile salt 
concentrations can consequently, be used to monitor the difference between two different 





Figure 6.9: UPLC-MS intensity of specific bile salts in TIM-1 illustrated as ratio of the 
intensity in CD to healthy conditions in the duodenum compartment (a), in the jejunum 
compartment (b) and in the ileum compartment (c). [GC: Glycocholic acid, TC: Taurocholic 
acid, TCDC: Taurochenodeoxycholic acid, GCDC: Glycochenodeoxycholic acid]. 
 
6.4.3. Light microscopy 
The contents of the gastric and duodenal compartment were examined with light microscopy 
as shown in Figure 6.10. In the stomach compartment, the emulsion droplets showed a 
polydisperse particle size distribution with similar droplet sizes for the different time points. 
In the duodenum compartment, the emulsion droplets were bigger during the first hour and 
their diameter decreased subsequently. Differences between healthy and CD conditions were 




Figure 6.10: Light microscopy pictures of the contents of the gastric and duodenal 
compartment after administration of Ciproxin® oral suspension in healthy conditions (scale 
bar is 30 µm). 
 
6.5. Conclusion 
The performance of Ciproxin® oral suspension was not impacted by CD conditions, most 
likely due to the low lipophilicity of ciprofloxacin. The digestion of excipients of a LBF can 
be followed in the TIM-1 system. By comparing the lipolysis of the medium chain TGs in 
healthy and CD conditions, reduced FA and MG concentrations were observed in CD 
conditions during the first hours, followed by higher concentrations at the end of the 
experiment. This indicates a delayed and reduced digestion process in CD conditions. 
Consequently, the GI luminal environment is expected to be different in CD patients 
compared to healthy subjects, suggesting a possible impact on the performance of LBFs in 
CD. 
For more lipophilic compounds, differences in drug product performance of LBFs are 
expected due to the differences observed in the luminal environment, which suggests an 
increased risk of altered drug product performance in patients with CD. However, the use of 
the TIM-1 system for the investigation of LBFs could be restricted due to drug binding to 
silicone membranes and filters of the TIM-1 system, as previously reported and as observed 
for another model drug in pretesting experiments.22 
In terms of the biorelevance of the TIM-1 conditions, bile acid concentrations were higher 
in healthy TIM-1 fasted state conditions compared to reported concentrations in human 
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intestinal fluids. Interestingly, the conditions defined for CD patients showed similar bile 
salt concentrations compared to human intestinal fluids of healthy subjects. Cholesterol 
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Conclusions and Future Directions 
Conclusions 
Pathophysiological changes in patients with GI diseases such as CD, UC, CED can impact 
on drug product performance. In the absence of clinical studies, in vitro and in silico tools 
can be used to indicate the direction and magnitude of these changes on the bioavailability 
of drugs in GI disease patient populations. 
To predict differences in drug solubility and dissolution in vitro, biorelevant media 
simulating the GI fluids of different GI compartments and prandial states in patients with 
CD, UC and CED have been developed. The developed GI disease media were compared to 
biorelevant media based on healthy subjects and differences in media characteristics were 
mainly observed in terms of surface tension, osmolality and buffer capacity. These results 
suggest a possible impact on drug or formulation performance due to altered wetting 
behaviour, osmotic pressure or ionisation. Drug solubility of six drugs with different 
physicochemical properties was determined in CD, UC and CED media and compared to 
healthy biorelevant media.  
For CD, differences in drug solubility considering gastric CD media were related to drug 
ionisation. In fasted state intestinal and colonic fluids of CD patients, drugs with moderate 
to high lipophilicity are at risk of a lower drug solubility.  
For UC, drugs with a high lipophilicity are at risk of altered drug solubility in UC intestinal 
fluids, especially in patients with low concentrations of bile salts and lecithin. In fasted and 
fed state colonic fluids of UC patients, major differences in drug solubility are expected due 
to drug ionisation indicating an increased risk for weak acids and bases. Additionally, a 
higher solubility is indicated for neutral compounds in fasted state colonic fluids of UC 
patients due to higher concentrations of soluble proteins. Decreased concentrations of 
lecithin in fed state colonic fluids of UC patients pose a risk of altered solubility to neutral 
compounds. 
For CED, differences in the intestinal fluid composition compared to healthy subjects are 
expected to only pose a minimal risk to hydrophilic compounds. The highest impact of 
differences in CED was observed for neutral compounds with moderate to high lipophilicity 
indicating a higher solubility in most cases as a result of increased surfactant concentrations 
(bile salts, lecithin). Additionally, it was shown that the concrete influence of cholesterol, 
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lecithin and bile salts on drug solubility was specific to each investigated drug indicating a 
complex interplay between drugs and media. 
For drugs with solubility- or dissolution rate-limited absorption, the described differences of 
drug solubility between healthy and GI disease media are likely to result in altered 
performance in these patients. Apart from drug dissolution, drug product performance can 
also be affected by differences in permeability, distribution, gut wall/hepatic metabolism and 
elimination. Therefore, pathophysiological differences considering all ADME processes 
need to be considered to identify all drugs at risk of altered drug product performance in 
patients with GI diseases. Results from solubility and dissolution experiments can be 
integrated in PBPK models offering the opportunity to integrate ADME processes 
mechanistically and to consider the special physiology of patient populations in order to 
predict a drug’s plasma concentration profile in vivo. 
This approach was pursued by investigating the performance of budesonide in patients with 
CD. An in vitro dissolution methodology was developed representative of conditions in 
healthy subjects and CD patients. For a controlled-release budesonide formulation 
(Entocort®), a similar performance was observed in the fasted state, while the release of 
budesonide was lower in the fed state in CD conditions compared to healthy conditions. By 
integrating these in vitro biorelevant dissolution profiles in PBPK models, the budesonide 
plasma concentration profile after administration of a controlled-release formulation of 
budesonide was successfully predicted for healthy subjects in the fasted and fed state. 
Pathophysiological differences in CD patients were identified in literature and included a 
reduced hepatic CYP3A4 activity, altered intestinal CYP3A4 activity, decreased 
concentration of human serum albumin, increased gastric pH and altered GI transit times. 
The impact of these differences on budesonide performance was investigated with the PBPK 
model and revealed the highest impact on the simulations for hepatic CYP3A4 enzyme 
abundance and human serum albumin concentration. A PBPK model with a population 
adapted to CD physiology successfully predicted the increased exposure of budesonide in 
CD patients compared to healthy subjects as reported in several PK studies. This mechanistic 
modelling approach has highlighted the importance of considering all ADME parameters in 
patients with GI diseases. Despite the location of CD in the GI tract, the main impact on 
budesonide performance was observed due to differences in metabolism and distribution, 
while differences in the GI tract showed only a minor impact. 
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For lipid-based formulations, in vitro tools need to additionally consider the enzymatic 
digestion of lipid excipients to simulate the dynamic luminal environment to which the 
formulation is exposed in the GI tract. Since in CD patients a reduced pancreatic lipase 
activity has been reported, differences in the performance of lipid-based formulations are 
expected. To consider such differences, a dynamic GI simulator (TIM-1, TNO) was used to 
simulate conditions in CD and healthy subjects and used to test the performance of a lipid-
based formulation of ciprofloxacin (Ciproxin® oral suspension). While the lipid digestion 
process was delayed and reduced in CD, the performance of the formulation was not 
affected. This was most likely due to the low lipophilicity of ciprofloxacin indicating a 
different purpose for the addition of lipid excipients in this formulation. The altered luminal 
environment suggests an impact on the performance of LBFs in CD in cases when lipid 
excipients are needed for drug solubilisation. For those lipophilic compounds, however, drug 
binding to membranes and filters of the TIM-1 system could limit the application of this in 
vitro tool.  
Future Directions 
The research portrayed within this thesis presented several in vitro and in silico tools to 
predict drug product performance in patients with GI diseases with the aim to improve the 
drug therapy of this patient population. In the future, this aim can further be achieved by 
additional characterisation of the physiology of GI disease patients, by extending the 
presented tools to further GI diseases and by investigating more drugs and formulations to 
target the refinement of developed in vitro/in silico tools. 
Considering the physiology, only a very limited amount of studies has been performed to 
characterise e.g., the luminal fluid composition, GI hydrodynamics, metabolic enzyme 
activities and distribution processes in patients with GI diseases. Further studies assessing 
those processes would help to increase the confidence in the developed in vitro and in silico 
tools and indicate when modifications are needed. Additionally, including a large number of 
patients in those studies would help to identify interpatient variability and allow to 
differentiate between findings specific to disease states or disease location when looking at 
specific patient populations. 
In terms of the extension to further GI diseases, the development of biorelevant media 
comprised three different GI diseases including CD, UC and CED, while the focus for in 
vitro dissolution testing and PBPK modelling was on CD patients. The extension of those 
approaches to other GI conditions would allow for the prediction of formulation performance 
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in these patients and could further guide prescribers for the drug therapy of the affected 
patients. 
Testing more drugs and formulations with the developed tools can be used for validation 
purposes and is expected to increase the confidence in the developed methods. Considering 
drug solubility in GI disease biorelevant media, the power of the developed statistical models 
could be increased by investigating a higher number of drugs with different physicochemical 
properties. The improved statistical models would further indicate the drugs that are at risk 
of altered performance in GI disease patients and therefore, narrow down the number of 
drugs for which in vitro studies are needed. For in vitro dissolution studies, different types 
of formulations and drugs should be investigated. This should especially include drugs at 
high risk of altered performance such as immediate-release formulations of BCS class II 
drugs with reduced drug solubility in biorelevant media of GI disease patients. Regarding 
the developed PBPK model, the developed CD patient population should also be used for 
the investigation of additional drugs and could further be validated with PK data in CD 
patients.  
In terms of the impact of enzymatic differences in CD, an altered luminal dynamic 
environment compared to healthy subjects is expected after the administration of lipid-based 
formulations. Further studies are needed to investigate compounds with a high lipophilicity, 
for which drug product performance is expected to be impacted by those changes.  
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